<?xml version="1.0" encoding="UTF-8"?>
<COCHRANE_REVIEW TYPE="INTERVENTION" REVMAN_VERSION="5" ID="000000000000000000" VERSION_NO="7.0" STAGE="R" STATUS="A">
<COVER_SHEET>
<TITLE>Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2018, Issue 5".]</TITLE>
<CONTACT>
<PERSON ID="17915" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marc</FIRST_NAME>
<LAST_NAME>Arbyn</LAST_NAME>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>marc.arbyn@sciensano.be</EMAIL_1>
<URL>www.iph.fgov.be</URL>
<ADDRESS>
<DEPARTMENT>Unit of Cancer Epidemiology, Belgian Cancer Centre</DEPARTMENT>
<ORGANISATION>Sciensano</ORGANISATION>
<ADDRESS_1>Juliette Wytsmanstreet 14</ADDRESS_1>
<CITY>Brussels</CITY>
<ZIP>B-1050</ZIP>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+ 32 2 642 50 21</PHONE_1>
<FAX_1>+32 2 642 54 10</FAX_1>
</ADDRESS>
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="17915" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marc</FIRST_NAME>
<LAST_NAME>Arbyn</LAST_NAME>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>marc.arbyn@sciensano.be</EMAIL_1>
<URL>www.iph.fgov.be</URL>
<ADDRESS>
<DEPARTMENT>Unit of Cancer Epidemiology, Belgian Cancer Centre</DEPARTMENT>
<ORGANISATION>Sciensano</ORGANISATION>
<ADDRESS_1>Juliette Wytsmanstreet 14</ADDRESS_1>
<CITY>Brussels</CITY>
<ZIP>B-1050</ZIP>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+ 32 2 642 50 21</PHONE_1>
<FAX_1>+32 2 642 54 10</FAX_1>
</ADDRESS>
<FOOTNOTE>Joint first author</FOOTNOTE>
</PERSON>
<PERSON ID="z1311271156270684578041692454896" ROLE="AUTHOR">
<FIRST_NAME>Lan</FIRST_NAME>
<LAST_NAME>Xu</LAST_NAME>
<SUFFIX>M.S.</SUFFIX>
<POSITION>Research Assistant</POSITION>
<EMAIL_1>Xu.Lan@wiv-isp.be</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Unit of Cancer Epidemiology, Belgian Cancer Centre</DEPARTMENT>
<ORGANISATION>Sciensano</ORGANISATION>
<ADDRESS_1>Juliette Wytsmanstreet 14</ADDRESS_1>
<CITY>Brussels</CITY>
<ZIP>B1050</ZIP>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+32 (0)2 642 57 32</PHONE_1>
<FAX_1>+32 (0)2 642 54 10</FAX_1>
</ADDRESS>
<FOOTNOTE>Joint first author</FOOTNOTE>
</PERSON>
<PERSON ID="B5CA304682E26AA2005347C326CCB268" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cindy</FIRST_NAME>
<LAST_NAME>Simoens</LAST_NAME>
<POSITION>Post-Doctoral Researcher</POSITION>
<EMAIL_1>cindy.simoens@ua.ac.be</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Laboratory of Cell Biology and Histology</DEPARTMENT>
<ORGANISATION>University of Antwerp</ORGANISATION>
<ADDRESS_1>Groenenborgerlaan 171</ADDRESS_1>
<CITY>Antwerp</CITY>
<ZIP>B-2020</ZIP>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1>+32-3-2653300</PHONE_1>
</ADDRESS>
</PERSON>
<PERSON ID="7854" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Pierre</FIRST_NAME>
<MIDDLE_INITIALS>PL</MIDDLE_INITIALS>
<LAST_NAME>Martin-Hirsch</LAST_NAME>
<POSITION>Consultant Gynaecological Oncologist</POSITION>
<EMAIL_1>martin.hirsch@me.com</EMAIL_1>
<ADDRESS>
<DEPARTMENT>Gynaecological Oncology Unit</DEPARTMENT>
<ORGANISATION>Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust</ORGANISATION>
<ADDRESS_1>Sharoe Green Lane</ADDRESS_1>
<ADDRESS_2>Fullwood</ADDRESS_2>
<CITY>Preston</CITY>
<ZIP>PR2 9HT</ZIP>
<REGION>Lancashire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 1772716565 ext: 4254</PHONE_1>
<PHONE_2>+ 44 1772716565</PHONE_2>
<FAX_1>+ 44 1772710162</FAX_1>
</ADDRESS>
</PERSON>
</CREATORS>
<DATES>
<UP_TO_DATE>
<DATE DAY="" MONTH="" YEAR="" />
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="" MONTH="" YEAR="" />
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR="" />
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR="" />
<REVIEW_PUBLISHED ISSUE="" YEAR="" />
<LAST_CITATION_ISSUE ISSUE="" YEAR="" />
</DATES>
<WHATS_NEW />
<HISTORY />
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES />
<EXTERNAL_SOURCES />
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO" />
<KEYWORDS />
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>HPV vaccination to prevent cancer and pre-cancerous changes of the cervix</TITLE>
<SUMMARY_BODY>
<P><B>Background</B><BR />
Human papillomaviruses (HPV) are sexually transmitted and are common in young people. Usually they are cleared by the immune system. However, when high-risk (hr) types persist, they can cause the development of abnormal cervical cells, which are referred to as cervical precancer if at least two thirds of the surface layer of the cervix is affected. Precancer can develop into cervical cancer after several years. Not everyone who has cervical precancer goes on to develop cervical cancer, but predicting who will is difficult. There are a number of different hrHPV types which can cause cervical precancer and cancer. HPV16 and 18 are the most important high-risk types, since they cause about 70% of cervical cancers worldwide. Preventive vaccination, by injection of HPV virus-like particles in the muscle, triggers the production of antibodies which protect against future HPV infections.</P>
<P><B>Review question</B><BR />
Does HPV vaccination prevent the development of cervical precancer or cancer and what are the harms?</P>
<P><B>Main results</B><BR />
We included 26 studies involving 73,428 adolescent girls and women. All trials evaluated vaccine safety over a period 0.5 to 7 years and ten trials, with follow-up 3.5 to 8 years, addressed protection against precancer. Cervical cancer outcomes are not available. Most participants enrolled were younger than 26 years of age. Three trials recruited women between 25 to 45 years. The studies compared HPV vaccine with a dummy vaccine.</P>
<P>We assessed protection against precancer in individuals who were free of hrHPV, free of HPV16/18 or those with or without HPV infection at the time of vaccination. We separately assessed precancer associated with HPV16/18 and any precancer.</P>
<P><I><B>Protection against cervical precancer</B></I> </P>
<P><I>1) Women free of hrHPV</I></P>
<P>Outcomes were only measured in the younger age group for this comparison (15 to 25 years). HPV vaccines reduce the risk of cervical precancer associated with HPV16/18 from 164 to 2/10,000 women (high certainty). They reduce also any precancer from 287 to 106/10,000 (high certainty).</P>
<P><I>2) Women free of HPV16/18</I> </P>
<P>The effect of HPV vaccines on risk of precancer differ by age group. In younger women, HPV vaccines reduce the risk of precancer associated with HPV16/18 from 113 to 6/10,000 women (high certainty). HPV vaccines lower the number of women with any precancer from 231 to 95/10,000 (high certainty). In women older than 25, the vaccines reduce the number with precancer associated with HPV16/18 from 45 to 14/10,000 (moderate certainty).</P>
<P><I>3) All women with or without HPV infection</I></P>
<P>In those vaccinated between 15 to 26 years of age, HPV vaccination reduces the risk of precancer associated with HPV16/18 from 341 to 157/10,000 (high certainty) and any precancer from 559 to 391/10,000 (high certainty).</P>
<P>In older women, vaccinated between 25 to 45 years of age, the effects of HPV vaccine on precancer are smaller, which may be due to previous exposure to HPV. The risk of precancer associated with HPV16/18 is probably reduced from 145/10,000 in unvaccinated women to 107/10,000 women following HPV vaccination (moderate certainty). The risk of any precancer is probably similar between unvaccinated and vaccinated women (343 versus 356/10,000, moderate certainty).</P>
<P><I><B>Adverse effects</B></I></P>
<P>The risk of serious adverse events is similar in HPV and control vaccines (placebo or vaccine against another infection than HPV (high certainty). The rate of death is similar overall (11/10,000 in control group, 14/10,000 in HPV vaccine group) (low certainty). The number of deaths overall is low although a higher number of deaths in older women was observed. No pattern in the cause or timing of death has been established.</P>
<P><I><B>Pregnancy outcomes</B></I></P>
<P>HPV vaccines did not increase the risk of miscarriage or termination of pregnancy. We do not have enough data to be certain about the risk of stillbirths and babies born with malformations (moderate certainty).</P>
<P><B>Conclusion</B><BR />
There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and women who are vaccinated between 15 and 26 years of age. The protection is lower when a part of the population is already infected with HPV. Longer-term follow-up is needed to assess the impact on cervical cancer. The vaccines do not increase the risk of serious adverse events, miscarriage or pregnancy termination. There are limited data from trials on the effect of vaccines on deaths, stillbirth and babies born with malformations.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P />
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P />
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P />
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P />
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P />
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P />
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P />
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P />
<CONDITION>
<P />
</CONDITION>
<INTERVENTION>
<P />
</INTERVENTION>
<THEORY>
<P />
</THEORY>
<IMPORTANCE>
<P />
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P />
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P />
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P />
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P />
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P />
<CRIT_OUTCOMES_PRIMARY>
<P />
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY>
<P />
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P />
<ELECTRONIC_SEARCHES>
<P />
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES>
<P />
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P />
<STUDY_SELECTION>
<P />
</STUDY_SELECTION>
<DATA_EXTRACTION>
<P />
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT>
<P />
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES>
<P />
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS>
<P />
</UNIT_OF_ANALYSIS>
<MISSING_DATA>
<P />
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT>
<P />
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT>
<P />
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS>
<P />
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS>
<P />
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS>
<P />
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P />
<SEARCH_RESULTS>
<P />
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR>
<P />
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR>
<P />
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P />
<ALLOCATION>
<P />
</ALLOCATION>
<BLINDING>
<P />
</BLINDING>
<EXCLUSIONS>
<P />
</EXCLUSIONS>
<SELECTIVE_REPORTING>
<P />
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES>
<P />
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P />
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P />
<SUMMARY_OF_RESULTS>
<P />
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS>
<P />
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE>
<P />
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES>
<P />
</POTENTIAL_BIASES>
<AGREEMENT>
<P />
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P />
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P />
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P />
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P />
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P />
</CONTRIBUTIONS>
<PRO_REV_DIFF>
<P />
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P />
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" NAME="African_2 country trial (ph3,2v)" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" NAME="African_3 country trial (ph3,4v)" YEAR="2015">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_-adolescent" NAME="Chinese trial (ph3,2v)_ adolescent" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_mid_x002d_adult" NAME="Chinese trial (ph3,2v)_mid-adult" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" NAME="Chinese trial (ph3,2v)_young" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Co_x002d_vaccination_x005f_dTpa_x005f_IPV--trial-_x0028_ph3_x002c_2v_x0029_" NAME="Co_x002d_vaccination_x005f_dTpa_x005f_IPV  trial _x0028_ph3_x002c_2v_x0029_" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Co_x002d_vaccination_x005f_HAB-trial-_x0028_Ph3_x002c_-2v_x0029_" NAME="Co-vaccination_HAB trial (Ph3, 2v)" YEAR="2012">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Co_x002d_vaccination_x005f_HepB-trial-_x0028_ph3_x002c_-2v_x0029_" NAME="Co-vaccination_HepB trial (ph3, 2v)" YEAR="2011">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" NAME="CVT (ph3,2v)" YEAR="2004">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" NAME="FUT I/II trials (ph3,4v)" YEAR="2002">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" NAME="FUTURE III trial (ph3,4v)" YEAR="2004">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" NAME="FUTURE II trial (ph3,4v)" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" NAME="FUTURE I trial (ph3,4v)" YEAR="2007">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-Kong-trial-_x0028_ph3_x002c_2v_x0029_" NAME="Hong Kong trial (ph3,2v)" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" NAME="Immunobridging(ph3,2v)" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" NAME="Indian trial (ph3,2v)" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" NAME="Japanese trial (ph2,2v)" YEAR="2006">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" NAME="Japanese trial (ph2,4v)" YEAR="2013">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_" NAME="Korean trial (ph2,4v)" YEAR="2008">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" NAME="Korean trial (ph3,2v)" YEAR="2010">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korean-trial-_x0028_ph3b_x002c_2v_x0029_" NAME="Korean trial (ph3b,2v)" YEAR="2011">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" NAME="Malaysian trial (ph3,2v)" YEAR="2014">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PATRICIA-_x0026_-CVT-_x0028_ph3_x002c_2v_x0029_" NAME="PATRICIA &amp; CVT (ph3,2v)" YEAR="">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" NAME="PATRICIA trial (ph3,2v)" YEAR="2004">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" NAME="Phase2 trial (ph2,1v)" YEAR="1998">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" NAME="Phase2 trial (ph2,2v)" YEAR="2003">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" NAME="Phase2 trial (ph2,4v)" YEAR="2003">
<IDENTIFIERS />
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" NAME="VIVIANE trial (ph3,2v)" YEAR="2014">
<IDENTIFIERS />
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES />
<AWAITING_STUDIES />
<ONGOING_STUDIES />
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES />
<OTHER_VERSIONS_REFERENCES />
<PENDING_REFERENCES />
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_-adolescent">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_mid_x002d_adult">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Co_x002d_vaccination_x005f_dTpa_x005f_IPV--trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Co_x002d_vaccination_x005f_HepB-trial-_x0028_ph3_x002c_-2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Co_x002d_vaccination_x005f_HAB-trial-_x0028_Ph3_x002c_-2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hong-Kong-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Korean-trial-_x0028_ph3b_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PATRICIA-_x0026_-CVT-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_">
<CHAR_METHODS><P /></CHAR_METHODS>
<CHAR_PARTICIPANTS><P /></CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS><P /></CHAR_INTERVENTIONS>
<CHAR_OUTCOMES><P /></CHAR_OUTCOMES>
<CHAR_NOTES><P /></CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P />
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS />
<SOF_TABLES />
<ADDITIONAL_TABLES />
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>High-grade cervical lesions in hrHPV DNA negative women at baseline</NAME>
<DICH_OUTCOME CHI2="1.4688667514185711" CI_END="0.05454495915561856" CI_START="0.0033169664401617163" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.013450791761051774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="194" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-1.2632453791188158" LOG_CI_START="-2.479258922489053" LOG_EFFECT_SIZE="-1.8712521508039344" METHOD="IV" NO="1" P_CHI2="0.4797773240672152" P_Q="1.0" P_Z="1.6179450933876287E-9" Q="0.0" RANDOM="YES" SCALE="902.35" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11815" TOTAL_2="11861" WEIGHT="100.0" Z="6.032147983161341">
<NAME>CIN2+ associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0159925216276031" CI_START="0.003390046583169666" EFFECT_SIZE="0.05868783499558993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.006890511266976648" LOG_CI_START="-2.4697943340463167" LOG_EFFECT_SIZE="-1.23145191138967" ORDER="209" O_E="0.0" SE="1.4548169379247362" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1733" TOTAL_2="1729" VAR="2.116492322872706" WEIGHT="24.10656495644201">
<FOOTNOTE>Kuhs, Am J Epidemiol (2014). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.09122948342310497" CI_START="3.51654561673267E-4" EFFECT_SIZE="0.00566403248620897" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="89" LOG_CI_END="-1.039864784273881" LOG_CI_START="-3.4538837445333033" LOG_EFFECT_SIZE="-2.2468742644035924" ORDER="140" O_E="0.0" SE="1.4180066868429584" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.010742963931344" WEIGHT="25.374381796361625">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.07371184337949531" CI_START="0.0014344707562172912" EFFECT_SIZE="0.010282873319979933" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="97" LOG_CI_END="-1.1324627278650716" LOG_CI_START="-2.84330830105543" LOG_EFFECT_SIZE="-1.9878855144602507" ORDER="139" O_E="0.0" SE="1.004959158514187" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="1.009942910281543" WEIGHT="50.51905324719636">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.08824858500298316" CI_START="3.4033477402014753E-4" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.005480334135304895" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-1.0542922494565479" LOG_CI_START="-3.468093674196878" LOG_EFFECT_SIZE="-2.261192961826713" METHOD="IV" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.4056811177490477E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4616" TOTAL_2="4680" WEIGHT="100.0" Z="3.672097233725494">
<NAME>CIN2+ associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08824858500298316" CI_START="3.4033477402014753E-4" EFFECT_SIZE="0.005480334135304896" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="92" LOG_CI_END="-1.0542922494565479" LOG_CI_START="-3.468093674196878" LOG_EFFECT_SIZE="-2.261192961826713" ORDER="165" O_E="0.0" SE="1.4178789054022254" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.010380590384613" WEIGHT="100.0">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.053276813958197895" CI_END="0.10340906605237156" CI_START="0.001994616565653169" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.014361804767743609" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.985441384221612" LOG_CI_START="-2.7001405783861343" LOG_EFFECT_SIZE="-1.8427909813038732" METHOD="IV" NO="3" P_CHI2="0.8174564258253477" P_Q="1.0" P_Z="2.5227445675335376E-5" Q="0.0" RANDOM="YES" SCALE="874.2357972157381" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10082" TOTAL_2="10132" WEIGHT="100.00000000000001" Z="4.212755177914046">
<NAME>CIN3+ associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.18492034327019202" CI_START="7.017668172126925E-4" EFFECT_SIZE="0.011391705786869726" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="44" LOG_CI_END="-0.7330153090463514" LOG_CI_START="-3.153807171090872" LOG_EFFECT_SIZE="-1.9434112400686119" ORDER="138" O_E="0.0" SE="1.42198512287793" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.0220416896861617" WEIGHT="50.17195060992325">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.2972277910796366" CI_START="0.0011065169084355452" EFFECT_SIZE="0.01813525782795949" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="27" LOG_CI_END="-0.5269105860680595" LOG_CI_START="-2.9560419453299005" LOG_EFFECT_SIZE="-1.7414762656989797" ORDER="135" O_E="0.0" SE="1.4268837848245606" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="2.035997335395263" WEIGHT="49.828049390076764">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.18492034327019202" CI_START="7.017668172126925E-4" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.011391705786869724" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.7330153090463514" LOG_CI_START="-3.153807171090872" LOG_EFFECT_SIZE="-1.9434112400686119" METHOD="IV" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.0016500155710059894" Q="0.0" RANDOM="YES" SCALE="881.1816825856392" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4616" TOTAL_2="4680" WEIGHT="100.0" Z="3.146917417731101">
<NAME>CIN3+ associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.18492034327019202" CI_START="7.017668172126925E-4" EFFECT_SIZE="0.011391705786869726" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="44" LOG_CI_END="-0.7330153090463514" LOG_CI_START="-3.153807171090872" LOG_EFFECT_SIZE="-1.9434112400686119" ORDER="140" O_E="0.0" SE="1.42198512287793" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.0220416896861617" WEIGHT="100.0">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09094760543145708" CI_END="0.8224155270893848" CI_START="0.013259856733166328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10442754456721043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.08490869885271135" LOG_CI_START="-1.8774611682639328" LOG_EFFECT_SIZE="-0.9811849335583219" METHOD="IV" NO="5" P_CHI2="0.7629759273021622" P_Q="1.0" P_Z="0.031901623197031805" Q="0.0" RANDOM="YES" SCALE="413.65853477741655" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10082" TOTAL_2="10132" WEIGHT="100.0" Z="2.145641106482413">
<NAME>AIS associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.803208368491898" CI_START="0.0074835225581454945" EFFECT_SIZE="0.14483740214734367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4476553810006966" LOG_CI_START="-2.1258939278766085" LOG_EFFECT_SIZE="-0.8391192734379559" ORDER="182" O_E="0.0" SE="1.5117156033090642" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.2852840652880877" WEIGHT="48.51530499436013">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3616302133537057" CI_START="0.004323415383517849" EFFECT_SIZE="0.07672609081059785" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.13405917945262782" LOG_CI_START="-2.3641730364757736" LOG_EFFECT_SIZE="-1.1150569285115726" ORDER="181" O_E="0.0" SE="1.4674739700852553" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="2.1534798528777808" WEIGHT="51.48469500563987">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.803208368491898" CI_START="0.0074835225581454945" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14483740214734367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4476553810006966" LOG_CI_START="-2.1258939278766085" LOG_EFFECT_SIZE="-0.8391192734379559" METHOD="IV" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.20120957298154607" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4616" TOTAL_2="4680" WEIGHT="100.0" Z="1.2781131093923177">
<NAME>AIS associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.803208368491898" CI_START="0.0074835225581454945" EFFECT_SIZE="0.14483740214734367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4476553810006966" LOG_CI_START="-2.1258939278766085" LOG_EFFECT_SIZE="-0.8391192734379559" ORDER="189" O_E="0.0" SE="1.5117156033090642" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.2852840652880877" WEIGHT="100.0">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.836304525581383" CI_END="0.5492629942465581" CI_START="0.25254160156471767" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37244027205346375" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="362" I2="59.33432124232067" I2_Q="87.81078508401905" ID="CMP-001.07" LOG_CI_END="-0.26021965991892715" LOG_CI_START="-0.5976670696570654" LOG_EFFECT_SIZE="-0.4289433647879963" METHOD="IV" NO="7" P_CHI2="0.043277320847763034" P_Q="0.004179908507091934" P_Z="6.267634536067699E-7" Q="8.203973815318706" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0928794945821225" TOTALS="YES" TOTAL_1="12574" TOTAL_2="12606" WEIGHT="100.0" Z="4.982782632969678">
<NAME>Any CIN2+ irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6323307102626736" CI_END="0.4275020338487301" CI_START="0.25357339883081786" DF="3" EFFECT_SIZE="0.3292463268285766" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="226" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.3690618147669679" LOG_CI_START="-0.5958963081520483" LOG_EFFECT_SIZE="-0.48247906145950803" NO="1" P_CHI2="0.6520815295928545" P_Z="7.573474560639943E-17" STUDIES="4" TAU2="0.0" TOTAL_1="7958" TOTAL_2="7926" WEIGHT="65.16465365433594" Z="8.337722977166234">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="0.4984803773670438" CI_START="0.07384789268164423" EFFECT_SIZE="0.19186381996537796" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="26" LOG_CI_END="-0.30235193297708973" LOG_CI_START="-1.1316618931724975" LOG_EFFECT_SIZE="-0.7170069130747936" ORDER="208" O_E="0.0" SE="0.48714077576929254" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1733" TOTAL_2="1729" VAR="0.23730613541710818" WEIGHT="11.899514245665493">
<FOOTNOTE>Kuhs, Am J Epidemiol (2014). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.954528900406429" CI_START="0.07609358871549424" EFFECT_SIZE="0.26950608446671437" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.02021091787583938" LOG_CI_START="-1.1186519332790859" LOG_EFFECT_SIZE="-0.5694314255774625" ORDER="509" O_E="0.0" SE="0.6452296898185859" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="254" TOTAL_2="251" VAR="0.41632135262338854" WEIGHT="7.7161077587605345">
<FOOTNOTE>Konno, Human Vaccines &amp; Immunother (2014). Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4725896637352654" CI_START="0.2647835479119851" EFFECT_SIZE="0.3537427990367515" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="172" LOG_CI_END="-0.3255157812898281" LOG_CI_START="-0.5771090028917475" LOG_EFFECT_SIZE="-0.45131239209078783" ORDER="168" O_E="0.0" SE="0.14778710377550003" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="0.021841028042350417" WEIGHT="34.248872982833774">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7738197684102529" CI_START="0.10697283047476973" EFFECT_SIZE="0.28771112405358185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.11136017975586271" LOG_CI_START="-0.9707265127186764" LOG_EFFECT_SIZE="-0.5410433462372696" ORDER="510" O_E="0.0" SE="0.5047960379143115" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="505" TOTAL_2="494" VAR="0.254819039893987" WEIGHT="11.300158667076142">
<FOOTNOTE>The GlaxoSmithKline Vaccine HPV-007 Study Group, Lancet (2009). Follow-up: 76 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7568986105627034" CI_START="0.4353374524158822" DF="0" EFFECT_SIZE="0.5740264043225609" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="136" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.12096229199556086" LOG_CI_START="-0.36117396854701234" LOG_EFFECT_SIZE="-0.24106813027128662" NO="2" P_CHI2="1.0" P_Z="8.357713008860512E-5" STUDIES="1" TAU2="0.0" TOTAL_1="4616" TOTAL_2="4680" WEIGHT="34.835346345664064" Z="3.9339041293517574">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="0.7568986105627034" CI_START="0.4353374524158822" EFFECT_SIZE="0.5740264043225609" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="136" LOG_CI_END="-0.12096229199556086" LOG_CI_START="-0.36117396854701234" LOG_EFFECT_SIZE="-0.24106813027128662" ORDER="169" O_E="0.0" SE="0.14110152787329855" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="0.019909641168179244" WEIGHT="34.835346345664064">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.137662932507704" CI_END="1.1039777757155063" CI_START="0.0393531862192913" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20843474515946553" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="113" I2="82.04291140682159" I2_Q="90.6746320338782" ID="CMP-001.08" LOG_CI_END="0.04296033065652182" LOG_CI_START="-1.4050200993548005" LOG_EFFECT_SIZE="-0.6810298843491392" METHOD="IV" NO="8" P_CHI2="0.0038149629195577406" P_Q="0.0010578761873184517" P_Z="0.06523225353887684" Q="10.723437441105894" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.583518539363737" TOTALS="YES" TOTAL_1="10336" TOTAL_2="10383" WEIGHT="100.0" Z="1.8436631021447634">
<NAME>Any CIN3+ irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.41422549140180465" CI_END="0.23237746551309188" CI_START="0.026234338114043403" DF="1" EFFECT_SIZE="0.07807860782797625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="46" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-0.6338059893532327" LOG_CI_START="-1.5811298884713505" LOG_EFFECT_SIZE="-1.1074679389122917" NO="1" P_CHI2="0.519832582925657" P_Z="4.592576900942771E-6" STUDIES="2" TAU2="0.0" TOTAL_1="5720" TOTAL_2="5703" WEIGHT="55.502483509118946" Z="4.582587383938161">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="4.096347652210431" CI_START="0.00953638782111478" EFFECT_SIZE="0.1976470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6123968075941262" LOG_CI_START="-2.020616095570986" LOG_EFFECT_SIZE="-0.7041096439884299" ORDER="511" O_E="0.0" SE="1.546644812943261" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="254" TOTAL_2="251" VAR="2.392110177404295" WEIGHT="18.196789432611915">
<FOOTNOTE>Konno, Human Vaccines &amp; Immunother (2014). Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.21888314006442647" CI_START="0.02112989240857406" EFFECT_SIZE="0.06800718491168546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="44" LOG_CI_END="-0.6597876895923271" LOG_CI_START="-1.675102714328735" LOG_EFFECT_SIZE="-1.167445201960531" ORDER="134" O_E="0.0" SE="0.5964010714205948" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="0.3556942379916335" WEIGHT="37.30569407650703">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8151130525014116" CI_START="0.3640806973912354" DF="0" EFFECT_SIZE="0.5447631858040819" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="67" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-0.08878215239802321" LOG_CI_START="-0.43880234561615705" LOG_EFFECT_SIZE="-0.2637922490070901" NO="2" P_CHI2="1.0" P_Z="0.003134315554285426" STUDIES="1" TAU2="0.0" TOTAL_1="4616" TOTAL_2="4680" WEIGHT="44.49751649088105" Z="2.9542484546456307">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="0.8151130525014116" CI_START="0.3640806973912354" EFFECT_SIZE="0.5447631858040819" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="67" LOG_CI_END="-0.08878215239802321" LOG_CI_START="-0.43880234561615705" LOG_EFFECT_SIZE="-0.2637922490070901" ORDER="142" O_E="0.0" SE="0.2056035941242317" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="0.04227283791680181" WEIGHT="44.49751649088105">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months. Based on own calculation from published data.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13716213357667853" CI_END="0.7587100774129308" CI_START="0.012357900818660526" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09683007738707665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.11992414746913145" LOG_CI_START="-1.9080552946434741" LOG_EFFECT_SIZE="-1.0139897210563027" METHOD="IV" NO="9" P_CHI2="0.7111187995718038" P_Q="1.0" P_Z="0.026225186426087243" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10082" TOTAL_2="10132" WEIGHT="100.00000000000001" Z="2.222860819917701">
<NAME>Any AIS irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.803208368491898" CI_START="0.0074835225581454945" EFFECT_SIZE="0.14483740214734367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4476553810006966" LOG_CI_START="-2.1258939278766085" LOG_EFFECT_SIZE="-0.8391192734379559" ORDER="193" O_E="0.0" SE="1.5117156033090642" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="4616" TOTAL_2="4680" VAR="2.2852840652880877" WEIGHT="48.276274598742965">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1639862604416065" CI_START="0.003798765415722391" EFFECT_SIZE="0.06649594536918481" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.06594785398258882" LOG_CI_START="-2.420357524503423" LOG_EFFECT_SIZE="-1.1772048352604172" ORDER="192" O_E="0.0" SE="1.4604680867327982" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5466" TOTAL_2="5452" VAR="2.1329670323649603" WEIGHT="51.72372540125705">
<FOOTNOTE>Lehtinen, Lancet Oncol (2012). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>High-grade cervical lesions in HPV16/18 DNA negative women at baseline</NAME>
<DICH_OUTCOME CHI2="4.255488529595766" CI_END="0.15988062994035987" CI_START="0.04210796857024825" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.08205028056332388" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="147" I2="0.0" I2_Q="3.7610755734395207" ID="CMP-002.01" LOG_CI_END="-0.7962041492592979" LOG_CI_START="-1.3756357098980037" LOG_EFFECT_SIZE="-1.0859199295786508" METHOD="IV" NO="1" P_CHI2="0.7499248593338756" P_Q="0.308035727138649" P_Z="2.0363775055429865E-13" Q="1.0390806068942466" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21723" TOTAL_2="21653" WEIGHT="100.0" Z="7.346385998451093">
<NAME>CIN2+ associated with HPV16/(18), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.216337932503957" CI_END="0.145443233357148" CI_START="0.03276098656439312" DF="5" EFFECT_SIZE="0.0690279929731078" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="135" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.8373064791883995" LOG_CI_START="-1.4846430283700869" LOG_EFFECT_SIZE="-1.1609747537792432" NO="1" P_CHI2="0.6666726501216048" P_Z="2.06164642589821E-12" STUDIES="6" TAU2="0.0" TOTAL_1="18303" TOTAL_2="18276" WEIGHT="80.12057120638454" Z="7.030249434375503">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="2.7697525107462235" CI_START="0.00739775231205706" EFFECT_SIZE="0.14314308589728925" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4424409647254069" LOG_CI_START="-2.1309002136137076" LOG_EFFECT_SIZE="-0.8442296244441503" ORDER="628" O_E="0.0" SE="1.5115933464006683" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2497" TOTAL_2="2502" VAR="2.2849144448827707" WEIGHT="5.070018620772125">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.793066896344111" CI_START="0.013014445858801361" EFFECT_SIZE="0.10159392789373814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.10069017776719673" LOG_CI_START="-1.885574318956069" LOG_EFFECT_SIZE="-0.9931322483616328" ORDER="197" O_E="0.0" SE="1.0484497798533365" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2635" TOTAL_2="2677" VAR="1.0992469408745098" WEIGHT="10.538631813894987">
<FOOTNOTE>Hildesheim, Vaccine (2014). Follow-up time: 53.8 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.12337316553789499" CI_START="0.0023687761221051424" EFFECT_SIZE="0.0170951282134616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="58" LOG_CI_END="-0.9087792918922567" LOG_CI_START="-2.6254759834008587" LOG_EFFECT_SIZE="-1.7671276376465577" ORDER="143" O_E="0.0" SE="1.0083961343778263" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5305" TOTAL_2="5260" VAR="1.0168627638281431" WEIGHT="11.392450578891218">
<FOOTNOTE>The FUTURE II study group, New Eng J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.13851739526223" CI_START="0.013585821513038129" EFFECT_SIZE="0.33251833740831294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9105452960806282" LOG_CI_START="-1.8669140953548768" LOG_EFFECT_SIZE="-0.47818439963712434" ORDER="141" O_E="0.0" SE="1.6314933951749386" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="408" TOTAL_2="407" VAR="2.6617706984994487" WEIGHT="4.3522001308969065">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.19601514803999381" CI_START="0.025802472437285576" EFFECT_SIZE="0.07111733582321818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="56" LOG_CI_END="-0.7077103650926401" LOG_CI_START="-1.5883386771986578" LOG_EFFECT_SIZE="-1.148024521145649" ORDER="144" O_E="0.0" SE="0.5172854297115238" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7344" TOTAL_2="7312" VAR="0.26758421579183583" WEIGHT="43.29313202628862">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1940563006743512" CI_START="0.003985574388202827" EFFECT_SIZE="0.06898550724637681" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.07702480459548232" LOG_CI_START="-2.3995090806290067" LOG_EFFECT_SIZE="-1.1612421380167621" ORDER="142" O_E="0.0" SE="1.4547282632213079" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="114" TOTAL_2="118" VAR="2.1162343198148825" WEIGHT="5.4741380356406895">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.999019756338044E-5" CI_END="0.7351250595687453" CI_START="0.036879894940914516" DF="1" EFFECT_SIZE="0.16465520023773572" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.13363877239810004" LOG_CI_START="-1.4332103247834322" LOG_EFFECT_SIZE="-0.7834245485907663" NO="2" P_CHI2="0.9933249641118912" P_Z="0.01812465035584397" STUDIES="2" TAU2="0.0" TOTAL_1="3420" TOTAL_2="3377" WEIGHT="19.879428793615453" Z="2.363061729112349">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.3748248576011113" CI_START="0.019973318943842806" EFFECT_SIZE="0.16571003401360543" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1382473758229131" LOG_CI_START="-1.6995497629093563" LOG_EFFECT_SIZE="-0.7806511935432217" ORDER="145" O_E="0.0" SE="1.0795311365338902" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1568" TOTAL_2="1559" VAR="1.1653874747461526" WEIGHT="9.940521100031754">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3576092738357686" CI_START="0.019716439765932327" EFFECT_SIZE="0.16360691144708422" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13277479598753936" LOG_CI_START="-1.7051715036747606" LOG_EFFECT_SIZE="-0.7861983538436106" ORDER="335" O_E="0.0" SE="1.0796187544025486" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1852" TOTAL_2="1818" VAR="1.1655766548577104" WEIGHT="9.938907693583701">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months. Age range is larger and contains data for women of 46 years and older</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.946456730888176" CI_END="0.20232507590220095" CI_START="0.048996419255404725" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09956507542700814" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="212" I2="29.62317949605226" I2_Q="87.07706662449706" ID="CMP-002.02" LOG_CI_END="-0.6939502880099149" LOG_CI_START="-1.3098356578172432" LOG_EFFECT_SIZE="-1.001892972913579" METHOD="IV" NO="2" P_CHI2="0.19162823371296211" P_Q="0.005406536626145764" P_Z="1.8088296553283643E-10" Q="7.7381811926356265" RANDOM="YES" SCALE="820.5758307883402" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2860848472902504" TOTALS="YES" TOTAL_1="21017" TOTAL_2="21013" WEIGHT="100.0" Z="6.376752037115896">
<NAME>CIN2+ associated with HPV16/(18), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9437189072650418" CI_END="0.10374383368487121" CI_START="0.028947040282286677" DF="5" EFFECT_SIZE="0.0548003369762889" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="195" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.9840377073987109" LOG_CI_START="-1.5383958345196733" LOG_EFFECT_SIZE="-1.2612167709591922" NO="1" P_CHI2="0.8568765520224906" P_Z="4.739106270696278E-19" STUDIES="6" TAU2="0.0" TOTAL_1="17215" TOTAL_2="17263" WEIGHT="67.78786796001691" Z="8.918204052011799">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="2.0715892207945177" CI_START="0.006011168937789769" EFFECT_SIZE="0.11159154437456324" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3163036425651847" LOG_CI_START="-2.2210410664551237" LOG_EFFECT_SIZE="-0.9523687119449696" ORDER="629" O_E="0.0" SE="1.490448842137405" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2543" TOTAL_2="2554" VAR="2.2214377510287306" WEIGHT="5.219514683703184">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.10890539185561425" CI_START="0.010910844785247396" EFFECT_SIZE="0.03447099979422054" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="87" LOG_CI_END="-0.9629506179928711" LOG_CI_START="-1.9621416223385424" LOG_EFFECT_SIZE="-1.4625461201657068" ORDER="153" O_E="0.0" SE="0.5869297420278882" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5865" TOTAL_2="5863" VAR="0.3444865220769234" WEIGHT="20.75585993505911">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.202591522031607" CI_START="0.00974427685199197" EFFECT_SIZE="0.20236406619385341" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6235171800723641" LOG_CI_START="-2.0112503854681423" LOG_EFFECT_SIZE="-0.6938666026978891" ORDER="150" O_E="0.0" SE="1.5476755103082867" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="422" TOTAL_2="427" VAR="2.3952994852080156" WEIGHT="4.881079844846131">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.13578160641357762" CI_START="0.02245571592479635" EFFECT_SIZE="0.05521841342736865" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="91" LOG_CI_END="-0.867159057552735" LOG_CI_START="-1.6486730943651449" LOG_EFFECT_SIZE="-1.2579160759589398" ORDER="154" O_E="0.0" SE="0.4590652137804831" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8040" TOTAL_2="8080" VAR="0.21074087050332063" WEIGHT="26.343344462456976">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0163451396245775" CI_START="0.0034583858053574487" EFFECT_SIZE="0.059286706808707734" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.007041214621800163" LOG_CI_START="-2.4611265599945247" LOG_EFFECT_SIZE="-1.2270426726863624" ORDER="152" O_E="0.0" SE="1.4498139684371572" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="126" TOTAL_2="127" VAR="2.101960543075498" WEIGHT="5.480654209691944">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.661649099533417" CI_START="0.007187319743606737" EFFECT_SIZE="0.1383116883116883" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4251507993800578" LOG_CI_START="-2.1434330341755086" LOG_EFFECT_SIZE="-0.8591411173977254" ORDER="151" O_E="0.0" SE="1.5087988585255756" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="219" TOTAL_2="212" VAR="2.27647399548808" WEIGHT="5.107414824259565">
<FOOTNOTE>De Carvalho,Vaccine (2010). Follow-up time: 88 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26455663098750737" CI_END="0.8057627554061686" CI_START="0.10861494819348154" DF="1" EFFECT_SIZE="0.29583421021693546" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.09379281078160165" LOG_CI_START="-0.9641104006109286" LOG_EFFECT_SIZE="-0.5289516056962651" NO="2" P_CHI2="0.6070068743519077" P_Z="0.017199796671452938" STUDIES="2" TAU2="0.0" TOTAL_1="3802" TOTAL_2="3750" WEIGHT="32.21213203998309" Z="2.382408695043422">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.3978845929336456" CI_START="0.09870616754364218" EFFECT_SIZE="0.37145636464702614" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14547131824730714" LOG_CI_START="-1.00565571008126" LOG_EFFECT_SIZE="-0.4300921959169765" ORDER="155" O_E="0.0" SE="0.6761777146108895" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1799" TOTAL_2="1782" VAR="0.4572163017364055" WEIGHT="17.608005905523125">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0092478001242875" CI_START="0.047235166506789696" EFFECT_SIZE="0.21833915792977202" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.003997811443834221" LOG_CI_START="-1.3257345493910286" LOG_EFFECT_SIZE="-0.6608683689735971" ORDER="337" O_E="0.0" SE="0.7810913710357421" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2003" TOTAL_2="1968" VAR="0.6101037299064953" WEIGHT="14.604126134459962">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months. Age range is larger and contains data for women of 46 years and older</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.198087055390161" CI_END="0.5073107474222647" CI_START="0.06928660615859215" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18748290577187957" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="72" I2="26.81219460758154" I2_Q="76.15651121100372" ID="CMP-002.03" LOG_CI_END="-0.2947259370188018" LOG_CI_START="-1.1593507110391368" LOG_EFFECT_SIZE="-0.7270383240289694" METHOD="IV" NO="3" P_CHI2="0.22394731897128994" P_Q="0.04056699924773288" P_Z="9.80176826400488E-4" Q="4.194017112384566" RANDOM="YES" SCALE="578.54" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4733133443517773" TOTALS="YES" TOTAL_1="1803" TOTAL_2="1910" WEIGHT="100.00000000000001" Z="3.2961556811547665">
<NAME>CIN2+ associated with HPV16/(18), 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5086960974082544" CI_END="0.2554708043963353" CI_START="0.0360593900774667" DF="4" EFFECT_SIZE="0.09597979677584054" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="67" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.5926587245470993" LOG_CI_START="-1.4429816233770882" LOG_EFFECT_SIZE="-1.0178201739620938" NO="1" P_CHI2="0.47655736362050016" P_Z="2.7044334983815346E-6" STUDIES="5" TAU2="0.0" TOTAL_1="1421" TOTAL_2="1537" WEIGHT="68.00321198483996" Z="4.692078471481571">
<NAME>women age 15-26 years</NAME>
<DICH_DATA CI_END="9.006595683928978" CI_START="0.015687467773800062" EFFECT_SIZE="0.375886524822695" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9545606672202983" LOG_CI_START="-1.80444715332948" LOG_EFFECT_SIZE="-0.42494324305459086" ORDER="630" O_E="0.0" SE="1.6206548510999137" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="46" TOTAL_2="52" VAR="2.6265221463936834" WEIGHT="8.321313960087448">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.30977921654918794" CI_START="0.017802061159045916" EFFECT_SIZE="0.07426108374384237" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="29" LOG_CI_END="-0.5089477229253696" LOG_CI_START="-1.7495297112766781" LOG_EFFECT_SIZE="-1.129238717101024" ORDER="294" O_E="0.0" SE="0.7287240009374415" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="560" TOTAL_2="603" VAR="0.5310386695422722" WEIGHT="25.682931866790533">
<FOOTNOTE>The FUTURE II study group, New Eng J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="10.688113808272274" CI_START="0.020375697871894336" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0289010695739755" LOG_CI_START="-1.6908875076568242" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="295" O_E="0.0" SE="1.5976172734359604" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="14" TOTAL_2="20" VAR="2.552380952380952" WEIGHT="8.525218284930148">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.22951429370373239" CI_START="0.0043307003436470854" EFFECT_SIZE="0.03152709359605911" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="35" LOG_CI_END="-0.6391902622689775" LOG_CI_START="-2.363441865589674" LOG_EFFECT_SIZE="-1.5013160639293257" ORDER="156" O_E="0.0" SE="1.0128339269736673" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="696" TOTAL_2="768" VAR="1.0258325636288999" WEIGHT="17.206266718801064">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.24587507882944" CI_START="0.012316920215132802" EFFECT_SIZE="0.29874213836477986" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8600908423892839" LOG_CI_START="-1.9094978717804536" LOG_EFFECT_SIZE="-0.524703514695585" ORDER="297" O_E="0.0" SE="1.6268701203885458" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="105" TOTAL_2="94" VAR="2.6467063886130417" WEIGHT="8.26748115423076">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4953738455973406" CI_END="2.665934936605473" CI_START="0.13962301406942615" DF="1" EFFECT_SIZE="0.6101031643597996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.42584954604632397" LOG_CI_START="-0.8550429910281582" LOG_EFFECT_SIZE="-0.21459672249091713" NO="2" P_CHI2="0.481539947348533" P_Z="0.5113529691728654" STUDIES="2" TAU2="0.0" TOTAL_1="382" TOTAL_2="373" WEIGHT="31.99678801516005" Z="0.6567324503945903">
<NAME>women age 24-45 years</NAME>
<DICH_DATA CI_END="6.794150673329869" CI_START="0.1371673007219217" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8321351739544001" LOG_CI_START="-0.8627494076423674" LOG_EFFECT_SIZE="-0.015307116843983656" ORDER="298" O_E="0.0" SE="0.9955835930439293" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.9911866907382603" WEIGHT="17.61331766818897">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.1474984850568393" CI_START="0.034835382563783504" EFFECT_SIZE="0.33112582781456956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49796552974682207" LOG_CI_START="-1.457979415661123" LOG_EFFECT_SIZE="-0.4800069429571506" ORDER="336" O_E="0.0" SE="1.1489317430162573" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="151" TOTAL_2="150" VAR="1.3200441501103752" WEIGHT="14.383470346971082">
<FOOTNOTE>Skinner, Lancet (2014). Follow-up time: 40 months. Age range is larger and contains data for women of 46 years and older</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7682264562784828" CI_END="0.6098487465971814" CI_START="0.006106119640140187" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06102302359857241" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="38" I2="43.4461577899552" I2_Q="43.4461577899552" ID="CMP-002.04" LOG_CI_END="-0.2147778644376" LOG_CI_START="-2.214234690613239" LOG_EFFECT_SIZE="-1.2145062775254194" METHOD="IV" NO="4" P_CHI2="0.18360184484412578" P_Q="0.18360184484412578" P_Z="0.017264061205876192" Q="1.7682264562784828" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.2273506097461928" TOTALS="YES" TOTAL_1="3822" TOTAL_2="3842" WEIGHT="100.0" Z="2.3810352209510817">
<NAME>CIN2+ associated with HPV6/11/16/18, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.2529921786196876" CI_START="9.497896595921853E-4" DF="0" EFFECT_SIZE="0.015501269470939414" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="32" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-0.5968929050487537" LOG_CI_START="-3.0223725629141396" LOG_EFFECT_SIZE="-1.8096327339814469" NO="1" P_CHI2="1.0" P_Z="0.003448662750778056" STUDIES="1" TAU2="0.0" TOTAL_1="2241" TOTAL_2="2258" WEIGHT="42.34973413945102" Z="2.924629750941606">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.2529921786196876" CI_START="9.497896595921853E-4" EFFECT_SIZE="0.015501269470939409" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="32" LOG_CI_END="-0.5968929050487537" LOG_CI_START="-3.0223725629141396" LOG_EFFECT_SIZE="-1.8096327339814469" ORDER="163" O_E="0.0" SE="1.4247387573480697" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2241" TOTAL_2="2258" VAR="2.0298805266897215" WEIGHT="42.34973413945102">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3854047902558027" CI_START="0.02012646159660173" DF="0" EFFECT_SIZE="0.16698292220113853" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.14157668494515763" LOG_CI_START="-1.6962325710699135" LOG_EFFECT_SIZE="-0.777327943062378" NO="2" P_CHI2="1.0" P_Z="0.0973194653837479" STUDIES="1" TAU2="0.0" TOTAL_1="1581" TOTAL_2="1584" WEIGHT="57.65026586054897" Z="1.6579900961891432">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.3854047902558027" CI_START="0.02012646159660173" EFFECT_SIZE="0.16698292220113853" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14157668494515763" LOG_CI_START="-1.6962325710699135" LOG_EFFECT_SIZE="-0.777327943062378" ORDER="164" O_E="0.0" SE="1.0795382542857894" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1581" TOTAL_2="1584" VAR="1.1654028424664098" WEIGHT="57.65026586054897">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.872963851948507" CI_END="2.413893448050101" CI_START="0.002811195060861582" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0823767281372875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="51" I2="79.47860828887251" I2_Q="79.47860828887251" ID="CMP-002.05" LOG_CI_END="0.3827180959414565" LOG_CI_START="-2.55110901888323" LOG_EFFECT_SIZE="-1.0841954614708869" METHOD="IV" NO="5" P_CHI2="0.027280732988766432" P_Q="0.027280732988766432" P_Z="0.14744683014890295" Q="4.872963851948507" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.801453397335872" TOTALS="YES" TOTAL_1="4484" TOTAL_2="4496" WEIGHT="100.0" Z="1.4486089149201298">
<NAME>CIN2+ associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.18779969011566944" CI_START="7.124978415649218E-4" DF="0" EFFECT_SIZE="0.011567492116010956" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="43" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.7263051286895342" LOG_CI_START="-3.147216446965577" LOG_EFFECT_SIZE="-1.9367607878275557" NO="1" P_CHI2="1.0" P_Z="0.0017127284927142457" STUDIES="1" TAU2="0.0" TOTAL_1="2667" TOTAL_2="2684" WEIGHT="43.523584488867925" Z="3.135993757519867">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.18779969011566944" CI_START="7.124978415649218E-4" EFFECT_SIZE="0.01156749211601096" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="43" LOG_CI_END="-0.7263051286895342" LOG_CI_START="-3.147216446965577" LOG_EFFECT_SIZE="-1.9367607878275555" ORDER="159" O_E="0.0" SE="1.4220552920596436" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2667" TOTAL_2="2684" VAR="2.0222412536748386" WEIGHT="43.523584488867925">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4073669943235354" CI_START="0.09937146804148804" DF="0" EFFECT_SIZE="0.37396807925151343" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.14840736170399424" LOG_CI_START="-1.0027382941830365" LOG_EFFECT_SIZE="-0.42716546623952123" NO="2" P_CHI2="1.0" P_Z="0.14577969714606656" STUDIES="1" TAU2="0.0" TOTAL_1="1817" TOTAL_2="1812" WEIGHT="56.47641551113207" Z="1.4546012053072188">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.4073669943235354" CI_START="0.09937146804148804" EFFECT_SIZE="0.3739680792515135" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14840736170399424" LOG_CI_START="-1.0027382941830365" LOG_EFFECT_SIZE="-0.4271654662395212" ORDER="161" O_E="0.0" SE="0.676188656530939" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1817" TOTAL_2="1812" VAR="0.4572310992211162" WEIGHT="56.47641551113207">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.12861017129823" CI_END="5.003901008001758" CI_START="0.011933440667059772" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24436398217173821" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" I2="68.03692549573711" I2_Q="68.03692549573711" ID="CMP-002.06" LOG_CI_END="0.6993087094738528" LOG_CI_START="-1.9232343218549377" LOG_EFFECT_SIZE="-0.6119628061905423" METHOD="IV" NO="6" P_CHI2="0.07692959826093382" P_Q="0.07692959826093382" P_Z="0.360347150675816" Q="3.12861017129823" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.2713007176609956" TOTALS="YES" TOTAL_1="662" TOTAL_2="654" WEIGHT="100.0" Z="0.9147038166262641">
<NAME>CIN2+ associated with HPV6/11/16/18, 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7354666348618142" CI_START="0.002570285419673923" DF="0" EFFECT_SIZE="0.043478260869565216" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-0.1334370246687149" LOG_CI_START="-2.590018647366471" LOG_EFFECT_SIZE="-1.3617278360175928" NO="1" P_CHI2="1.0" P_Z="0.02978879990237676" STUDIES="1" TAU2="0.0" TOTAL_1="426" TOTAL_2="426" WEIGHT="44.327852145553685" Z="2.1728873086734133">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.7354666348618142" CI_START="0.002570285419673923" EFFECT_SIZE="0.043478260869565216" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.1334370246687149" LOG_CI_START="-2.590018647366471" LOG_EFFECT_SIZE="-1.3617278360175928" ORDER="355" O_E="0.0" SE="1.4430082054478126" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="426" TOTAL_2="426" VAR="2.0822726809897163" WEIGHT="44.327852145553685">
<FOOTNOTE>Garland 2007</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.800586638346506" CI_START="0.13724587812104727" DF="0" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.832546377825013" LOG_CI_START="-0.8625006897643184" LOG_EFFECT_SIZE="-0.014977155969652801" NO="2" P_CHI2="1.0" P_Z="0.9723701254768602" STUDIES="1" TAU2="0.0" TOTAL_1="236" TOTAL_2="228" WEIGHT="55.672147854446315" Z="0.034635836199057676">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="6.800586638346506" CI_START="0.13724587812104727" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.832546377825013" LOG_CI_START="-0.8625006897643184" LOG_EFFECT_SIZE="-0.014977155969652801" ORDER="356" O_E="0.0" SE="0.99567903812028" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="236" TOTAL_2="228" VAR="0.9913767469521261" WEIGHT="55.672147854446315">
<FOOTNOTE>Castellsagu 2011</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7620823718374563" CI_END="0.28633186085402024" CI_START="0.019012881764520387" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07378342507523347" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="59" I2="27.59086331413376" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.5431303242689255" LOG_CI_START="-1.7209520525413107" LOG_EFFECT_SIZE="-1.132041188405118" METHOD="IV" NO="7" P_CHI2="0.2513169970115726" P_Q="1.0" P_Z="1.6484762842818647E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.41042883047217926" TOTALS="YES" TOTAL_1="14890" TOTAL_2="14830" WEIGHT="99.99999999999999" Z="3.767564997369176">
<NAME>CIN3+ associated with HPV16/18 or HPV6/11/16/18, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4276299081933714" CI_START="0.0015608600295537495" EFFECT_SIZE="0.025835449118232347" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="19" LOG_CI_END="-0.36893192809115033" LOG_CI_START="-2.8066360406390305" LOG_EFFECT_SIZE="-1.5877839843650905" ORDER="164" O_E="0.0" SE="1.4319194625405933" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2241" TOTAL_2="2258" VAR="2.050393347202542" WEIGHT="19.451544703229402">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.2422660237360457" CI_START="0.004508848998516226" EFFECT_SIZE="0.03305058121269243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="30" LOG_CI_END="-0.6157074886218803" LOG_CI_START="-2.3459343089846856" LOG_EFFECT_SIZE="-1.480820898803283" ORDER="160" O_E="0.0" SE="1.0163437990420032" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5305" TOTAL_2="5260" VAR="1.0329547178511318" WEIGHT="33.16290576495904">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9084926416277853" CI_START="0.04364611637685677" EFFECT_SIZE="0.1991285403050109" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.041678585927097625" LOG_CI_START="-1.360054393679762" LOG_EFFECT_SIZE="-0.7008664898034298" ORDER="157" O_E="0.0" SE="0.7744204755394145" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7344" TOTAL_2="7312" VAR="0.5997270729346929" WEIGHT="47.38554953181154">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1526769638485135" CI_END="0.13959525631285996" CI_START="0.020824262746284863" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0539163082526426" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.8551293395362979" LOG_CI_START="-1.6814303652339255" LOG_EFFECT_SIZE="-1.2682798523851118" METHOD="IV" NO="8" P_CHI2="0.5619523835326984" P_Q="1.0" P_Z="1.7806137107823653E-9" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16572" TOTAL_2="16627" WEIGHT="100.0" Z="6.016651936003356">
<NAME>CIN3+ associated with HPV 16/18 or HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3114181391699019" CI_START="0.0011577673156790175" EFFECT_SIZE="0.018988147435716106" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="26" LOG_CI_END="-0.5066560946838815" LOG_CI_START="-2.9363787149355707" LOG_EFFECT_SIZE="-1.721517404809726" ORDER="165" O_E="0.0" SE="1.4272310944567863" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2667" TOTAL_2="2684" VAR="2.036988596984316" WEIGHT="11.565467429689766">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated with HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.17504353769987027" CI_START="0.010337652967496025" EFFECT_SIZE="0.042538680597123214" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="47" LOG_CI_END="-0.7568539179928783" LOG_CI_START="-1.985578051084096" LOG_EFFECT_SIZE="-1.371215984538487" ORDER="162" O_E="0.0" SE="0.7217586380603337" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5865" TOTAL_2="5863" VAR="0.5209355316147078" WEIGHT="45.22387866315858">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.3883949890162475" CI_START="0.021490753144632193" EFFECT_SIZE="0.0913613749434645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="22" LOG_CI_END="-0.410726381896451" LOG_CI_START="-1.667748364367729" LOG_EFFECT_SIZE="-1.03923737313209" ORDER="132" O_E="0.0" SE="0.738380934862795" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8040" TOTAL_2="8080" VAR="0.5452064049688551" WEIGHT="43.210653907151645">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05224982710202897" CI_END="0.24273301903517724" CI_START="0.014114205357388776" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.058531903075856435" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.6148711424591855" LOG_CI_START="-1.8503435680034899" LOG_EFFECT_SIZE="-1.2326073552313375" METHOD="IV" NO="9" P_CHI2="0.9742134085619365" P_Q="1.0" P_Z="9.197659231920547E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1682" TOTAL_2="1797" WEIGHT="100.0" Z="3.9108376251590533">
<NAME>CIN3+ associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1635970231710928" CI_START="0.003819573577399004" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.06580260152137628" LOG_CI_START="-2.417985119632739" LOG_EFFECT_SIZE="-1.1760912590556813" ORDER="179" O_E="0.0" SE="1.4589892023534372" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="426" TOTAL_2="426" VAR="2.1286494925839192" WEIGHT="24.74213442689955">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated with HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4743881774564609" CI_START="0.008457205243049744" EFFECT_SIZE="0.06334033613445378" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="17" LOG_CI_END="-0.32386614285079274" LOG_CI_START="-2.072773129637853" LOG_EFFECT_SIZE="-1.1983196362443231" ORDER="163" O_E="0.0" SE="1.027316621267926" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="560" TOTAL_2="603" VAR="1.0553794403333472" WEIGHT="49.903693288385064">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7439889367220978" CI_START="0.002617825106438305" EFFECT_SIZE="0.04413199426111908" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.12843352245985806" LOG_CI_START="-2.582059371477374" LOG_EFFECT_SIZE="-1.355246446968616" ORDER="158" O_E="0.0" SE="1.441271969356724" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="696" TOTAL_2="768" VAR="2.0772648896534096" WEIGHT="25.354172284715386">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months. Associated to HPV 16/18.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5084665669216819" CI_END="0.6954456870392187" CI_START="0.022282390406855035" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12448370297099694" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.15773678190517798" LOG_CI_START="-1.65203822082237" LOG_EFFECT_SIZE="-0.904887501363774" METHOD="IV" NO="10" P_CHI2="0.7755108779920714" P_Q="1.0" P_Z="0.017608602742830583" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14884" TOTAL_2="14823" WEIGHT="100.0" Z="2.3737471791750298">
<NAME>AIS associated with HPV16/18 or HPV6/11/16/18, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.374997347479142" CI_START="0.004368905795549603" EFFECT_SIZE="0.07750634735469704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.13830186036534842" LOG_CI_START="-2.3596273196562043" LOG_EFFECT_SIZE="-1.1106627296454281" ORDER="305" O_E="0.0" SE="1.4672959652935207" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2241" TOTAL_2="2258" VAR="2.1529574497666446" WEIGHT="35.786249596172375">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.11124349604317" CI_START="0.013467040429816755" EFFECT_SIZE="0.33050634501821835" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.909087438930263" LOG_CI_START="-1.8707278360678905" LOG_EFFECT_SIZE="-0.48082019856881375" ORDER="159" O_E="0.0" SE="1.63287725284145" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5305" TOTAL_2="5260" VAR="2.6662881228470403" WEIGHT="28.896454215540114">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6363620506209244" CI_START="0.005005192567106481" EFFECT_SIZE="0.09050031587161986" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.21387939908529907" LOG_CI_START="-2.3005792090492108" LOG_EFFECT_SIZE="-1.043349904981956" ORDER="183" O_E="0.0" SE="1.4770054331890603" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7338" TOTAL_2="7305" VAR="2.1815450496700035" WEIGHT="35.31729618828751">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.029793102442833154" CI_END="0.717919167174697" CI_START="0.01190923535950469" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09246549805729194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-0.14392445161594203" LOG_CI_START="-1.9241161217924707" LOG_EFFECT_SIZE="-1.0340202867042065" METHOD="IV" NO="11" P_CHI2="0.8629605520922148" P_Q="1.0" P_Z="0.022793317607231554" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8532" TOTAL_2="8547" WEIGHT="100.0" Z="2.276881254054018">
<NAME>AIS associated with HPV16/18 or 6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.373474912378679" CI_START="0.004363243936978292" EFFECT_SIZE="0.07741321646868873" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1378207310918483" LOG_CI_START="-2.360190506123396" LOG_EFFECT_SIZE="-1.1111848875157737" ORDER="187" O_E="0.0" SE="1.4673441660952844" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2667" TOTAL_2="2684" VAR="2.1530989017738658" WEIGHT="50.78608716628854">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.062568468336228" CI_START="0.005981504212737715" EFFECT_SIZE="0.11107322801833541" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3144083741562948" LOG_CI_START="-2.2231895870578686" LOG_EFFECT_SIZE="-0.9543906064507867" ORDER="306" O_E="0.0" SE="1.4905976037296935" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5865" TOTAL_2="5863" VAR="2.221881216244704" WEIGHT="49.213912833711454">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9710063001650937" CI_START="0.00796248270360179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1538069773363891" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.47290357274746553" LOG_CI_START="-2.0989514980460386" LOG_EFFECT_SIZE="-0.8130239626492864" METHOD="IV" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.21527829279640276" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="986" TOTAL_2="1029" WEIGHT="100.0" Z="1.2391815568899782">
<NAME>AIS associated with HPV16/18 or HPV6/11/16/18, 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [vaccinated]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="359" O_E="0.0" SE="0.0" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="426" TOTAL_2="426" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up time: 36 months. Associated to HPV 16/18/6/11.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.9710063001650937" CI_START="0.00796248270360179" EFFECT_SIZE="0.1538069773363891" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47290357274746553" LOG_CI_START="-2.0989514980460386" LOG_EFFECT_SIZE="-0.8130239626492864" ORDER="360" O_E="0.0" SE="1.5107203994720257" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="560" TOTAL_2="603" VAR="2.2822761253809167" WEIGHT="100.0">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007). Follow-up time: 36 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6333027774152183" CI_END="0.6403834912820692" CI_START="0.2494434824649145" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39967422756344895" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.19355987247028086" LOG_CI_START="-0.6030278389547109" LOG_EFFECT_SIZE="-0.3982938557124958" METHOD="IV" NO="13" P_CHI2="0.7285847517508841" P_Q="1.0" P_Z="1.3731472125954445E-4" Q="0.0" RANDOM="YES" SCALE="846.99" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3641" TOTAL_2="3679" WEIGHT="100.0" Z="3.8129557198939934">
<NAME>Any CIN2+ irrespective of HPV types, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7124902867218568" CI_START="0.20923832840840662" EFFECT_SIZE="0.3861091511488787" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="37" LOG_CI_END="-0.1472210519536322" LOG_CI_START="-0.6793587581815201" LOG_EFFECT_SIZE="-0.4132899050675761" ORDER="198" O_E="0.0" SE="0.31258032276238984" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2643" TOTAL_2="2697" VAR="0.0977064581782398" WEIGHT="59.2095549665856">
<FOOTNOTE>Hildesheim, Vaccine (2012). Follow-up time: 53.8 months</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1496683657076268" CI_START="0.05243073422069906" EFFECT_SIZE="0.24551569506726456" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.06057258147164964" LOG_CI_START="-1.2804140605436591" LOG_EFFECT_SIZE="-0.6099207395360048" ORDER="158" O_E="0.0" SE="0.7877021915107265" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="446" TOTAL_2="438" VAR="0.6204747425108013" WEIGHT="9.323757293785699">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010), Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1418417589794414" CI_START="0.21264429265778248" EFFECT_SIZE="0.4927536231884058" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.057605921804935935" LOG_CI_START="-0.6723462691949362" LOG_EFFECT_SIZE="-0.3073701736950002" ORDER="176" O_E="0.0" SE="0.42877753031494525" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="552" TOTAL_2="544" VAR="0.1838501705029838" WEIGHT="31.4666877396287">
<FOOTNOTE>Mao, Obstet Gynecol (2006). Follow-up time: 48 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6652174865955824" CI_END="0.5212512579871884" CI_START="0.32017868615752076" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4085260615190821" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="221" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-0.2829528838911166" LOG_CI_START="-0.49460758182416936" LOG_EFFECT_SIZE="-0.388780232857643" METHOD="IV" NO="14" P_CHI2="0.7170507570031353" P_Q="1.0" P_Z="6.005277510860243E-13" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9567" TOTAL_2="9576" WEIGHT="100.0" Z="7.200362304673232">
<NAME>Any CIN2+ irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0214220166355497" CI_START="0.1078369431453218" EFFECT_SIZE="0.3318840579710145" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.009205214788639957" LOG_CI_START="-0.9672324315833746" LOG_EFFECT_SIZE="-0.4790136083973673" ORDER="170" O_E="0.0" SE="0.5735643069232237" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="460" TOTAL_2="458" VAR="0.32897601417631794" WEIGHT="4.698581829083585">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5472307372020946" CI_START="0.3266732031593696" EFFECT_SIZE="0.4228068327133225" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="192" LOG_CI_END="-0.2618295168757429" LOG_CI_START="-0.48588648902417503" LOG_EFFECT_SIZE="-0.3738580029499589" ORDER="172" O_E="0.0" SE="0.1316121745398885" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8602" TOTAL_2="8621" VAR="0.017321764487118075" WEIGHT="89.23575444999959">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.778537546294566" CI_START="0.10761991015531325" EFFECT_SIZE="0.28945835760046595" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.10872043800229156" LOG_CI_START="-0.9681073748528772" LOG_EFFECT_SIZE="-0.5384139064275844" ORDER="171" O_E="0.0" SE="0.5048081407399796" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="505" TOTAL_2="497" VAR="0.2548312589573551" WEIGHT="6.065663720916833">
<FOOTNOTE>The GlaxoSmithKline Vaccine HPV-007 Study Group, Lancet (2009). Follow-up time: 77 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.378514598767028" CI_START="0.15101431907941126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.528725799877914" LOG_CI_START="-0.82098187123439" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="IV" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.6712765862022991" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="20" WEIGHT="100.0" Z="0.4243966203806214">
<NAME>Any CIN2+ irrespective of HPV types, 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.378514598767028" CI_START="0.15101431907941126" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.528725799877914" LOG_CI_START="-0.82098187123439" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="357" O_E="0.0" SE="0.7928249671720918" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="14" TOTAL_2="20" VAR="0.6285714285714286" WEIGHT="100.0">
<FOOTNOTE>Konno 2010</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>High-grade cervical lesions in women regardless of baseline HPV DNA status</NAME>
<DICH_OUTCOME CHI2="8.646960908979699" CI_END="0.6686987004404816" CI_START="0.41127906684721366" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5244251877237646" ESTIMABLE="YES" EVENTS_1="331" EVENTS_2="668" I2="53.740972786796355" I2_Q="80.32286292643398" ID="CMP-003.01" LOG_CI_END="-0.17476952081397176" LOG_CI_START="-0.385863394512462" LOG_EFFECT_SIZE="-0.2803164576632169" METHOD="IV" NO="1" P_CHI2="0.07055571205102751" P_Q="0.024174942250942855" P_Z="1.9361733738499126E-7" Q="5.082040117225111" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03504640142876797" TOTALS="YES" TOTAL_1="22006" TOTAL_2="22046" WEIGHT="99.99999999999999" Z="5.205363392767011">
<NAME>CIN2+ associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.217569591531806" CI_END="0.5671824697218975" CI_START="0.3691054119318715" DF="2" EFFECT_SIZE="0.4575479418894125" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="596" I2="37.841282275176866" ID="CMP-003.01.01" LOG_CI_END="-0.2462772006400456" LOG_CI_START="-0.43284958700451287" LOG_EFFECT_SIZE="-0.33956339382227924" NO="1" P_CHI2="0.20013080912899883" P_Z="9.727841549034388E-13" STUDIES="3" TAU2="0.013590739258461198" TOTAL_1="17404" TOTAL_2="17448" WEIGHT="69.5248056472821" Z="7.134303584022856">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.6145925981394678" CI_START="0.43330685959723203" EFFECT_SIZE="0.5160495990033481" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="360" LOG_CI_END="-0.21141267448403755" LOG_CI_START="-0.3632044356791143" LOG_EFFECT_SIZE="-0.28730855508157593" ORDER="158" O_E="0.0" SE="0.08916323190732417" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.007950081924159271" WEIGHT="35.759672000245175">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5037109644401764" CI_START="0.3103355222477485" EFFECT_SIZE="0.3953724891939995" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="228" LOG_CI_END="-0.29781859561034596" LOG_CI_START="-0.5081685104834349" LOG_EFFECT_SIZE="-0.40299355304689044" ORDER="157" O_E="0.0" SE="0.12356058124532408" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.015267217237682335" WEIGHT="30.55912459919981">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3291774598019206" CI_START="0.09739413965215114" EFFECT_SIZE="0.3597972972972973" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12358296790110009" LOG_CI_START="-1.011467174469464" LOG_EFFECT_SIZE="-0.44394210328418204" ORDER="156" O_E="0.0" SE="0.6667340722172895" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="148" TOTAL_2="142" VAR="0.4445343230554498" WEIGHT="3.2060090478371137">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05964272518573627" CI_END="1.0463548324910077" CI_START="0.5170658500567219" DF="1" EFFECT_SIZE="0.7355503727977586" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="72" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.01967898439830374" LOG_CI_START="-0.2864541445363386" LOG_EFFECT_SIZE="-0.1333875800690175" NO="2" P_CHI2="0.8070615240096046" P_Z="0.08763978427228764" STUDIES="2" TAU2="0.0" TOTAL_1="4602" TOTAL_2="4598" WEIGHT="30.475194352717892" Z="1.7079814512727356">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.3699629484043108" CI_START="0.4410985524912408" EFFECT_SIZE="0.777360066833751" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.13670882152052954" LOG_CI_START="-0.35546436739977927" LOG_EFFECT_SIZE="-0.10937777293962486" ORDER="159" O_E="0.0" SE="0.2891049674683666" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1862" TOTAL_2="1861" VAR="0.08358168221488532" WEIGHT="12.961013064016901">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1141541235378742" CI_START="0.4528747698205254" EFFECT_SIZE="0.7103325223033252" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="45" LOG_CI_END="0.04694527196174891" LOG_CI_START="-0.344021873693153" LOG_EFFECT_SIZE="-0.14853830086570202" ORDER="343" O_E="0.0" SE="0.2296560366762728" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2740" TOTAL_2="2737" VAR="0.05274189518185356" WEIGHT="17.51418128870099">
<FOOTNOTE>Skinner, Lancet (2014). Follow-up time: 43 months. Age range is larger and contains data also for women of 46 years and older. No data reported for age group. 24-45.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1680596186097167" CI_END="0.8551622859377271" CI_START="0.3819008197184622" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714780643138737" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="402" I2="53.87580713111308" I2_Q="53.87580713111308" ID="CMP-003.02" LOG_CI_END="-0.06795146047736605" LOG_CI_START="-0.41804940944856545" LOG_EFFECT_SIZE="-0.24300043496296572" METHOD="IV" NO="2" P_CHI2="0.14090399822256727" P_Q="0.14090399822256727" P_Z="0.006512544266799028" Q="2.1680596186097167" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05337541387761174" TOTALS="YES" TOTAL_1="10424" TOTAL_2="10459" WEIGHT="99.99999999999999" Z="2.720793435977318">
<NAME>CIN2+ associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5922808855522804" CI_START="0.41887078483914153" DF="0" EFFECT_SIZE="0.4980854940434478" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="375" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.2274722829476435" LOG_CI_START="-0.37791992950656655" LOG_EFFECT_SIZE="-0.30269610622710497" NO="1" P_CHI2="1.0" P_Z="3.1009254555884525E-15" STUDIES="1" TAU2="0.0" TOTAL_1="8562" TOTAL_2="8598" WEIGHT="69.12053282842713" Z="7.886776297737296">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.5922808855522804" CI_START="0.41887078483914153" EFFECT_SIZE="0.4980854940434478" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="375" LOG_CI_END="-0.2274722829476435" LOG_CI_START="-0.37791992950656655" LOG_EFFECT_SIZE="-0.30269610622710497" ORDER="166" O_E="0.0" SE="0.08837369231657269" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.007809909493664259" WEIGHT="69.12053282842713">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3699629484043108" CI_START="0.4410985524912408" DF="0" EFFECT_SIZE="0.777360066833751" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.13670882152052954" LOG_CI_START="-0.35546436739977927" LOG_EFFECT_SIZE="-0.10937777293962486" NO="2" P_CHI2="1.0" P_Z="0.3836763500708661" STUDIES="1" TAU2="0.0" TOTAL_1="1862" TOTAL_2="1861" WEIGHT="30.879467171572855" Z="0.8711425185152686">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.3699629484043108" CI_START="0.4410985524912408" EFFECT_SIZE="0.777360066833751" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.13670882152052954" LOG_CI_START="-0.35546436739977927" LOG_EFFECT_SIZE="-0.10937777293962486" ORDER="167" O_E="0.0" SE="0.2891049674683666" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1862" TOTAL_2="1861" VAR="0.08358168221488532" WEIGHT="30.879467171572855">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.009003546570192214" CI_END="0.668339566634152" CI_START="0.4539647930305657" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5508199642725478" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="286" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.17500282727639055" LOG_CI_START="-0.342977827287049" LOG_EFFECT_SIZE="-0.2589903272817198" METHOD="IV" NO="3" P_CHI2="0.9244045670383736" P_Q="1.0" P_Z="1.5043651928521005E-9" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17256" TOTAL_2="17306" WEIGHT="100.0" Z="6.043895981952111">
<NAME>CIN3+ associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7014611826989016" CI_START="0.4381774912850827" EFFECT_SIZE="0.5544046367671105" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="192" LOG_CI_END="-0.15399635686100516" LOG_CI_START="-0.35834993545115845" LOG_EFFECT_SIZE="-0.25617314615608183" ORDER="137" O_E="0.0" SE="0.12003830363038442" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.014409194338460364" WEIGHT="67.5654704159703">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7631563855078956" CI_START="0.3869623141591566" EFFECT_SIZE="0.5434268681262205" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="94" LOG_CI_END="-0.11738645758396297" LOG_CI_START="-0.4123313283910846" LOG_EFFECT_SIZE="-0.2648588929875238" ORDER="136" O_E="0.0" SE="0.17325207711276033" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.03001628222388585" WEIGHT="32.4345295840297">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6793264963739694" CI_START="0.42544872891106217" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5376044962590162" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="198" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.16792144590597685" LOG_CI_START="-0.37115276952214993" LOG_EFFECT_SIZE="-0.26953710771406336" METHOD="IV" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="2.0054181579819217E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8562" TOTAL_2="8598" WEIGHT="100.0" Z="5.1988346502568055">
<NAME>CIN3+ associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6793264963739694" CI_START="0.42544872891106217" EFFECT_SIZE="0.5376044962590162" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="198" LOG_CI_END="-0.16792144590597685" LOG_CI_START="-0.37115276952214993" LOG_EFFECT_SIZE="-0.26953710771406336" ORDER="139" O_E="0.0" SE="0.11937908550341672" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.01425136605563208" WEIGHT="100.0">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12647185419889428" CI_END="0.7782709739338916" CI_START="0.16920646785362187" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3628890774497794" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.1088691665130827" LOG_CI_START="-0.7715830402364074" LOG_EFFECT_SIZE="-0.4402261033747451" METHOD="IV" NO="5" P_CHI2="0.722118634139902" P_Q="1.0" P_Z="0.00921639805837383" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17256" TOTAL_2="17306" WEIGHT="100.0" Z="2.6039210642182136">
<NAME>AIS associated with HPV16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0347756140086897" CI_START="0.15592589008018143" EFFECT_SIZE="0.40168185003503853" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.014846185384423212" LOG_CI_START="-0.8070817681631034" LOG_EFFECT_SIZE="-0.3961177913893401" ORDER="186" O_E="0.0" SE="0.48280454852280486" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.2331002320743094" WEIGHT="65.01066719423217">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0914424999908443" CI_START="0.08272546510777823" EFFECT_SIZE="0.3004830917874396" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.03800086089310375" LOG_CI_START="-1.082360782425302" LOG_EFFECT_SIZE="-0.5221799607660991" ORDER="185" O_E="0.0" SE="0.6581059751648087" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.4331034745476239" WEIGHT="34.98933280576784">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.011861808717903499" CI_END="0.9806181546402505" CI_START="0.1597028317248529" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39573664997931096" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.008500070719560177" LOG_CI_START="-0.7966873832254816" LOG_EFFECT_SIZE="-0.4025937269725209" METHOD="IV" NO="6" P_CHI2="0.913272344732693" P_Q="1.0" P_Z="0.04525916480365792" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10396" TOTAL_2="10434" WEIGHT="100.0" Z="2.0022377745695183">
<NAME>AIS associated with HPV6/11/16/18, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0347756140086897" CI_START="0.15592589008018143" EFFECT_SIZE="0.40168185003503853" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.014846185384423212" LOG_CI_START="-0.8070817681631034" LOG_EFFECT_SIZE="-0.3961177913893401" ORDER="190" O_E="0.0" SE="0.48280454852280486" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.2331002320743094" WEIGHT="91.95839391792713">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.186046302985119" CI_START="0.013602836221282388" EFFECT_SIZE="0.33369663941871025" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9130741968294145" LOG_CI_START="-1.866370530833339" LOG_EFFECT_SIZE="-0.4766481670019623" ORDER="191" O_E="0.0" SE="1.6326595915023971" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1834" TOTAL_2="1836" VAR="2.665577341724774" WEIGHT="8.04160608207287">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.25419266127365" CI_END="0.9653039413502296" CI_START="0.6544243322116029" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7948071383671338" ESTIMABLE="YES" EVENTS_1="900" EVENTS_2="1160" I2="69.2387059499256" I2_Q="85.44604738658872" ID="CMP-003.07" LOG_CI_END="-0.015335920575498423" LOG_CI_START="-0.18414056149324856" LOG_EFFECT_SIZE="-0.09973824103437354" METHOD="IV" NO="7" P_CHI2="0.006154620211941797" P_Q="0.008760694984029316" P_Z="0.02055336171423459" Q="6.870985680402121" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.032684296201590024" TOTALS="YES" TOTAL_1="22512" TOTAL_2="22554" WEIGHT="100.0" Z="2.31608988053825">
<NAME>Any CIN2+ irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.0041383410377005" CI_END="0.8474483210362682" CI_START="0.5805330864785352" DF="3" EFFECT_SIZE="0.7014070069811374" ESTIMABLE="YES" EVENTS_1="735" EVENTS_2="1001" I2="57.16817895467876" ID="CMP-003.07.01" LOG_CI_END="-0.07188677639697483" LOG_CI_START="-0.2361730233576732" LOG_EFFECT_SIZE="-0.154029899877324" NO="1" P_CHI2="0.07176606939435348" P_Z="2.3765580887608571E-4" STUDIES="4" TAU2="0.017053372635586962" TOTAL_1="17868" TOTAL_2="17911" WEIGHT="66.0981914670575" Z="3.6752078994669146">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.9212407619173185" CI_START="0.717511379326867" EFFECT_SIZE="0.8130195137728424" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="520" LOG_CI_END="-0.035626854159701356" LOG_CI_START="-0.14417120687316531" LOG_EFFECT_SIZE="-0.08989903051643333" ORDER="179" O_E="0.0" SE="0.06375949008710018" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.0040652725761670255" WEIGHT="26.754184734981454">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7844268759094251" CI_START="0.2725919613067945" EFFECT_SIZE="0.46241589571068126" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="41" LOG_CI_END="-0.10544753502056664" LOG_CI_START="-0.5644869555871018" LOG_EFFECT_SIZE="-0.33496724530383426" ORDER="512" O_E="0.0" SE="0.2696420279225615" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="464" TOTAL_2="463" VAR="0.07270682322219144" WEIGHT="9.329104362745378">
<FOOTNOTE>Konno, Human Vaccines &amp; Immunother (2014). Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7776484063997554" CI_START="0.5800835342240294" EFFECT_SIZE="0.6716405556308035" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="428" LOG_CI_END="-0.10921671364506695" LOG_CI_START="-0.23650946188481548" LOG_EFFECT_SIZE="-0.1728630877649412" ORDER="178" O_E="0.0" SE="0.07477239042529436" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.005590910369912652" WEIGHT="25.687771277583423">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5183318700367388" CI_START="0.2694660348454836" EFFECT_SIZE="0.6396396396396397" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.18136670803703234" LOG_CI_START="-0.5694959681721966" LOG_EFFECT_SIZE="-0.19406463006758215" ORDER="177" O_E="0.0" SE="0.4410604528354926" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="148" TOTAL_2="142" VAR="0.19453432305544982" WEIGHT="4.327131091747256">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0920198178473237" CI_END="1.3036429472144084" CI_START="0.8298308207448805" DF="1" EFFECT_SIZE="1.0400976381307705" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="159" I2="8.426570318908727" ID="CMP-003.07.02" LOG_CI_END="0.11515865942657995" LOG_CI_START="-0.08101043907699597" LOG_EFFECT_SIZE="0.017074110174791948" NO="2" P_CHI2="0.2960245868049858" P_Z="0.7329668935522711" STUDIES="2" TAU2="0.0024351180597461334" TOTAL_1="4644" TOTAL_2="4643" WEIGHT="33.901808532942496" Z="0.34118157514040026">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="1.7485434895342014" CI_START="0.8425621680427873" EFFECT_SIZE="1.2137778188198356" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.2426764384924706" LOG_CI_START="-0.07439804506570878" LOG_EFFECT_SIZE="0.08413919671338094" ORDER="180" O_E="0.0" SE="0.18625112118608148" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1911" TOTAL_2="1908" VAR="0.03468948014307241" WEIGHT="14.593285479223571">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2435965978279613" CI_START="0.7324581422664564" EFFECT_SIZE="0.9544016207938637" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="108" LOG_CI_END="0.09467952525072641" LOG_CI_START="-0.13521718886070364" LOG_EFFECT_SIZE="-0.020268831804988625" ORDER="246" O_E="0.0" SE="0.1350424678761424" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2733" TOTAL_2="2735" VAR="0.018236468130078957" WEIGHT="19.308523053718922">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months. Age range is larger and contains data for women of 46 years and older</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.499167641958099" CI_END="0.9314222230163244" CI_START="0.48586595472352634" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6727156513985204" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="472" I2="69.22682856973618" I2_Q="84.28701316171183" ID="CMP-003.08" LOG_CI_END="-0.030853404348076704" LOG_CI_START="-0.3134835314653356" LOG_EFFECT_SIZE="-0.1721684679067062" METHOD="IV" NO="8" P_CHI2="0.038790414903715376" P_Q="0.011644826017908727" P_Z="0.01694568388358448" Q="6.364162398222582" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05063817870237293" TOTALS="YES" TOTAL_1="17720" TOTAL_2="17769" WEIGHT="100.0" Z="2.3878841212889093">
<NAME>Any CIN3+ HPV type, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13500524373551964" CI_END="0.7096013843547236" CI_START="0.4313666140096318" DF="1" EFFECT_SIZE="0.5532615533955386" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="172" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="-0.14898554591444865" LOG_CI_START="-0.3651534705280269" LOG_EFFECT_SIZE="-0.25706950822123775" NO="1" P_CHI2="0.7132979495346171" P_Z="3.1372134833787666E-6" STUDIES="2" TAU2="0.0" TOTAL_1="9158" TOTAL_2="9171" WEIGHT="52.3589368501273" Z="4.6616257110089405">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="1.4673252491038582" CI_START="0.2804326511253147" EFFECT_SIZE="0.6414716748768473" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.16652639075850958" LOG_CI_START="-0.5521714223101913" LOG_EFFECT_SIZE="-0.19282251577584086" ORDER="513" O_E="0.0" SE="0.42216665300810596" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="464" TOTAL_2="463" VAR="0.17822468291206653" WEIGHT="12.043058274118138">
<FOOTNOTE>Konno, Human Vaccines &amp; Immunother (2014). Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7077371734467732" CI_START="0.41996035131944814" EFFECT_SIZE="0.5451802931164517" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="158" LOG_CI_END="-0.15012799275306205" LOG_CI_START="-0.3767917096401708" LOG_EFFECT_SIZE="-0.26345985119661636" ORDER="133" O_E="0.0" SE="0.1331433893029817" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.017727162115085338" WEIGHT="40.31587857600916">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9607526171218643" CI_START="0.688656888731664" DF="0" EFFECT_SIZE="0.8134057463209531" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="300" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-0.017388423829488152" LOG_CI_START="-0.16199710384781726" LOG_EFFECT_SIZE="-0.08969276383865271" NO="2" P_CHI2="1.0" P_Z="0.015044151648737297" STUDIES="1" TAU2="0.0" TOTAL_1="8562" TOTAL_2="8598" WEIGHT="47.64106314987271" Z="2.431314451875696">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="0.9607526171218643" CI_START="0.688656888731664" EFFECT_SIZE="0.8134057463209531" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="300" LOG_CI_END="-0.017388423829488152" LOG_CI_START="-0.16199710384781726" LOG_EFFECT_SIZE="-0.08969276383865271" ORDER="141" O_E="0.0" SE="0.08494385446727727" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.007215458411757982" WEIGHT="47.64106314987271">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3728501157090206" CI_END="0.6701290482624228" CI_START="0.14915912620193025" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3161579720351112" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.1738415561774244" LOG_CI_START="-0.8263501694699656" LOG_EFFECT_SIZE="-0.500095862823695" METHOD="IV" NO="9" P_CHI2="0.5414550834745407" P_Q="1.0" P_Z="0.002661818004479189" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17256" TOTAL_2="17306" WEIGHT="100.0" Z="3.004312464186532">
<NAME>Any AIS irrespective of HPV types, at least 1 dose</NAME>
<GROUP_LABEL_1>Favours vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9618955358724459" CI_START="0.14742769002317563" EFFECT_SIZE="0.3765767344078486" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.016872090807936446" LOG_CI_START="-0.8314209391712308" LOG_EFFECT_SIZE="-0.42414651498958367" ORDER="195" O_E="0.0" SE="0.47847002561042706" STUDY_ID="STD-FUT-I_x002f_II-trials-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="8562" TOTAL_2="8598" VAR="0.22893356540764273" WEIGHT="64.17091468461228">
<FOOTNOTE>Munoz, JNCI (2010). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8108289716213457" CI_START="0.06589069916123895" EFFECT_SIZE="0.231140839836492" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.0910707419838478" LOG_CI_START="-1.181175884162024" LOG_EFFECT_SIZE="-0.6361233130729358" ORDER="194" O_E="0.0" SE="0.6403331566229417" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8694" TOTAL_2="8708" VAR="0.4100265514707008" WEIGHT="35.829085315387715">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Infection with HPV vaccine types in hrHPV DNA negative women at baseline</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.20026428429812737" CI_START="0.019983132809893334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06326063381130255" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.6983964971133538" LOG_CI_START="-1.6993364252494532" LOG_EFFECT_SIZE="-1.1988664611814035" METHOD="IV" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.6653218883995326E-6" Q="0.0" RANDOM="YES" SCALE="626.4708135378553" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="193" TOTAL_2="175" WEIGHT="100.0" Z="4.695057156055504">
<NAME>Incident HPV16/18 infection, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20026428429812737" CI_START="0.019983132809893334" EFFECT_SIZE="0.06326063381130256" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="43" LOG_CI_END="-0.6983964971133538" LOG_CI_START="-1.6993364252494532" LOG_EFFECT_SIZE="-1.1988664611814035" ORDER="196" O_E="0.0" SE="0.587957068519698" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="193" TOTAL_2="175" VAR="0.34569351442227686" WEIGHT="100.0">
<FOOTNOTE>De Calvalho, Vaccine (2010). Follow-up time: 88 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.3457100978893433" CI_START="0.0012875760786813925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.021098058019659555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.46128793491066705" LOG_CI_START="-2.8902271004806583" LOG_EFFECT_SIZE="-1.6757575176956627" METHOD="IV" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.006842568470720475" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="193" TOTAL_2="175" WEIGHT="100.0" Z="2.704410574016988">
<NAME>Persistent HPV16/18 infection (6M), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3457100978893433" CI_START="0.0012875760786813925" EFFECT_SIZE="0.021098058019659555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="21" LOG_CI_END="-0.46128793491066705" LOG_CI_START="-2.8902271004806583" LOG_EFFECT_SIZE="-1.6757575176956627" ORDER="206" O_E="0.0" SE="1.426770889298594" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="193" TOTAL_2="175" VAR="2.0356751705499008" WEIGHT="100.0">
<FOOTNOTE>Naud, Hum Vaccin Immunother (2014). Follow-up time: 113 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.09391048718969604" CI_START="0.047561282866702845" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06683190290107717" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="521" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-1.02728590641015" LOG_CI_START="-1.3227464397048152" LOG_EFFECT_SIZE="-1.1750161730574826" METHOD="IV" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="8.627298338262549E-55" Q="0.0" RANDOM="YES" SCALE="700.2076122326761" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5427" TOTAL_2="5399" WEIGHT="100.0" Z="15.589150637238966">
<NAME>Persistent HPV16/18 infection (6M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.09391048718969604" CI_START="0.047561282866702845" EFFECT_SIZE="0.06683190290107718" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="521" LOG_CI_END="-1.02728590641015" LOG_CI_START="-1.3227464397048152" LOG_EFFECT_SIZE="-1.1750161730574826" ORDER="207" O_E="0.0" SE="0.17355497981051407" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5427" TOTAL_2="5399" VAR="0.030121331017027943" WEIGHT="100.0">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7318299998702574" CI_START="0.0025501931670667464" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.043200785468826705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.13558979147271966" LOG_CI_START="-2.5934269222272714" LOG_EFFECT_SIZE="-1.3645083568499956" METHOD="IV" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.02953941769027371" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="193" TOTAL_2="175" WEIGHT="100.0" Z="2.1762119243506484">
<NAME>Persistent HPV16/18 infection(12M), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7318299998702574" CI_START="0.0025501931670667464" EFFECT_SIZE="0.043200785468826705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.13558979147271966" LOG_CI_START="-2.5934269222272714" LOG_EFFECT_SIZE="-1.3645083568499956" ORDER="228" O_E="0.0" SE="1.4437456970952396" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="193" TOTAL_2="175" VAR="2.0844016378810193" WEIGHT="100.0">
<FOOTNOTE>Naud, Hum Vaccin Immunother (2014). Follow-up time: 113 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.037927506528034206" CI_END="0.11605265111230964" CI_START="0.052009769514269485" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07769087228156957" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="326" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-0.9353449340508383" LOG_CI_START="-1.2839150708339493" LOG_EFFECT_SIZE="-1.1096300024423937" METHOD="IV" NO="5" P_CHI2="0.8455888589721221" P_Q="1.0" P_Z="9.768084184374669E-36" Q="0.0" RANDOM="YES" SCALE="513.3226774139575" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7095" TOTAL_2="7058" WEIGHT="100.00000000000001" Z="12.478606807934453">
<NAME>Persistent HPV16/18 infection (12M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0159925216276031" CI_START="0.003390046583169666" EFFECT_SIZE="0.05868783499558993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.006890511266976648" LOG_CI_START="-2.4697943340463167" LOG_EFFECT_SIZE="-1.23145191138967" ORDER="211" O_E="0.0" SE="1.4548169379247362" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1733" TOTAL_2="1729" VAR="2.116492322872706" WEIGHT="1.980791940272731">
<FOOTNOTE>Kuhs, Am J Epidemio (2014). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.1171841984437778" CI_START="0.05209482036580128" EFFECT_SIZE="0.07813251415152987" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="318" LOG_CI_END="-0.9311309462644856" LOG_CI_START="-1.2832054551722025" LOG_EFFECT_SIZE="-1.107168200718344" ORDER="229" O_E="0.0" SE="0.20681030932931957" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="5362" TOTAL_2="5329" VAR="0.042770504044888843" WEIGHT="98.01920805972728">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>HPV16/18 infection in HPV16/18 DNA negative women at baseline</NAME>
<DICH_OUTCOME CHI2="6.26880595790101" CI_END="0.311732220377898" CI_START="0.09597378632007603" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17296855641309847" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="190" I2="52.14399647800723" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.5062183070938953" LOG_CI_START="-1.0178473712431344" LOG_EFFECT_SIZE="-0.7620328391685148" METHOD="IV" NO="1" P_CHI2="0.09924008343217627" P_Q="1.0" P_Z="5.269293528804011E-9" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17620027932432702" TOTALS="YES" TOTAL_1="4022" TOTAL_2="4012" WEIGHT="100.00000000000001" Z="5.838436572365761">
<NAME>Incident HPV16/18 infection, 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5454859142547055" CI_START="0.17248222405697453" EFFECT_SIZE="0.30673542945412047" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="49" LOG_CI_END="-0.2632164594485754" LOG_CI_START="-0.7632556564849826" LOG_EFFECT_SIZE="-0.513236057966779" ORDER="631" O_E="0.0" SE="0.293725499573131" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2497" TOTAL_2="2502" VAR="0.08627466909948538" WEIGHT="34.41103695320807">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.23271879330870104" CI_START="0.06329224051147211" EFFECT_SIZE="0.1213643021552626" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="81" LOG_CI_END="-0.6331685436548231" LOG_CI_START="-1.1986495302608904" LOG_EFFECT_SIZE="-0.9159090369578566" ORDER="166" O_E="0.0" SE="0.3321663307084321" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1003" TOTAL_2="986" VAR="0.11033447125630347" WEIGHT="31.521604731017046">
<FOOTNOTE>Kreimer, Lancet Oncol (2011).Follow-uptime: 54 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.3946138514996381" CI_START="0.0808399956401562" EFFECT_SIZE="0.17860734037204626" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="39" LOG_CI_END="-0.40382767447085455" LOG_CI_START="-1.0923737185790017" LOG_EFFECT_SIZE="-0.7481006965249282" ORDER="198" O_E="0.0" SE="0.4044553546670133" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="408" TOTAL_2="406" VAR="0.1635841339188195" WEIGHT="26.581664130190546">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.36040374171779277" CI_START="0.006741032660111782" EFFECT_SIZE="0.04928989139515455" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="21" LOG_CI_END="-0.4432107088168515" LOG_CI_START="-2.171273568711681" LOG_EFFECT_SIZE="-1.3072421387642665" ORDER="197" O_E="0.0" SE="1.0150726779513375" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="114" TOTAL_2="118" VAR="1.0303725415232998" WEIGHT="7.485694185584353">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.479859971433015" CI_END="0.36551871338315833" CI_START="0.14487334213326364" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23011718236600376" ESTIMABLE="YES" EVENTS_1="407" EVENTS_2="1586" I2="79.465971491243" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.4370903836555088" LOG_CI_START="-0.8390115208747325" LOG_EFFECT_SIZE="-0.6380509522651207" METHOD="IV" NO="2" P_CHI2="6.324182221270069E-4" P_Q="1.0" P_Z="4.880583166111878E-10" Q="0.0" RANDOM="YES" SCALE="534.21" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1876297137339959" TOTALS="YES" TOTAL_1="11909" TOTAL_2="11963" WEIGHT="100.00000000000001" Z="6.222896836893743">
<NAME>Incident HPV16/18 infection, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7393964740244503" CI_START="0.34540986330450874" EFFECT_SIZE="0.5053660406285934" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="78" LOG_CI_END="-0.13112262478722328" LOG_CI_START="-0.46166526515431183" LOG_EFFECT_SIZE="-0.2963939449707676" ORDER="632" O_E="0.0" SE="0.1941623831640862" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2609" TOTAL_2="2637" VAR="0.03769903103595743" WEIGHT="24.736616705438315">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.3803775316497807" CI_START="0.09410886405453493" EFFECT_SIZE="0.18920068027210885" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="49" LOG_CI_END="-0.41978514412343537" LOG_CI_START="-1.026369468722903" LOG_EFFECT_SIZE="-0.7230773064231693" ORDER="201" O_E="0.0" SE="0.3563106349105601" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="432" TOTAL_2="445" VAR="0.12695726855036643" WEIGHT="17.718059252221458">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.2869290524373293" CI_START="0.22848644897599735" EFFECT_SIZE="0.2560456996308532" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="1359" LOG_CI_END="-0.5422254758933331" LOG_CI_START="-0.6411395518718648" LOG_EFFECT_SIZE="-0.591682513882599" ORDER="203" O_E="0.0" SE="0.058102617862362343" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8261" TOTAL_2="8284" VAR="0.0033759142024597077" WEIGHT="29.181709734470274">
<FOOTNOTE>Szarewski, Int J Cancer (2011). Follow-up time: 39 months. Regardless of women's initial cytology results.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.35978082523800325" CI_START="0.034861279209523574" EFFECT_SIZE="0.11199294532627865" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="27" LOG_CI_END="-0.44396198639133666" LOG_CI_START="-1.4576566808105254" LOG_EFFECT_SIZE="-0.9508093336009309" ORDER="200" O_E="0.0" SE="0.595449281371496" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="126" TOTAL_2="127" VAR="0.35455984668583096" WEIGHT="10.280298993171185">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.23794539931016484" CI_START="0.06099125217045912" EFFECT_SIZE="0.12046820265998348" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="73" LOG_CI_END="-0.6235226878962155" LOG_CI_START="-1.2147324503422752" LOG_EFFECT_SIZE="-0.9191275691192453" ORDER="202" O_E="0.0" SE="0.34727954099633807" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="481" TOTAL_2="470" VAR="0.12060307959462724" WEIGHT="18.083315314698776">
<FOOTNOTE>Harper, Lancet (2006). Follow-up time: 54 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.319876273059841" CI_END="0.8392876701582785" CI_START="0.2597836693414337" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4669402858896847" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="47" I2="13.788505739486462" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.07608915699121394" LOG_CI_START="-0.585388153254588" LOG_EFFECT_SIZE="-0.330738655122901" METHOD="IV" NO="3" P_CHI2="0.31350561925291887" P_Q="1.0" P_Z="0.010909000253697036" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04881269752719426" TOTALS="YES" TOTAL_1="148" TOTAL_2="183" WEIGHT="99.99999999999997" Z="2.545600353003159">
<NAME>Incident HPV16/18 infection, 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1033220288253676" CI_START="0.3523024996697853" EFFECT_SIZE="0.6234605911330049" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="0.042702289348580995" LOG_CI_START="-0.45308427538548174" LOG_EFFECT_SIZE="-0.20519099301845037" ORDER="633" O_E="0.0" SE="0.29122748230786444" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="112" TOTAL_2="135" VAR="0.08481344645137749" WEIGHT="66.97757329578212">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1070369143717502" CI_START="0.06625858044315655" EFFECT_SIZE="0.2708333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="0.04416210275827185" LOG_CI_START="-1.1787578728957728" LOG_EFFECT_SIZE="-0.5672978850687505" ORDER="285" O_E="0.0" SE="0.7183492472506957" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="24" TOTAL_2="39" VAR="0.5160256410256411" WEIGHT="15.845161777594775">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9613296128873157" CI_START="0.06501412123598661" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.017127679434027897" LOG_CI_START="-1.1869923032218967" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="286" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="12" TOTAL_2="9" VAR="0.47222222222222215" WEIGHT="17.177264926623085">
<FOOTNOTE>Rowhani-Rahbar, Vaccine (2009). Follow-up time: 102 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.895883020465209" CI_END="0.09152252755913204" CI_START="0.05509028077150926" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0710070541576735" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="912" I2="0.0" I2_Q="67.23059941180534" ID="CMP-005.04" LOG_CI_END="-1.0384719945625671" LOG_CI_START="-1.2589250142085189" LOG_EFFECT_SIZE="-1.148698504385543" METHOD="IV" NO="4" P_CHI2="0.791688639862359" P_Q="0.08065651938957807" P_Z="0.0" Q="3.0516273781347563" RANDOM="YES" SCALE="924.01" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17084" TOTAL_2="17029" WEIGHT="99.99999999999999" Z="20.425283367009058">
<NAME>Persistent HPV16/18 infection (6M), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2332347248798048" CI_END="0.0842695742177057" CI_START="0.047830431626104786" DF="5" EFFECT_SIZE="0.06348740117362606" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="795" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-1.0743292003990166" LOG_CI_START="-1.3202956999979971" LOG_EFFECT_SIZE="-1.1973124501985069" NO="1" P_CHI2="0.9987138532820635" P_Z="0.0" STUDIES="6" TAU2="0.0" TOTAL_1="13701" TOTAL_2="13684" WEIGHT="80.3304468111327" Z="19.081373150054844">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.5029827987905396" CI_START="0.008790765141267233" EFFECT_SIZE="0.06649514008004574" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.29844686686869876" LOG_CI_START="-2.0559733226317576" LOG_EFFECT_SIZE="-1.1772100947502282" ORDER="634" O_E="0.0" SE="1.0323797400114867" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2332" TOTAL_2="2326" VAR="1.065807927586185" WEIGHT="1.5733609306215703">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.1251314357981836" CI_START="0.03267247387685856" EFFECT_SIZE="0.06394023433871632" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="143" LOG_CI_END="-0.902633572171893" LOG_CI_START="-1.4858179806028464" LOG_EFFECT_SIZE="-1.1942257763873696" ORDER="211" O_E="0.0" SE="0.3425654083217216" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2635" TOTAL_2="2677" VAR="0.11735105897862785" WEIGHT="14.289607332101252">
<FOOTNOTE>Herrero, Cancer Discovery (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5441561608436007" CI_START="0.001961890261162476" EFFECT_SIZE="0.032673761223811104" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" LOG_CI_END="-0.2642764494556067" LOG_CI_START="-2.7073252886505" LOG_EFFECT_SIZE="-1.4858008690530533" ORDER="208" O_E="0.0" SE="1.4350589814298724" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="387" TOTAL_2="392" VAR="2.0593942801825427" WEIGHT="0.8142688211517264">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5433231578033039" CI_START="0.009481163349046015" EFFECT_SIZE="0.07177280550774527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.26494178384562583" LOG_CI_START="-2.0231383709875206" LOG_EFFECT_SIZE="-1.144040077416573" ORDER="214" O_E="0.0" SE="1.0327733785006188" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="415" TOTAL_2="417" VAR="1.0666208513395823" WEIGHT="1.572161795547881">
<FOOTNOTE>Yoshikawa, Cancer Science (2013). Follow-up time: 30 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.09120940959124679" CI_START="0.04475747532259157" EFFECT_SIZE="0.06389290178860539" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="497" LOG_CI_END="-1.0399603555010224" LOG_CI_START="-1.349134419113992" LOG_EFFECT_SIZE="-1.1945473873075074" ORDER="212" O_E="0.0" SE="0.18161037540255584" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7177" TOTAL_2="7122" VAR="0.032982328453857256" WEIGHT="50.8423944403093">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.1335633128386567" CI_START="0.029382690695901874" EFFECT_SIZE="0.06264542688383748" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="111" LOG_CI_END="-0.8743128174575523" LOG_CI_START="-1.531908436562225" LOG_EFFECT_SIZE="-1.2031106270098888" ORDER="210" O_E="0.0" SE="0.38627492181289774" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="755" TOTAL_2="750" VAR="0.14920831522156025" WEIGHT="11.238653491400987">
<FOOTNOTE>Mao, Obstet Gynecol (2006). Follow-up time: 48 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6110209174506476" CI_END="0.19878176662887456" CI_START="0.06328563076733394" DF="1" EFFECT_SIZE="0.11216073058853218" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="117" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-0.7016234540213344" LOG_CI_START="-1.198694886931525" LOG_EFFECT_SIZE="-0.9501591704764297" NO="2" P_CHI2="0.43440385987391905" P_Z="6.731766407892651E-14" STUDIES="2" TAU2="0.0" TOTAL_1="3383" TOTAL_2="3345" WEIGHT="19.669553188867283" Z="7.492998512552732">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="0.30604376311976933" CI_START="0.06331004928683423" EFFECT_SIZE="0.13919642857142858" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="50" LOG_CI_END="-0.5142164665822683" LOG_CI_START="-1.1985273483804115" LOG_EFFECT_SIZE="-0.8563719074813398" ORDER="213" O_E="0.0" SE="0.4019675993617255" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1568" TOTAL_2="1559" VAR="0.16157795093662866" WEIGHT="10.378275891544957">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.2026272553996752" CI_START="0.03832345750560921" EFFECT_SIZE="0.08812137658813371" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="67" LOG_CI_END="-0.6933021380796061" LOG_CI_START="-1.416535316193967" LOG_EFFECT_SIZE="-1.0549187271367866" ORDER="338" O_E="0.0" SE="0.42483074888634587" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1815" TOTAL_2="1786" VAR="0.18048116519933347" WEIGHT="9.291277297322326">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.930683229715108" CI_END="0.17395681475289135" CI_START="0.08027677842812911" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11817230078990998" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="915" I2="44.01324208473239" I2_Q="67.91219884935204" ID="CMP-005.05" LOG_CI_END="-0.759558553110102" LOG_CI_START="-1.0954100644227176" LOG_EFFECT_SIZE="-0.9274843087664099" METHOD="IV" NO="5" P_CHI2="0.11186124499706773" P_Q="0.0775057958466262" P_Z="2.614064598146434E-27" Q="3.116449130637319" RANDOM="YES" SCALE="547.1470264381644" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08633626366674024" TOTALS="YES" TOTAL_1="15171" TOTAL_2="15152" WEIGHT="100.0" Z="10.825235439932987">
<NAME>Persistent HPV16/18 infection (6M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5704048179385226" CI_END="0.12486112016256885" CI_START="0.0773312961344036" DF="3" EFFECT_SIZE="0.0982632803185654" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="750" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-0.9035727732150746" LOG_CI_START="-1.11164471063791" LOG_EFFECT_SIZE="-1.0076087419264923" NO="1" P_CHI2="0.666118831992792" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="11389" TOTAL_2="11414" WEIGHT="54.81900993408158" Z="18.982635228415">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.29768059451223483" CI_START="0.028072556496921145" EFFECT_SIZE="0.09141474338137032" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="33" LOG_CI_END="-0.5262494756352553" LOG_CI_START="-1.551718035461412" LOG_EFFECT_SIZE="-1.0389837555483334" ORDER="635" O_E="0.0" SE="0.6023653081931226" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2517" TOTAL_2="2531" VAR="0.36284396451459555" WEIGHT="8.66461332951528">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4019468307607829" CI_START="0.0014800066876867776" EFFECT_SIZE="0.024390243902439025" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="20" LOG_CI_END="-0.39583139127963246" LOG_CI_START="-2.8297363221598384" LOG_EFFECT_SIZE="-1.6127838567197355" ORDER="215" O_E="0.0" SE="1.429687804422749" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="418" TOTAL_2="418" VAR="2.0440072181151407" WEIGHT="1.8269227595163944">
<FOOTNOTE>Konno, Int J Cancer. (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.13002951624508483" CI_START="0.07897215872759539" EFFECT_SIZE="0.10133465150766188" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="663" LOG_CI_END="-0.8859580531750716" LOG_CI_START="-1.1025259902550293" LOG_EFFECT_SIZE="-0.9942420217150504" ORDER="218" O_E="0.0" SE="0.12721307826934528" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7973" TOTAL_2="7995" VAR="0.016183167282762565" WEIGHT="37.96327151261458">
<FOOTNOTE>Szarewski, Int J Cancer (2011). Follow-up time: 39 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.23789123192874667" CI_START="0.013887666700639355" EFFECT_SIZE="0.05747829277241042" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="34" LOG_CI_END="-0.6236215646678058" LOG_CI_START="-1.8573707149649705" LOG_EFFECT_SIZE="-1.2404961398163883" ORDER="216" O_E="0.0" SE="0.7247103580413434" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="481" TOTAL_2="470" VAR="0.5252051030524122" WEIGHT="6.364202332435326">
<FOOTNOTE>Harper, Lancet (2006). Follow-up time: 54 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7506072149929954" CI_END="0.28748957488461513" CI_START="0.09747546020758731" DF="1" EFFECT_SIZE="0.16740125034408043" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="165" I2="42.87696340815086" ID="CMP-005.05.02" LOG_CI_END="-0.5413778993297405" LOG_CI_START="-1.011104705715315" LOG_EFFECT_SIZE="-0.7762413025225278" NO="2" P_CHI2="0.18580052831243443" P_Z="9.305163677409131E-11" STUDIES="2" TAU2="0.06668127019191397" TOTAL_1="3782" TOTAL_2="3738" WEIGHT="45.18099006591842" Z="6.477829136316191">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="0.3520344202677441" CI_START="0.12826384165201488" EFFECT_SIZE="0.21249302844394868" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="84" LOG_CI_END="-0.4534148711766288" LOG_CI_START="-0.8918957565964982" LOG_EFFECT_SIZE="-0.6726553138865635" ORDER="219" O_E="0.0" SE="0.25756584261101984" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1793" TOTAL_2="1778" VAR="0.06634016327992465" WEIGHT="25.491643145502202">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.2339660881203386" CI_START="0.06325860710468122" EFFECT_SIZE="0.12165676653694082" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="81" LOG_CI_END="-0.630847086220208" LOG_CI_START="-1.1988803750730106" LOG_EFFECT_SIZE="-0.9148637306466093" ORDER="339" O_E="0.0" SE="0.33366556568226435" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1989" TOTAL_2="1960" VAR="0.11133270972206546" WEIGHT="19.68934692041622">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9398254926441263" CI_END="0.44024759651452705" CI_START="0.15736541364580556" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2632104578698959" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="71" I2="0.0" I2_Q="44.81797538504648" ID="CMP-005.06" LOG_CI_END="-0.35630300633928297" LOG_CI_START="-0.8030907123410163" LOG_EFFECT_SIZE="-0.5796968593401497" METHOD="IV" NO="6" P_CHI2="0.5849898732713826" P_Q="0.17824657443689262" P_Z="3.656610137984635E-7" Q="1.812184324474776" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="624" WEIGHT="100.0" Z="5.086017144138998">
<NAME>Persistent HPV16/18 infection (6M), 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10518089501443059" CI_END="0.4243005453983011" CI_START="0.032145521211549656" DF="1" EFFECT_SIZE="0.11678767992461009" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="23" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="-0.3723264099884622" LOG_CI_START="-1.4928795281397027" LOG_EFFECT_SIZE="-0.9326029690640825" NO="1" P_CHI2="0.7456988079345859" P_Z="0.0011045784893560736" STUDIES="2" TAU2="0.0" TOTAL_1="206" TOTAL_2="231" WEIGHT="15.897818404451813" Z="3.26243923939359">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.5531515172778754" CI_START="0.030626861732031895" EFFECT_SIZE="0.13015873015873017" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.2571558920142992" LOG_CI_START="-1.5138975021254306" LOG_EFFECT_SIZE="-0.885526697069865" ORDER="636" O_E="0.0" SE="0.7382162427505792" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="175" TOTAL_2="205" VAR="0.5449632210607821" WEIGHT="12.638933812915091" />
<DICH_DATA CI_END="1.3252473349151486" CI_START="0.0044396145069517425" EFFECT_SIZE="0.07670454545454546" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12229693952905565" LOG_CI_START="-2.352654738167343" LOG_EFFECT_SIZE="-1.1151788993191436" ORDER="287" O_E="0.0" SE="1.453798866687254" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="31" TOTAL_2="26" VAR="2.1135311447811445" WEIGHT="3.258884591536722">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.022460273154920808" CI_END="0.5377834994082697" CI_START="0.17515331036960471" DF="1" EFFECT_SIZE="0.30691132299657636" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="48" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="-0.26939252718871753" LOG_CI_START="-0.7565816501723442" LOG_EFFECT_SIZE="-0.5129870886805309" NO="2" P_CHI2="0.880869151374889" P_Z="3.6673061914188585E-5" STUDIES="2" TAU2="0.0" TOTAL_1="399" TOTAL_2="393" WEIGHT="84.10218159554819" Z="4.127498628008925">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="0.605568529457164" CI_START="0.1637523089165418" EFFECT_SIZE="0.3149019607843137" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="34" LOG_CI_END="-0.2178367025935681" LOG_CI_START="-0.7858125677169804" LOG_EFFECT_SIZE="-0.5018246351552742" ORDER="289" O_E="0.0" SE="0.33363183469936847" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="225" TOTAL_2="219" VAR="0.11131020112486673" WEIGHT="61.87891147311488">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8507671407864688" CI_START="0.09595181706919398" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.07018929221864954" LOG_CI_START="-1.017946796481902" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="340" O_E="0.0" SE="0.5567174494795436" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="174" TOTAL_2="174" VAR="0.3099343185550082" WEIGHT="22.22327012243331">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016). Follow-up time: 71 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32392067734512214" CI_END="0.21234791839391437" CI_START="0.06458389685018609" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11710788213397208" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-0.6729519919582911" LOG_CI_START="-1.189875754155117" LOG_EFFECT_SIZE="-0.9314138730567041" METHOD="IV" NO="7" P_CHI2="0.5692610693488285" P_Q="1.0" P_Z="1.6284871257262793E-12" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2000" TOTAL_2="2008" WEIGHT="100.0" Z="7.0630827189445515">
<NAME>Persistent HPV6/11/16/18 infection (6M), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.21039461779813035" CI_START="0.05362350134427376" EFFECT_SIZE="0.10621721174238197" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="85" LOG_CI_END="-0.6769653742638787" LOG_CI_START="-1.2706448321873052" LOG_EFFECT_SIZE="-0.9738051032255919" ORDER="168" O_E="0.0" SE="0.34873025234493304" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1581" TOTAL_2="1586" VAR="0.1216127889005607" WEIGHT="75.81391934342345">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5333542169970099" CI_START="0.04741507373972895" EFFECT_SIZE="0.1590252480844115" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.272984266784366" LOG_CI_START="-1.32408356969121" LOG_EFFECT_SIZE="-0.798533918237788" ORDER="227" O_E="0.0" SE="0.6174209335529428" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="419" TOTAL_2="422" VAR="0.3812086091893875" WEIGHT="24.186080656576543">
<FOOTNOTE>Yoshikawa, Cancer Sc (2013). Follow-up time: 30 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8206658115443304" CI_END="0.3662620593654362" CI_START="0.04585419434541836" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12959418062357533" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="187" I2="73.82655146183028" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-0.4362080670347144" LOG_CI_START="-1.3386209326710243" LOG_EFFECT_SIZE="-0.8874144998528694" METHOD="IV" NO="8" P_CHI2="0.05062416377988843" P_Q="1.0" P_Z="1.1583487188608827E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4294552822961695" TOTALS="YES" TOTAL_1="2067" TOTAL_2="2062" WEIGHT="100.0" Z="3.854777619651583">
<NAME>Persistent HPV6/11/16/18 infection (6M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3051038416011654" CI_START="0.13270263639758134" EFFECT_SIZE="0.20121651064339802" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="129" LOG_CI_END="-0.5155523240662645" LOG_CI_START="-0.8771204489400254" LOG_EFFECT_SIZE="-0.6963363865031449" ORDER="169" O_E="0.0" SE="0.21238690634193058" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1811" TOTAL_2="1808" VAR="0.04510819798549599" WEIGHT="59.20950720224481">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.18567456487595974" CI_START="0.025217328929121118" EFFECT_SIZE="0.06842672413793104" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="58" LOG_CI_END="-0.731247585170227" LOG_CI_START="-1.5983009166835456" LOG_EFFECT_SIZE="-1.1647742509268864" ORDER="226" O_E="0.0" SE="0.5093114189141346" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="256" TOTAL_2="254" VAR="0.25939812143632907" WEIGHT="40.7904927977552">
<FOOTNOTE>Villa, Br J Cancer (2006). Follow-up time: 60 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2638013851466215" CI_END="0.1318626529869611" CI_START="0.06255651598746259" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09082327983357606" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="330" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-0.8798781907945975" LOG_CI_START="-1.2037274468016919" LOG_EFFECT_SIZE="-1.0418028187981447" METHOD="IV" NO="9" P_CHI2="0.9666861980940173" P_Q="1.0" P_Z="1.8560800132404055E-36" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11146" TOTAL_2="11121" WEIGHT="100.0" Z="12.610163314946396">
<NAME>Persistent HPV16/18 infection (12M), 3 doses</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.0862494958661495" CI_START="0.009439974335149346" EFFECT_SIZE="0.19640287769784173" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6113248800081102" LOG_CI_START="-2.025029186434788" LOG_EFFECT_SIZE="-0.706852153213339" ORDER="637" O_E="0.0" SE="1.5486074287916578" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="1111" TOTAL_2="1091" VAR="2.3981849685087093" WEIGHT="1.5089621100765571">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.18787889923686701" CI_START="0.04438717004236657" EFFECT_SIZE="0.09132038462358484" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="89" LOG_CI_END="-0.7261219929680041" LOG_CI_START="-1.3527425430612" LOG_EFFECT_SIZE="-1.039432268014602" ORDER="231" O_E="0.0" SE="0.3680800129464918" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2635" TOTAL_2="2677" VAR="0.13548289593068955" WEIGHT="26.710163121152043">
<FOOTNOTE>Herrero, Cancer Discovery (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.375379373611508" CI_START="0.004396752971124769" EFFECT_SIZE="0.07776376628835645" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.13842250699606207" LOG_CI_START="-2.3568679342645673" LOG_EFFECT_SIZE="-1.1092227136342525" ORDER="230" O_E="0.0" SE="1.4657459570833864" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="365" TOTAL_2="369" VAR="2.1484112107062923" WEIGHT="1.6843936730553133">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.1396713118306554" CI_START="0.057319156807792114" EFFECT_SIZE="0.08947536993145859" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="233" LOG_CI_END="-0.8548927878234807" LOG_CI_START="-1.241700206907221" LOG_EFFECT_SIZE="-1.0482964973653508" ORDER="232" O_E="0.0" SE="0.22721259269739383" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7035" TOTAL_2="6984" VAR="0.051625562280271785" WEIGHT="70.09648109571609">
<FOOTNOTE>Paavonen, Lancet (2009). Follow-up time: 35 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7877923982028565" CI_END="0.19565174559967852" CI_START="0.12333266655457847" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.15533914992965028" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="538" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-0.7085162729821812" LOG_CI_START="-0.9089218785914512" LOG_EFFECT_SIZE="-0.8087190757868162" METHOD="IV" NO="10" P_CHI2="0.7747150773123453" P_Q="1.0" P_Z="2.3187135986382754E-56" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14717" TOTAL_2="14747" WEIGHT="100.00000000000001" Z="15.81852221482332">
<NAME>Persistent HPV16/18 infection (12M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7509790152702515" CI_START="0.03769783633830771" EFFECT_SIZE="0.16825660168671366" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.12437219838819323" LOG_CI_START="-1.423683575345909" LOG_EFFECT_SIZE="-0.7740278868670512" ORDER="638" O_E="0.0" SE="0.7632219345200072" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="2411" TOTAL_2="2434" VAR="0.5825077213324622" WEIGHT="2.37899345863494">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.26097977727344285" CI_START="0.11754328434077849" EFFECT_SIZE="0.17514685314685316" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="160" LOG_CI_END="-0.5833931438449241" LOG_CI_START="-0.9298021785939775" LOG_EFFECT_SIZE="-0.7565976612194507" ORDER="130" O_E="0.0" SE="0.20348238176397113" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3575" TOTAL_2="3578" VAR="0.04140507968833849" WEIGHT="33.468890027147324">
<FOOTNOTE>Kreimer, J Natl Cancer Inst (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9123652313379169" CI_START="0.0031112125715171152" EFFECT_SIZE="0.053278158541316435" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.039831273292141076" LOG_CI_START="-2.507070314997688" LOG_EFFECT_SIZE="-1.2734507941449145" ORDER="233" O_E="0.0" SE="1.4492684261280637" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="406" TOTAL_2="411" VAR="2.100378970971715" WEIGHT="0.6597771534596715">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.20065016249382844" CI_START="0.11176316765754793" EFFECT_SIZE="0.14975078547811355" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="341" LOG_CI_END="-0.6975604842224701" LOG_CI_START="-0.9517012976893465" LOG_EFFECT_SIZE="-0.8246308909559084" ORDER="235" O_E="0.0" SE="0.1492835718477589" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="7844" TOTAL_2="7854" VAR="0.022285584823624995" WEIGHT="62.182889505560645">
<FOOTNOTE>Szarewski, Int J Cancer (2011). Follow-up time: 39 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4586618741772322" CI_START="0.008131542879675062" EFFECT_SIZE="0.061070686070686074" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="16" LOG_CI_END="-0.3385073586746535" LOG_CI_START="-2.0898270435134245" LOG_EFFECT_SIZE="-1.214167201094039" ORDER="234" O_E="0.0" SE="1.0287338520465485" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="481" TOTAL_2="470" VAR="1.0582933383465298" WEIGHT="1.3094498551974336">
<FOOTNOTE>Harper, Lancet (2006). Follow-up time: 54 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5177356457022688" CI_END="0.32803594212176396" CI_START="0.055245466902552505" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1346198305723772" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-0.4840785690627945" LOG_CI_START="-1.2577033516695437" LOG_EFFECT_SIZE="-0.8708909603661691" METHOD="IV" NO="11" P_CHI2="0.77192505948167" P_Q="1.0" P_Z="1.020554227707207E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1959" TOTAL_2="1953" WEIGHT="100.0" Z="4.412772070273386">
<NAME>Persistent HPV16/18 infection (12M), 1 or 2 doses (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9411703530326572" CI_START="0.0453583318069965" EFFECT_SIZE="0.20661538461538462" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.026331761603443096" LOG_CI_START="-1.3433429263448375" LOG_EFFECT_SIZE="-0.6848373439741402" ORDER="639" O_E="0.0" SE="0.7736188774795025" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="1300" TOTAL_2="1343" VAR="0.5984861675926456" WEIGHT="34.504984293305085">
<FOOTNOTE>Zhu, Int J Cancer (2014). Follow-up: 15 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.3347910750173314" CI_START="0.031150199360003194" EFFECT_SIZE="0.1021215390147429" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="27" LOG_CI_END="-0.47522612810526643" LOG_CI_START="-1.5065391695289772" LOG_EFFECT_SIZE="-0.9908826488171218" ORDER="717" O_E="0.0" SE="0.6057983856141764" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="618" TOTAL_2="568" VAR="0.3669916840127424" WEIGHT="56.27036445825179">
<FOOTNOTE>Kreimer, J Natl Cancer Inst (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.745988347730392" CI_START="0.007790109464552641" EFFECT_SIZE="0.14625850340136054" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43869869002851153" LOG_CI_START="-2.108456439693653" LOG_EFFECT_SIZE="-0.8348788748325707" ORDER="291" O_E="0.0" SE="1.4962115318200409" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="41" TOTAL_2="42" VAR="2.2386489479512734" WEIGHT="9.22465124844312">
<FOOTNOTE>Konno, Int J Gynecol Cancer (2010). Follow-up time: 24 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Infection with HPV types included in the vaccine in women regardless of HPV DNA status at baseline</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.33090410438429935" CI_START="0.1679463275926731" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23574165757601187" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="170" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.4802978460151302" LOG_CI_START="-0.7748294882419346" LOG_EFFECT_SIZE="-0.6275636671285324" METHOD="IV" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="6.696997394144726E-17" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2103" TOTAL_2="2107" WEIGHT="100.0" Z="8.352258360279281">
<NAME>Incident HPV16/18 infection, at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.33090410438429935" CI_START="0.1679463275926731" EFFECT_SIZE="0.23574165757601187" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="170" LOG_CI_END="-0.4802978460151302" LOG_CI_START="-0.7748294882419346" LOG_EFFECT_SIZE="-0.6275636671285324" ORDER="170" O_E="0.0" SE="0.17300934459916753" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2103" TOTAL_2="2107" VAR="0.029932233318633497" WEIGHT="100.0">
<FOOTNOTE>kreimer, Lancet Oncol (2011). Follow-up time: 54 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.664711387326076" CI_END="0.5682214072293648" CI_START="0.4120325019301101" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4838653615118188" ESTIMABLE="YES" EVENTS_1="893" EVENTS_2="1991" I2="68.95923861798829" I2_Q="78.48489704619105" ID="CMP-006.02" LOG_CI_END="-0.24548240865170504" LOG_CI_START="-0.3850685246169677" LOG_EFFECT_SIZE="-0.3152754666343364" METHOD="IV" NO="2" P_CHI2="0.021642172701614282" P_Q="0.031091671327554637" P_Z="8.464560217345015E-19" Q="4.647897814604526" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017257749711912993" TOTALS="YES" TOTAL_1="16911" TOTAL_2="16936" WEIGHT="100.0" Z="8.853725251100709">
<NAME>Persistent HPV16/18 infection (6M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.613621073435041" CI_END="0.5055961310699644" CI_START="0.37923191624638936" DF="1" EFFECT_SIZE="0.4378791952495839" ESTIMABLE="YES" EVENTS_1="735" EVENTS_2="1713" I2="61.738906601112" ID="CMP-006.02.01" LOG_CI_END="-0.29619625802747945" LOG_CI_START="-0.4210951194711048" LOG_EFFECT_SIZE="-0.3586456887492921" NO="1" P_CHI2="0.10594963531622248" P_Z="2.1628565198820223E-29" STUDIES="2" TAU2="0.006796901717891001" TOTAL_1="12590" TOTAL_2="12609" WEIGHT="62.993505184598234" Z="11.256029479123033">
<NAME>Age group 15-26 years</NAME>
<DICH_DATA CI_END="0.5539632238933745" CI_START="0.41045224177254797" EFFECT_SIZE="0.47683901592317657" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="486" LOG_CI_END="-0.2565190659400162" LOG_CI_START="-0.3867373679995219" LOG_EFFECT_SIZE="-0.3216282169697691" ORDER="222" O_E="0.0" SE="0.07649087522074466" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3727" TOTAL_2="3739" VAR="0.00585085399203553" WEIGHT="29.092828394964638">
<FOOTNOTE>Herrero, Cancer Discovery (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.45405711106824465" CI_START="0.3721750084179422" EFFECT_SIZE="0.4110823629566835" ESTIMABLE="YES" EVENTS_1="504" EVENTS_2="1227" LOG_CI_END="-0.3428895183722502" LOG_CI_START="-0.4292527931358998" LOG_EFFECT_SIZE="-0.386071155754075" ORDER="223" O_E="0.0" SE="0.050730215101272624" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8863" TOTAL_2="8870" VAR="0.002573554724221389" WEIGHT="33.90067678963359">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05058804794135075" CI_END="0.6885293318858281" CI_START="0.47060030558212956" DF="1" EFFECT_SIZE="0.5692294036570232" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="278" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="-0.16207755372976435" LOG_CI_START="-0.32734779515279494" LOG_EFFECT_SIZE="-0.24471267444127956" NO="2" P_CHI2="0.8220431689384352" P_Z="6.4686837326779115E-9" STUDIES="2" TAU2="0.0" TOTAL_1="4321" TOTAL_2="4327" WEIGHT="37.00649481540177" Z="5.804166852249141">
<NAME>Age group 24-45 years</NAME>
<DICH_DATA CI_END="0.7447095553234194" CI_START="0.45161090189121406" EFFECT_SIZE="0.5799301284867121" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="157" LOG_CI_END="-0.1280130737145591" LOG_CI_START="-0.34523558274784677" LOG_EFFECT_SIZE="-0.23662432823120294" ORDER="224" O_E="0.0" SE="0.12759757707491462" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1856" TOTAL_2="1857" VAR="0.01628114167538878" WEIGHT="20.045225533625043">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7438866433438158" CI_START="0.41383971197573305" EFFECT_SIZE="0.5548421705530318" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="121" LOG_CI_END="-0.12849323907916183" LOG_CI_START="-0.38316783685925154" LOG_EFFECT_SIZE="-0.2558305379692067" ORDER="342" O_E="0.0" SE="0.14959711939561535" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2465" TOTAL_2="2470" VAR="0.02237929813146599" WEIGHT="16.96126928177673">
<FOOTNOTE>Skinner, Lancet (2014). Follow-up time: 43 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6508328493967879" CI_START="0.41804098130942247" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5216079016179114" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="211" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.18653053509639275" LOG_CI_START="-0.3787811414686682" LOG_EFFECT_SIZE="-0.2826558382825305" METHOD="IV" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="8.250379139028737E-9" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1856" TOTAL_2="1857" WEIGHT="100.0" Z="5.763261541874957">
<NAME>Persistent HPV6/11/16/18 infection (6M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6508328493967879" CI_START="0.41804098130942247" EFFECT_SIZE="0.5216079016179114" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="211" LOG_CI_END="-0.18653053509639275" LOG_CI_START="-0.3787811414686682" LOG_EFFECT_SIZE="-0.2826558382825305" ORDER="204" O_E="0.0" SE="0.1129289578389242" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1856" TOTAL_2="1857" VAR="0.012752949518585521" WEIGHT="100.0">
<FOOTNOTE>Castellsague, Br J Cancer (2011). Follow-up time: 45 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7322257006189878" CI_END="0.5370985361469839" CI_START="0.4016539775762113" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46446502924740907" ESTIMABLE="YES" EVENTS_1="488" EVENTS_2="1068" I2="42.27080226077564" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.26994603128518463" LOG_CI_START="-0.39614792786440955" LOG_EFFECT_SIZE="-0.3330469795747971" METHOD="IV" NO="4" P_CHI2="0.18812700760991907" P_Q="1.0" P_Z="4.423209446124697E-25" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00489871379684068" TOTALS="YES" TOTAL_1="12375" TOTAL_2="12410" WEIGHT="99.99999999999999" Z="10.344695330575648">
<NAME>Persistent HPV16/18 infection (12M), at least 1 dose</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.616179010824181" CI_START="0.4220220226053073" EFFECT_SIZE="0.5099422638249926" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="301" LOG_CI_END="-0.21029309933048432" LOG_CI_START="-0.3746648854212448" LOG_EFFECT_SIZE="-0.2924789923758646" ORDER="236" O_E="0.0" SE="0.09655280080317633" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3727" TOTAL_2="3739" VAR="0.009322443342937846" WEIGHT="38.64310650658056">
<FOOTNOTE>Herrero, Cancer Discovery (2011). Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4961646923091971" CI_START="0.386527182113711" EFFECT_SIZE="0.43792823656689506" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="767" LOG_CI_END="-0.30437414389464884" LOG_CI_START="-0.41281995937335897" LOG_EFFECT_SIZE="-0.3585970516340039" ORDER="237" O_E="0.0" SE="0.0637016088276386" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="8648" TOTAL_2="8671" VAR="0.004057894967229485" WEIGHT="61.35689349341943">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011). Follow-up time: 44 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0172740021598032" CI_END="0.2712293046912315" CI_START="0.12267383066929409" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18240816263600296" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="160" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.5666633893693532" LOG_CI_START="-0.9112480730356015" LOG_EFFECT_SIZE="-0.7389557312024774" METHOD="IV" NO="5" P_CHI2="0.6013146824690236" P_Q="1.0" P_Z="4.234514091565973E-17" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3575" TOTAL_2="3578" WEIGHT="100.0" Z="8.406215876554233">
<NAME>Persistent HPV16/18 infection (12M) by dose (post hoc analysis)</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vaccine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.29244335884149997" CI_START="0.12518875321803047" EFFECT_SIZE="0.19133901714041615" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="133" LOG_CI_END="-0.5339582366745311" LOG_CI_START="-0.9024346857801137" LOG_EFFECT_SIZE="-0.7181964612273224" ORDER="309" O_E="0.0" SE="0.2164448901924592" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2957" TOTAL_2="3010" VAR="0.04684839049042572" WEIGHT="87.45254819707391">
<FOOTNOTE>Kreimer, J Natl Cancer Inst (2011). 3 doses. Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7741643857917262" CI_START="0.002695996835780965" EFFECT_SIZE="0.04568527918781726" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.11116681158835523" LOG_CI_START="-2.5692806218561812" LOG_EFFECT_SIZE="-1.3402237167222681" ORDER="307" O_E="0.0" SE="1.4439082200109223" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="196" TOTAL_2="188" VAR="2.0848709478151104" WEIGHT="1.9651149782737647">
<FOOTNOTE>Kreimer, J Natl Cancer Inst (2011). 1 dose. Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.5379930409532317" CI_START="0.04693645659029611" EFFECT_SIZE="0.15890716476163924" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.26922334198260256" LOG_CI_START="-1.3284897000243479" LOG_EFFECT_SIZE="-0.7988565210034753" ORDER="308" O_E="0.0" SE="0.6222183021667589" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="422" TOTAL_2="380" VAR="0.3871556155512841" WEIGHT="10.58233682465233">
<FOOTNOTE>Kreimer, J Natl Cancer Inst (2011). 2 doses. Follow-up time: 50 months.</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="104.1804772591145" CI_END="1.1992225917715245" CI_START="1.1613483937821674" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1801335647888114" ESTIMABLE="YES" EVENTS_1="7492" EVENTS_2="6172" I2="93.28089083083215" I2_Q="98.04050361751938" ID="CMP-007.01" LOG_CI_END="0.07889980145237384" LOG_CI_START="0.06496252361431001" LOG_EFFECT_SIZE="0.07193116253334192" METHOD="IV" NO="1" P_CHI2="4.440892098500626E-16" P_Q="9.082734564458406E-13" P_Z="0.0" Q="51.03352110985014" RANDOM="NO" SCALE="4.17395508633698" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9099" TOTAL_2="9014" WEIGHT="100.0" Z="20.23099339333154">
<NAME>Overall local/injection site adverse events</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="42.201872253724765" CI_END="1.333143981014767" CI_START="1.2557334362994774" DF="1" EFFECT_SIZE="1.2938599121858743" ESTIMABLE="YES" EVENTS_1="2647" EVENTS_2="1984" I2="97.63043688207047" ID="CMP-007.01.01" LOG_CI_END="0.12487705622813343" LOG_CI_START="0.09889745832577002" LOG_EFFECT_SIZE="0.11188725727695167" NO="1" P_CHI2="8.232337034286275E-11" P_Z="6.094518734990849E-64" STUDIES="2" TAU2="0.0" TOTAL_1="3257" TOTAL_2="3246" WEIGHT="28.780018279015028" Z="16.88209304978066">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="3.363692805733935" CI_START="2.1534261290126526" EFFECT_SIZE="2.6913684210526316" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="75" LOG_CI_END="0.5268163263451079" LOG_CI_START="0.3331299783449914" LOG_EFFECT_SIZE="0.4299731523450496" ORDER="199" O_E="0.0" SE="0.11377231957815367" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="380" TOTAL_2="376" VAR="0.01294414070219353" WEIGHT="0.517795050108367">
<FOOTNOTE>Hildesheim, Vaccine (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3157331775249779" CI_START="1.2386577402218637" EFFECT_SIZE="1.2766139136042742" ESTIMABLE="YES" EVENTS_1="2443" EVENTS_2="1909" LOG_CI_END="0.11916782599710218" LOG_CI_START="0.09295132084977024" LOG_EFFECT_SIZE="0.10605957342343622" ORDER="182" O_E="0.0" SE="0.015399704897336197" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2877" TOTAL_2="2870" VAR="2.3715091092504047E-4" WEIGHT="28.26222322890666">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.94508389553959" CI_END="1.158890391026987" CI_START="1.1156485898258202" DF="5" EFFECT_SIZE="1.1370639518127164" ESTIMABLE="YES" EVENTS_1="4845" EVENTS_2="4188" I2="54.31738991020771" ID="CMP-007.01.02" LOG_CI_END="0.06404236191422213" LOG_CI_START="0.04752742082679258" LOG_EFFECT_SIZE="0.05578489137050736" NO="2" P_CHI2="0.052479786899743974" P_Z="5.093179618835802E-40" STUDIES="6" TAU2="0.0" TOTAL_1="5842" TOTAL_2="5768" WEIGHT="71.21998172098498" Z="13.240904389407179">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="2.372397998078905" CI_START="0.8777442056792388" EFFECT_SIZE="1.4430379746835442" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="9" LOG_CI_END="0.37518754888698774" LOG_CI_START="-0.056632028794925536" LOG_EFFECT_SIZE="0.15927776004603114" ORDER="571" O_E="0.0" SE="0.2536529574717392" STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="79" TOTAL_2="19" VAR="0.06433982283415994" WEIGHT="0.10417206153610266">
<FOOTNOTE>Mugo, Hum Vaccine Immunother (2015).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1501368585012428" CI_START="1.0934536270456943" EFFECT_SIZE="1.12143716699917" ESTIMABLE="YES" EVENTS_1="2320" EVENTS_2="2068" LOG_CI_END="0.06074952153227005" LOG_CI_START="0.0388003694996612" LOG_EFFECT_SIZE="0.04977494551596563" ORDER="105" O_E="0.0" SE="0.012893040554009295" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="1.662304947273283E-4" WEIGHT="40.31999059195591">
<FOOTNOTE>Garland, New Engl J Med (2007), population who completed the safety diary card</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1548387385457144" CI_START="1.017097967346789" EFFECT_SIZE="1.0837823275862069" ESTIMABLE="YES" EVENTS_1="378" EVENTS_2="348" LOG_CI_END="0.06252134366595849" LOG_CI_START="0.0073627863829152235" LOG_EFFECT_SIZE="0.03494206502443688" ORDER="106" O_E="0.0" SE="0.0324004095873217" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="448" TOTAL_2="447" VAR="0.0010497865414262082" WEIGHT="6.384547447518577">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2451166489223628" CI_START="1.1452089515613502" EFFECT_SIZE="1.1941183911505429" ESTIMABLE="YES" EVENTS_1="1450" EVENTS_2="1213" LOG_CI_END="0.0952100402752767" LOG_CI_START="0.0588847340391392" LOG_EFFECT_SIZE="0.07704738715720795" ORDER="66" O_E="0.0" SE="0.021337664696272986" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1890" TOTAL_2="1888" VAR="4.552959346905745E-4" WEIGHT="14.721001161710582">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2621008760310617" CI_START="1.102880298447828" EFFECT_SIZE="1.1798076923076923" ESTIMABLE="YES" EVENTS_1="409" EVENTS_2="338" LOG_CI_END="0.10109406818291822" LOG_CI_START="0.04252837867352962" LOG_EFFECT_SIZE="0.0718112234282239" ORDER="67" O_E="0.0" SE="0.03440177592265346" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="480" TOTAL_2="468" VAR="0.0011834821866324595" WEIGHT="5.663297732071014">
<FOOTNOTE>Yoshikawa, Cancer Sc (2013).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2044477472528057" CI_START="1.0264442042849509" EFFECT_SIZE="1.1118895671476137" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="212" LOG_CI_END="0.08078796367681765" LOG_CI_START="0.011335346858343616" LOG_EFFECT_SIZE="0.04606165526758062" ORDER="62" O_E="0.0" SE="0.04079681091516961" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="272" TOTAL_2="274" VAR="0.001664379780848102" WEIGHT="4.026972726192798">
<FOOTNOTE>Villa, Lancet Oncol (2005).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="519.3511448989927" CI_END="1.4931664852214088" CI_START="1.2257719479748919" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3528790009607914" ESTIMABLE="YES" EVENTS_1="10591" EVENTS_2="8329" I2="97.68942456026859" I2_Q="90.37349934704365" ID="CMP-007.02" LOG_CI_END="0.17410823343297507" LOG_CI_START="0.08840967821766332" LOG_EFFECT_SIZE="0.1312589558253192" METHOD="IV" NO="2" P_CHI2="6.661338147750939E-16" P_Q="3.080028229995868E-5" P_Z="1.926320343902728E-9" Q="20.775981554478857" RANDOM="YES" SCALE="16.575700908405878" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.027794032518162395" TOTALS="YES" TOTAL_1="12887" TOTAL_2="12804" WEIGHT="100.0" Z="6.003901125744871">
<NAME>Pain at injection site</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0855965676716" CI_START="1.0112990647034297" DF="0" EFFECT_SIZE="1.0477894795862108" ESTIMABLE="YES" EVENTS_1="975" EVENTS_2="947" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.035668461545895196" LOG_CI_START="0.0048796055850155815" LOG_EFFECT_SIZE="0.020274033565455384" NO="1" P_CHI2="1.0" P_Z="0.009845237108301154" STUDIES="1" TAU2="0.0" TOTAL_1="1130" TOTAL_2="1150" WEIGHT="9.011344847899577" Z="2.5812180654024885">
<NAME>Monovalent vaccine</NAME>
<DICH_DATA CI_END="1.0855965676716" CI_START="1.0112990647034297" EFFECT_SIZE="1.0477894795862108" ESTIMABLE="YES" EVENTS_1="975" EVENTS_2="947" LOG_CI_END="0.035668461545895196" LOG_CI_START="0.0048796055850155815" LOG_EFFECT_SIZE="0.020274033565455384" ORDER="68" O_E="0.0" SE="0.018085526398715666" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="1130" TOTAL_2="1150" VAR="3.270862651186412E-4" WEIGHT="9.011344847899577">
<FOOTNOTE>Koutsky, New Engl J Med (2002).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="438.1231748568761" CI_END="1.7484448227009644" CI_START="1.2646280550238933" DF="7" EFFECT_SIZE="1.4869876850360653" ESTIMABLE="YES" EVENTS_1="6825" EVENTS_2="4990" I2="98.4022757978309" ID="CMP-007.02.02" LOG_CI_END="0.24265193142672883" LOG_CI_START="0.10196281214975722" LOG_EFFECT_SIZE="0.172307371788243" NO="2" P_CHI2="-4.440892098500626E-16" P_Z="1.579648262856044E-6" STUDIES="8" TAU2="0.05103582158680027" TOTAL_1="8440" TOTAL_2="8457" WEIGHT="65.09588121834533" Z="4.8008864468168975">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="1.0937711581338045" CI_START="0.9396131938669756" EFFECT_SIZE="1.0137661521542751" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="207" LOG_CI_END="0.038926467193233664" LOG_CI_START="-0.027050893572387984" LOG_EFFECT_SIZE="0.005937786810422834" ORDER="573" O_E="0.0" SE="0.038755428306929136" STUDY_ID="STD-Co_x002d_vaccination_x005f_dTpa_x005f_IPV--trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="246" TOTAL_2="247" VAR="0.0015019832232535243" WEIGHT="8.649950938777177">
<FOOTNOTE>Garcis-Sicilia, J Adolesc Health (2010)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9626578262129182" CI_START="1.6718200466261943" EFFECT_SIZE="1.811411245004995" ESTIMABLE="YES" EVENTS_1="635" EVENTS_2="352" LOG_CI_END="0.2928445904095793" LOG_CI_START="0.22318952850775658" LOG_EFFECT_SIZE="0.25801705945866793" ORDER="1147" O_E="0.0" SE="0.04091572815924782" STUDY_ID="STD-Co_x002d_vaccination_x005f_HepB-trial-_x0028_ph3_x002c_-2v_x0029_" TOTAL_1="728" TOTAL_2="731" VAR="0.001674096810801465" WEIGHT="8.599429439038701">
<FOOTNOTE>Schmeinck, Vaccine (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.554367452638924" CI_START="2.1465253414966523" EFFECT_SIZE="2.7621621621621624" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="45" LOG_CI_END="0.550762323414214" LOG_CI_START="0.3317360200491839" LOG_EFFECT_SIZE="0.441249171731699" ORDER="189" O_E="0.0" SE="0.1286571347943061" STUDY_ID="STD-Hong-Kong-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="148" TOTAL_2="146" VAR="0.01655265833348025" WEIGHT="5.714273015604389">
<FOOTNOTE>Ngan, Hong Kong Med (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7821931735478602" CI_START="1.6185624001362422" EFFECT_SIZE="1.698408331492769" ESTIMABLE="YES" EVENTS_1="2150" EVENTS_2="1263" LOG_CI_END="0.25095477582826126" LOG_CI_START="0.20912944733602284" LOG_EFFECT_SIZE="0.23004211158214208" ORDER="201" O_E="0.0" SE="0.024568404995055953" STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3065" TOTAL_2="3058" VAR="6.036065240010904E-4" WEIGHT="8.9235974331754">
<FOOTNOTE>Medina, J Adolesc Health (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5297852055003638" CI_START="1.1522278161279327" EFFECT_SIZE="1.3276524644945698" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="105" LOG_CI_END="0.18463045655971905" LOG_CI_START="0.06153835539411012" LOG_EFFECT_SIZE="0.12308440597691457" ORDER="191" O_E="0.0" SE="0.07230490954040636" STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="171" TOTAL_2="174" VAR="0.005227999943646346" WEIGHT="7.673940093117196">
<FOOTNOTE>Bhatla, J Obstet Gynaecol Res (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.311014111072953" CI_START="1.7007182718426068" EFFECT_SIZE="1.9825195901145267" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="147" LOG_CI_END="0.36380259729321895" LOG_CI_START="0.23063237762336902" LOG_EFFECT_SIZE="0.29721748745829396" ORDER="185" O_E="0.0" SE="0.07822484623728869" STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="474" TOTAL_2="483" VAR="0.006119126568847459" WEIGHT="7.472294109042698">
<FOOTNOTE>Kim, J Kor Med Sci (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.186780735121125" CI_START="1.135774648717437" EFFECT_SIZE="1.1609976195224594" ESTIMABLE="YES" EVENTS_1="2786" EVENTS_2="2402" LOG_CI_END="0.07437048784829525" LOG_CI_START="0.05529217069979118" LOG_EFFECT_SIZE="0.06483132927404323" ORDER="70" O_E="0.0" SE="0.011206697932224239" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3077" TOTAL_2="3080" VAR="1.2559007854411904E-4" WEIGHT="9.076379810907063">
<FOOTNOTE>Paavonen, Lancet (2007) &amp; Paavonen, Lancet (2009).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1146928479217693" CI_START="1.0300017488475908" EFFECT_SIZE="1.0715108878529065" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="469" LOG_CI_END="0.047155214622455956" LOG_CI_START="0.012837962097612562" LOG_EFFECT_SIZE="0.029996588360034274" ORDER="69" O_E="0.0" SE="0.020158124006232687" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="531" TOTAL_2="538" VAR="4.063499634506546E-4" WEIGHT="8.9860163786827">
<FOOTNOTE>Harper, Lancet (2004).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.46737705356503" CI_END="1.1910294131755044" CI_START="1.074312683536579" DF="3" EFFECT_SIZE="1.1311666566158909" ESTIMABLE="YES" EVENTS_1="2791" EVENTS_2="2392" I2="32.846501111743905" ID="CMP-007.02.03" LOG_CI_END="0.07592248677420069" LOG_CI_START="0.03113070312375622" LOG_EFFECT_SIZE="0.053526594948978407" NO="3" P_CHI2="0.2152189854184947" P_Z="2.808496009364749E-6" STUDIES="4" TAU2="9.218038503397461E-4" TOTAL_1="3317" TOTAL_2="3197" WEIGHT="25.892773933755095" Z="4.684350109108472">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="2.3316058074073145" CI_START="0.8603290969222025" EFFECT_SIZE="1.4163150492264416" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="9" LOG_CI_END="0.3676551283603126" LOG_CI_START="-0.06533538871260922" LOG_EFFECT_SIZE="0.15115986982385168" ORDER="572" O_E="0.0" SE="0.25434077306626107" STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="79" TOTAL_2="19" VAR="0.0646892288439433" WEIGHT="2.74005366087494">
<FOOTNOTE>Mugo, Hum Vaccin Immunother (2014)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1628663168248348" CI_START="1.1022416997599103" EFFECT_SIZE="1.1321482878362499" ESTIMABLE="YES" EVENTS_1="2281" EVENTS_2="2014" LOG_CI_END="0.06552979108069487" LOG_CI_START="0.042276837131345564" LOG_EFFECT_SIZE="0.0539033141060202" ORDER="107" O_E="0.0" SE="0.013658900253826219" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="1.8656555614397395E-4" WEIGHT="9.05660051268127">
<FOOTNOTE>Garland, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1707730220638821" CI_START="1.0239359593067028" EFFECT_SIZE="1.0948957016434893" ESTIMABLE="YES" EVENTS_1="372" EVENTS_2="339" LOG_CI_END="0.06847270649853492" LOG_CI_START="0.01027279512668073" LOG_EFFECT_SIZE="0.039372750812607826" ORDER="108" O_E="0.0" SE="0.03418691603403475" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="448" TOTAL_2="447" VAR="0.0011687452279181424" WEIGHT="8.749474967026767">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8799129791781748" CI_START="1.0859001558615882" EFFECT_SIZE="1.4287749287749287" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="30" LOG_CI_END="0.2741377463182418" LOG_CI_START="0.035789895462983834" LOG_EFFECT_SIZE="0.15496382089061284" ORDER="72" O_E="0.0" SE="0.1400067074332685" STUDY_ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="117" TOTAL_2="59" VAR="0.01960187812630484" WEIGHT="5.346644793172116">
<FOOTNOTE>Kang, Int J Gynecol Cancer (2008).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="170.84121372940535" CI_END="2.269173327872093" CI_START="1.3168515118735702" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7286307666796707" ESTIMABLE="YES" EVENTS_1="3354" EVENTS_2="1750" I2="95.31728918019093" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.3558676701746813" LOG_CI_START="0.11953680669328862" LOG_EFFECT_SIZE="0.23770223843398494" METHOD="IV" NO="3" P_CHI2="-6.661338147750939E-16" P_Q="0.39014883767180686" P_Z="8.057800555021064E-5" Q="0.7384781781923737" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14876563393126271" TOTALS="YES" TOTAL_1="11044" TOTAL_2="11062" WEIGHT="99.99999999999999" Z="3.9426744311950146">
<NAME>Swelling at injection site</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="160.91084289181435" CI_END="2.293084157512143" CI_START="1.1481349782080719" DF="6" EFFECT_SIZE="1.622581316672443" ESTIMABLE="YES" EVENTS_1="2637" EVENTS_2="1333" I2="96.2712270396632" ID="CMP-007.03.01" LOG_CI_END="0.36041999388058815" LOG_CI_START="0.05999294803148322" LOG_EFFECT_SIZE="0.21020647095603567" NO="1" P_CHI2="-6.661338147750939E-16" P_Z="0.006092832100400024" STUDIES="7" TAU2="0.2033708659279618" TOTAL_1="8292" TOTAL_2="8311" WEIGHT="82.68903273242313" Z="2.742743159003255">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="1.0891335458413316" CI_START="0.6397120837015928" EFFECT_SIZE="0.8347046723479283" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="83" LOG_CI_END="0.03708113472919461" LOG_CI_START="-0.19401544569425846" LOG_EFFECT_SIZE="-0.07846715548253197" ORDER="576" O_E="0.0" SE="0.13574727528725877" STUDY_ID="STD-Co_x002d_vaccination_x005f_dTpa_x005f_IPV--trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="246" TOTAL_2="247" VAR="0.01842732274791482" WEIGHT="11.526517381972523">
<FOOTNOTE>Garcis-Sicilia, J Adolesc Health (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.8328849303860193" CI_START="1.83532754333637" EFFECT_SIZE="2.280191163003663" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="96" LOG_CI_END="0.45222893416980975" LOG_CI_START="0.2637135822499096" LOG_EFFECT_SIZE="0.35797125820985964" ORDER="578" O_E="0.0" SE="0.1107348508837913" STUDY_ID="STD-Co_x002d_vaccination_x005f_HepB-trial-_x0028_ph3_x002c_-2v_x0029_" TOTAL_1="728" TOTAL_2="731" VAR="0.012262207200255493" WEIGHT="11.967821885731748">
<FOOTNOTE>Schmeinck, Vaccine (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.146398075936032" CI_START="2.4142923117305934" EFFECT_SIZE="2.756143081259805" ESTIMABLE="YES" EVENTS_1="721" EVENTS_2="261" LOG_CI_END="0.4978136678249615" LOG_CI_START="0.3827898513810697" LOG_EFFECT_SIZE="0.4403017596030155" ORDER="203" O_E="0.0" SE="0.06756555915621622" STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3065" TOTAL_2="3058" VAR="0.004565104784092154" WEIGHT="12.568598687074148">
<FOOTNOTE>Medina, J Adolesc Health (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.6465345889723224" CI_START="1.5458932788346067" EFFECT_SIZE="2.374269005847953" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="24" LOG_CI_END="0.561880337391289" LOG_CI_START="0.18917950897879157" LOG_EFFECT_SIZE="0.37552992318504025" ORDER="192" O_E="0.0" SE="0.21892631150835581" STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="171" TOTAL_2="174" VAR="0.04792872987065364" WEIGHT="9.797700778283017">
<FOOTNOTE>Bhatla, J Obstet Gynaecol Res (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8560544764926158" CI_START="0.5501383179065849" EFFECT_SIZE="0.6862567811934901" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="147" LOG_CI_END="-0.06749859737035249" LOG_CI_START="-0.25952810477604565" LOG_EFFECT_SIZE="-0.16351335107319906" ORDER="186" O_E="0.0" SE="0.11279908321149627" STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="474" TOTAL_2="483" VAR="0.012723633173354062" WEIGHT="11.933626028889345">
<FOOTNOTE>Kim, J Kor Med Sci (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.305912589860114" CI_START="1.9556631028137192" EFFECT_SIZE="2.1235790944306854" ESTIMABLE="YES" EVENTS_1="1292" EVENTS_2="609" LOG_CI_END="0.36284284048647164" LOG_CI_START="0.2912940420718799" LOG_EFFECT_SIZE="0.3270684412791758" ORDER="75" O_E="0.0" SE="0.042028118360995376" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3077" TOTAL_2="3080" VAR="0.0017663627329658365" WEIGHT="12.80227834620807">
<FOOTNOTE>Paavonen, Lancet (2007) &amp; Paavonen, Lancet (2009).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.996760108913606" CI_START="1.3336304606092941" EFFECT_SIZE="1.631851740746296" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="113" LOG_CI_END="0.30032589179452235" LOG_CI_START="0.12503550637862806" LOG_EFFECT_SIZE="0.2126806990865752" ORDER="74" O_E="0.0" SE="0.10296644009469819" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="531" TOTAL_2="538" VAR="0.01060208778577507" WEIGHT="12.092489624264294">
<FOOTNOTE>Harper, Lancet (2004).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.581969355066831" CI_END="9.147949983030433" CI_START="0.8512327874611243" DF="1" EFFECT_SIZE="2.7905259295713307" ESTIMABLE="YES" EVENTS_1="717" EVENTS_2="417" I2="82.08517574371335" ID="CMP-007.03.02" LOG_CI_END="0.9613237814098674" LOG_CI_START="-0.06995165673699201" LOG_EFFECT_SIZE="0.4456860623364377" NO="2" P_CHI2="0.01814642126913213" P_Z="0.09025115688532287" STUDIES="2" TAU2="0.6214884076815964" TOTAL_1="2752" TOTAL_2="2751" WEIGHT="17.310967267576856" Z="1.6940743438252932">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="15.865616810545136" CI_START="2.0839088952422515" EFFECT_SIZE="5.75" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="1.2004569609122524" LOG_CI_START="0.31887872846700877" LOG_EFFECT_SIZE="0.7596678446896304" ORDER="579" O_E="0.0" SE="0.5178434176209664" STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="79" TOTAL_2="79" VAR="0.26816180517336263" WEIGHT="4.6222731836613695">
<FOOTNOTE>Mugo, HUm Vaccine Immunother (2015).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8738968844029986" CI_START="1.505733589242599" EFFECT_SIZE="1.679758756971563" ESTIMABLE="YES" EVENTS_1="694" EVENTS_2="413" LOG_CI_END="0.272745689130796" LOG_CI_START="0.1777481385600535" LOG_EFFECT_SIZE="0.22524691384542475" ORDER="120" O_E="0.0" SE="0.055802031450713455" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="0.003113866714026414" WEIGHT="12.688694083915486">
<FOOTNOTE>Garland, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.658130725925268" CI_END="1.9692994882542958" CI_START="1.5028174835362806" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7203190696111015" ESTIMABLE="YES" EVENTS_1="3234" EVENTS_2="1939" I2="81.9221333157079" I2_Q="77.038225121859" ID="CMP-007.04" LOG_CI_END="0.29431176804548287" LOG_CI_START="0.17690623893271165" LOG_EFFECT_SIZE="0.23560900348909725" METHOD="IV" NO="4" P_CHI2="4.244966068778222E-5" P_Q="0.03689928243553375" P_Z="3.6470748309127265E-15" Q="4.355064037109664" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.020122812693066736" TOTALS="YES" TOTAL_1="9991" TOTAL_2="10005" WEIGHT="100.0" Z="7.866497681356136">
<NAME>Redness at injection site</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6295400934808235" CI_START="1.3150908053500157" DF="0" EFFECT_SIZE="1.4638965789583074" ESTIMABLE="YES" EVENTS_1="659" EVENTS_2="450" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="0.2120650503877059" LOG_CI_START="0.11895574134356818" LOG_EFFECT_SIZE="0.165510395865637" NO="1" P_CHI2="1.0" P_Z="3.214005942651849E-12" STUDIES="1" TAU2="0.0" TOTAL_1="2673" TOTAL_2="2672" WEIGHT="20.576660470743494" Z="6.96803398701711">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="1.6295400934808235" CI_START="1.3150908053500157" EFFECT_SIZE="1.4638965789583074" ESTIMABLE="YES" EVENTS_1="659" EVENTS_2="450" LOG_CI_END="0.2120650503877059" LOG_CI_START="0.11895574134356818" LOG_EFFECT_SIZE="0.165510395865637" ORDER="141" O_E="0.0" SE="0.05469286903103955" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="0.0029913099228464453" WEIGHT="20.576660470743494">
<FOOTNOTE>Garland, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.283381086853773" CI_END="2.109352052977955" CI_START="1.5313498497271458" DF="4" EFFECT_SIZE="1.797263461307061" ESTIMABLE="YES" EVENTS_1="2575" EVENTS_2="1489" I2="81.20599361691313" ID="CMP-007.04.02" LOG_CI_END="0.3241490699745821" LOG_CI_START="0.1850744202534141" LOG_EFFECT_SIZE="0.2546117451139981" NO="2" P_CHI2="2.782209859140128E-4" P_Z="7.155446256312848E-13" STUDIES="5" TAU2="0.023253431536541816" TOTAL_1="7318" TOTAL_2="7333" WEIGHT="79.42333952925651" Z="7.176431527454326">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="2.2553341783269447" CI_START="1.825107252501531" EFFECT_SIZE="2.028848630548639" ESTIMABLE="YES" EVENTS_1="850" EVENTS_2="418" LOG_CI_END="0.35321090144704687" LOG_CI_START="0.2612883908752031" LOG_EFFECT_SIZE="0.307249646161125" ORDER="204" O_E="0.0" SE="0.05399573773366685" STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3065" TOTAL_2="3058" VAR="0.0029155396934029344" WEIGHT="20.64433450658145">
<FOOTNOTE>Medina, J Adolesc Health (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.840098232625853" CI_START="1.4168863192216636" EFFECT_SIZE="2.006015037593985" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="35" LOG_CI_END="0.45333336157857035" LOG_CI_START="0.15133500697628077" LOG_EFFECT_SIZE="0.30233418427742553" ORDER="193" O_E="0.0" SE="0.17739532840934988" STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="171" TOTAL_2="174" VAR="0.0314691025414611" WEIGHT="9.218720626763563">
<FOOTNOTE>Bhatla, J Obstet Gynaecol Res (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.017771869821169" CI_START="1.6709273795194735" EFFECT_SIZE="2.245546179090483" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="54" LOG_CI_END="0.4796864059423647" LOG_CI_START="0.22295757535161398" LOG_EFFECT_SIZE="0.3513219906469893" ORDER="187" O_E="0.0" SE="0.15080378591721402" STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="474" TOTAL_2="483" VAR="0.02274178184696492" WEIGHT="11.095671340191982">
<FOOTNOTE>Kim, J Kor Med (2010).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7001417801889178" CI_START="1.4787064412251747" EFFECT_SIZE="1.5855631811319875" ESTIMABLE="YES" EVENTS_1="1348" EVENTS_2="851" LOG_CI_END="0.23048514007602627" LOG_CI_START="0.16988196465937164" LOG_EFFECT_SIZE="0.20018355236769894" ORDER="78" O_E="0.0" SE="0.03559860523029943" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3077" TOTAL_2="3080" VAR="0.001267260694342702" WEIGHT="22.23514826399483">
<FOOTNOTE>Paavonen, Lancet (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7637843406808131" CI_START="1.211465480036691" EFFECT_SIZE="1.4617673696467848" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="131" LOG_CI_END="0.24644548250896378" LOG_CI_START="0.08331104369583618" LOG_EFFECT_SIZE="0.16487826310239997" ORDER="77" O_E="0.0" SE="0.09582597688732691" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="531" TOTAL_2="538" VAR="0.009182617846410512" WEIGHT="16.229464791724673">
<FOOTNOTE>Harper, Lancet (2004).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.608263560618663" CI_END="1.0729861721283547" CI_START="0.9759217604358402" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0233037447536373" ESTIMABLE="YES" EVENTS_1="5799" EVENTS_2="5525" I2="72.66507358677431" I2_Q="21.792443342331637" ID="CMP-007.05" LOG_CI_END="0.03059412512806824" LOG_CI_START="-0.010584998289242522" LOG_EFFECT_SIZE="0.01000456341941283" METHOD="IV" NO="5" P_CHI2="5.916091064320783E-4" P_Q="0.25815052143557304" P_Z="0.3409166908072627" Q="1.2786488195472203" RANDOM="YES" SCALE="2.3" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0027479406468080385" TOTALS="YES" TOTAL_1="9137" TOTAL_2="9054" WEIGHT="100.0" Z="0.9523555800050425">
<NAME>Overall systemic event and general symptoms</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.726606053423204" CI_END="1.1888778608419228" CI_START="0.9665772268896424" DF="1" EFFECT_SIZE="1.0719805342650006" ESTIMABLE="YES" EVENTS_1="2222" EVENTS_2="1994" I2="90.67738672400607" ID="CMP-007.05.01" LOG_CI_END="0.07513723974313603" LOG_CI_START="-0.014763441302117583" LOG_EFFECT_SIZE="0.03018689922050926" NO="1" P_CHI2="0.001056066253507626" P_Z="0.18809500192342699" STUDIES="2" TAU2="0.005058495236520847" TOTAL_1="3257" TOTAL_2="3246" WEIGHT="35.8296016976453" Z="1.3162355299034083">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="1.0660647282617752" CI_START="0.9683942300553932" EFFECT_SIZE="1.0160565593087196" ESTIMABLE="YES" EVENTS_1="344" EVENTS_2="335" LOG_CI_END="0.027783574553107985" LOG_CI_START="-0.013947806862036366" LOG_EFFECT_SIZE="0.006917883845535796" ORDER="200" O_E="0.0" SE="0.024513220016925366" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="380" TOTAL_2="376" VAR="6.008979555981904E-4" WEIGHT="17.47170072091483">
<FOOTNOTE>Hildesheim, Vaccine (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.176605079316789" CI_START="1.0838065082673498" EFFECT_SIZE="1.129252957766309" ESTIMABLE="YES" EVENTS_1="1878" EVENTS_2="1659" LOG_CI_END="0.07063071887251549" LOG_CI_START="0.03495175462627998" LOG_EFFECT_SIZE="0.05279123674939775" ORDER="183" O_E="0.0" SE="0.020958000211960134" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2877" TOTAL_2="2870" VAR="4.39237772884521E-4" WEIGHT="18.357900976730473">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5691041741512075" CI_END="1.0368374456194773" CI_START="0.9791505533464685" DF="5" EFFECT_SIZE="1.0075812416915324" ESTIMABLE="YES" EVENTS_1="3577" EVENTS_2="3531" I2="0.0" ID="CMP-007.05.02" LOG_CI_END="0.01571067345345322" LOG_CI_START="-0.00915052631676574" LOG_EFFECT_SIZE="0.003280073568343755" NO="2" P_CHI2="0.4706911696848236" P_Z="0.6050322878575539" STUDIES="6" TAU2="0.0" TOTAL_1="5880" TOTAL_2="5808" WEIGHT="64.1703983023547" Z="0.517177458852695">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="1.0671329598403339" CI_START="0.9854592981533505" EFFECT_SIZE="1.025483348299992" ESTIMABLE="YES" EVENTS_1="1745" EVENTS_2="1701" LOG_CI_END="0.028218533883252964" LOG_CI_START="-0.0063613084240518964" LOG_EFFECT_SIZE="0.010928612729600518" ORDER="121" O_E="0.0" SE="0.020312370544290928" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="4.125923971285778E-4" WEIGHT="18.512670176360835">
<FOOTNOTE>Garland, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1377676625766462" CI_START="0.9213003405620338" EFFECT_SIZE="1.0238289578891258" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="268" LOG_CI_END="0.05605358616923108" LOG_CI_START="-0.0355987682986985" LOG_EFFECT_SIZE="0.010227408935266281" ORDER="122" O_E="0.0" SE="0.0538370467009334" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="448" TOTAL_2="447" VAR="0.0028984275974784836" WEIGHT="10.362396374535727">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0396816534557978" CI_START="0.9362665192653834" EFFECT_SIZE="0.9866200498799618" ESTIMABLE="YES" EVENTS_1="1121" EVENTS_2="1135" LOG_CI_END="0.016900380344865344" LOG_CI_START="-0.02860050663559" LOG_EFFECT_SIZE="-0.0058500631453623515" ORDER="84" O_E="0.0" SE="0.02672744624534252" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1890" TOTAL_2="1888" VAR="7.143563827976739E-4" WEIGHT="16.899158369018227">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1288922959858863" CI_START="0.8500873105456103" EFFECT_SIZE="0.9796208530805687" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="211" LOG_CI_END="0.05265250924978927" LOG_CI_START="-0.07053646659059816" LOG_EFFECT_SIZE="-0.008941978670404433" ORDER="85" O_E="0.0" SE="0.07236181420390865" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="480" TOTAL_2="468" VAR="0.0052362321548809964" WEIGHT="7.328236409351094">
<FOOTNOTE>Yoshikawa, Cancer Sc (2013).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0619857037622038" CI_START="0.48492031832755406" EFFECT_SIZE="0.7176199868507561" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" LOG_CI_END="0.026118670399897216" LOG_CI_START="-0.314329618415578" LOG_EFFECT_SIZE="-0.1441054740078404" ORDER="86" O_E="0.0" SE="0.19998101009641908" STUDY_ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="117" TOTAL_2="59" VAR="0.03999240439918407" WEIGHT="1.3689619435904616">
<FOOTNOTE>kang, Int J Gynecol Cancer (2008).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1093116717003761" CI_START="0.8861061407947838" EFFECT_SIZE="0.9914473684210526" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="190" LOG_CI_END="0.0450535824727806" LOG_CI_START="-0.05251425373306208" LOG_EFFECT_SIZE="-0.0037303356301407373" ORDER="80" O_E="0.0" SE="0.05731182995589042" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="272" TOTAL_2="274" VAR="0.003284645852892898" WEIGHT="9.698975029498364">
<FOOTNOTE>Villa, Lancet Oncol (2005).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.36967351729105" CI_END="1.0509168260708557" CI_START="0.9226283750852474" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9846855760025629" ESTIMABLE="YES" EVENTS_1="2376" EVENTS_2="2382" I2="6.122903475691484" I2_Q="39.71982044314234" ID="CMP-007.06" LOG_CI_END="0.021568345516491793" LOG_CI_START="-0.03497319296052064" LOG_EFFECT_SIZE="-0.006702423722014441" METHOD="IV" NO="6" P_CHI2="0.3784824394211761" P_Q="0.19034462441419664" P_Z="0.6421695508193622" Q="3.31784015028282" RANDOM="YES" SCALE="317.3930343856375" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0014167161414542775" TOTALS="YES" TOTAL_1="36000" TOTAL_2="35597" WEIGHT="99.99999999999999" Z="0.4646675509056401">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7782791833354936" CI_START="0.511783290528959" DF="0" EFFECT_SIZE="0.9539882451721242" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-007.06.01" LOG_CI_END="0.24999994463409178" LOG_CI_START="-0.2909138977171673" LOG_EFFECT_SIZE="-0.02045697654153772" NO="1" P_CHI2="1.0" P_Z="0.8821463526764929" STUDIES="1" TAU2="0.0" TOTAL_1="1191" TOTAL_2="1196" WEIGHT="1.0775239956105944" Z="0.1482488859213102">
<NAME>Monovalent vaccine</NAME>
<DICH_DATA CI_END="1.7782791833354936" CI_START="0.511783290528959" EFFECT_SIZE="0.9539882451721242" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.24999994463409178" LOG_CI_START="-0.2909138977171673" LOG_EFFECT_SIZE="-0.02045697654153772" ORDER="88" O_E="0.0" SE="0.31773546856383245" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="1191" TOTAL_2="1196" VAR="0.10095582798347816" WEIGHT="1.0775239956105944">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00365378?sect=X30156#evnt. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.799418367971827" CI_END="1.0676674103040278" CI_START="0.9574361575550054" DF="14" EFFECT_SIZE="1.0110506331871771" ESTIMABLE="YES" EVENTS_1="2203" EVENTS_2="2175" I2="0.0" ID="CMP-007.06.02" LOG_CI_END="0.028435986433222708" LOG_CI_START="-0.018890175423004835" LOG_EFFECT_SIZE="0.0047729055051089425" NO="2" P_CHI2="0.5423750644974832" P_Z="0.6925994531100078" STUDIES="15" TAU2="0.0" TOTAL_1="23261" TOTAL_2="22970" WEIGHT="89.65389187300904" Z="0.39532987779762147">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="1.2147254706279775" CI_START="0.30616495940382954" EFFECT_SIZE="0.6098412698412699" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.08447813796474318" LOG_CI_START="-0.5140445158205569" LOG_EFFECT_SIZE="-0.21478318892790685" ORDER="129" O_E="0.0" SE="0.3515751695684039" STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="450" TOTAL_2="226" VAR="0.12360509985705195" WEIGHT="0.8823169932808932">
<FOOTNOTE>Sow, J Infect Dis (2013) or https://clinicaltrials.gov/ct2/show/results/NCT00481767?sect=Xe0156#outcome8. Follow-up: 12 month.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="12.873728203173261" CI_START="0.4906910841850034" EFFECT_SIZE="2.513368983957219" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1097043358393928" LOG_CI_START="-0.3091918330409558" LOG_EFFECT_SIZE="0.40025625139921844" ORDER="227" O_E="0.0" SE="0.8334666332496287" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_-adolescent" TOTAL_1="374" TOTAL_2="376" VAR="0.694666628740471" WEIGHT="0.15847078312875085">
<FOOTNOTE>Zhu, Hum Vaccin Immunother (2014) or https://clinicaltrials.gov/ct2/show/results/NCT00996125?sect=X30156#evnt. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.934926747385658" CI_START="0.20263725303111402" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6932807105127872" LOG_CI_START="-0.6932807105127872" LOG_EFFECT_SIZE="0.0" ORDER="228" O_E="0.0" SE="0.8144730423001509" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_mid_x002d_adult" TOTAL_1="606" TOTAL_2="606" VAR="0.6633663366336634" WEIGHT="0.16593213729778136">
<FOOTNOTE>Zhu, Hum Vaccin Immunother (2014) or https://clinicaltrials.gov/ct2/show/results/NCT01277042?sect=X30156#evnt. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.9679693519152727" CI_START="0.49346609668747815" EFFECT_SIZE="0.6911295521121474" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="81" LOG_CI_END="-0.014138393213086362" LOG_CI_START="-0.3067426799291727" LOG_EFFECT_SIZE="-0.16044053657112953" ORDER="640" O_E="0.0" SE="0.17187720643160806" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="3026" TOTAL_2="3025" VAR="0.029541774090733615" WEIGHT="3.563121843442795">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00779766. Follow-up: 72 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1128429269902034" CI_START="0.9475290713463519" EFFECT_SIZE="1.0268646576669116" ESTIMABLE="YES" EVENTS_1="912" EVENTS_2="891" LOG_CI_END="0.046433869855482784" LOG_CI_START="-0.02340745647164003" LOG_EFFECT_SIZE="0.011513206691921391" ORDER="201" O_E="0.0" SE="0.04102514080469299" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3727" TOTAL_2="3739" VAR="0.0016830621780448854" WEIGHT="35.58605210328134">
<FOOTNOTE>Hildesheim, Vaccine (2014) or https://clinicaltrials.gov/ct2/show/results/NCT00128661?sect=X30156#evnt. Follow-up: 54 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="28.12337741867024" CI_START="0.3114277549882628" EFFECT_SIZE="2.9594594594594597" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4490674751746793" LOG_CI_START="-0.5066426849563948" LOG_EFFECT_SIZE="0.4712123951091422" ORDER="190" O_E="0.0" SE="1.1487938289824173" STUDY_ID="STD-Hong-Kong-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="148" TOTAL_2="146" VAR="1.3197272615080833" WEIGHT="0.0834949669774606">
<FOOTNOTE>Ngan, Hong Kong Med J (2010) or https://www.gsk-clinicalstudyregister.com/files2/gsk-106001-clinical-study-report-redact.pdf. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8313072142110105" CI_START="0.5911317690048808" EFFECT_SIZE="1.0404536862003781" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.26276120625953514" LOG_CI_START="-0.22831569987499684" LOG_EFFECT_SIZE="0.017222753192269166" ORDER="199" O_E="0.0" SE="0.28846100553331405" STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1035" TOTAL_2="1032" VAR="0.08320975171329063" WEIGHT="1.303479580119734">
<FOOTNOTE>Medina, J Adolesc Health (2010). Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.7256195487052475" CI_START="0.09381870678214849" EFFECT_SIZE="0.5056818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4354652354205385" LOG_CI_START="-1.0277105577590124" LOG_EFFECT_SIZE="-0.29612266116923697" ORDER="277" O_E="0.0" SE="0.8594767037506554" STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="176" TOTAL_2="178" VAR="0.7387002042900919" WEIGHT="0.14904249550462967">
<FOOTNOTE>Bhatla, J Obstet Gynaecol Res (2010) or http://www.gsk-clinicalstudyregister.com/files2/20003.pdf. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.260518696872794" CI_START="0.4674985852542497" EFFECT_SIZE="0.7676527258302165" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.10054929181211776" LOG_CI_START="-0.33021969905285875" LOG_EFFECT_SIZE="-0.11483520362037053" ORDER="255" O_E="0.0" SE="0.25303583757498194" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="519" TOTAL_2="521" VAR="0.06402713509727263" WEIGHT="1.6855498369729645">
<FOOTNOTE>Konno, Hum Vaccine Immunother (2014), Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.1722722739376" CI_START="0.013765530089890357" EFFECT_SIZE="0.33540372670807456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9123428275026073" LOG_CI_START="-1.8612070599203698" LOG_EFFECT_SIZE="-0.47443211620888115" ORDER="286" O_E="0.0" SE="1.6291969331656226" STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="160" TOTAL_2="161" VAR="2.65428264703627" WEIGHT="0.04153665671491032">
<FOOTNOTE>Kim, J Kor Med Sci (2010) or https://www.gsk-clinicalstudyregister.com/files2/b9fddc53-e326-40a9-aa58-8d736ee8dd2c. Follow-up; 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="11.072212492096398" CI_START="0.09398969214720357" EFFECT_SIZE="1.0201342281879195" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0442344119446347" LOG_CI_START="-1.0269197728796378" LOG_EFFECT_SIZE="0.008657319532498544" ORDER="97" O_E="0.0" SE="1.2166062205443406" STUDY_ID="STD-Korean-trial-_x0028_ph3b_x002c_2v_x0029_" TOTAL_1="149" TOTAL_2="76" VAR="1.4801306958671847" WEIGHT="0.074455175644204">
<FOOTNOTE>Kim, J Gynecol Oncol (2011) or http://www.gsk-clinicalstudyregister.com/files2/793fb6b5-639f-48ec-81b8-3020c37c6963. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.886859856965218" CI_START="0.40934221335887666" EFFECT_SIZE="1.6790123456790123" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8380212454703001" LOG_CI_START="-0.38791346648716457" LOG_EFFECT_SIZE="0.22505388949156774" ORDER="275" O_E="0.0" SE="0.7201201182785101" STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="135" TOTAL_2="136" VAR="0.5185729847494553" WEIGHT="0.21213664924002243">
<FOOTNOTE>Lim, Med J Malaysia (2014) or http://www.gsk-clinicalstudyregister.com/files2/786bc06a-75ce-4bba-819b-cc9e7b77f649. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1046875003305168" CI_START="0.9195672749011523" EFFECT_SIZE="1.0078861415340024" ESTIMABLE="YES" EVENTS_1="835" EVENTS_2="829" LOG_CI_END="0.04323943994295089" LOG_CI_START="-0.03641649258189832" LOG_EFFECT_SIZE="0.0034114736805262672" ORDER="90" O_E="0.0" SE="0.04679028906832164" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="9319" TOTAL_2="9325" VAR="0.0021893311510970993" WEIGHT="30.589968416158115">
<FOOTNOTE>http://www.gsk-clinicalstudyregister.com/files2/0595d189-d8bf-46d2-8787-2dd8ec2dafeb. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.088631600201398" CI_START="0.6259656817770256" EFFECT_SIZE="1.143421052631579" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.31986184442790316" LOG_CI_START="-0.20344947609215294" LOG_EFFECT_SIZE="0.0582061841678751" ORDER="287" O_E="0.0" SE="0.3073956601062955" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="560" TOTAL_2="553" VAR="0.09449209185218513" WEIGHT="1.1501432985553806">
<FOOTNOTE>The GSK study group, Lancet (2009). Follow-up: 76 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2632406905640132" CI_START="0.9218905883628365" EFFECT_SIZE="1.0791523078175453" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="269" LOG_CI_END="0.10148610639447454" LOG_CI_START="-0.035320618740143396" LOG_EFFECT_SIZE="0.033082743827165584" ORDER="184" O_E="0.0" SE="0.08036094754828578" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2877" TOTAL_2="2870" VAR="0.006457881890858339" WEIGHT="14.008190936690074">
<FOOTNOTE>http://www.gsk-clinicalstudyregister.com/files2/dd3cf931-232e-41de-a818-6525cf6a6a78. Follow-up: 84 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.534534661070325" CI_END="1.022269384171438" CI_START="0.6453692613249228" DF="5" EFFECT_SIZE="0.8122445674412385" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="187" I2="9.658168099121662" ID="CMP-007.06.03" LOG_CI_END="0.009565354353667824" LOG_CI_START="-0.19019172370881182" LOG_EFFECT_SIZE="-0.09031318467757202" NO="3" P_CHI2="0.3541739922988013" P_Z="0.07635165750995461" STUDIES="7" TAU2="0.008436197322635864" TOTAL_1="11548" TOTAL_2="11431" WEIGHT="9.268584131380349" Z="1.7722584953088953">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="278" O_E="0.0" SE="0.0" STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="79" TOTAL_2="19" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Mugo, Hum Vacc Immunother (2014) or https://clinicaltrials.gov/ct2/show/results/NCT01245764?sect=X30156#evnt. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6555538119986573" CI_START="0.7451550852776976" EFFECT_SIZE="1.110695431683086" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="45" LOG_CI_END="0.2189433015932279" LOG_CI_START="-0.127753330377936" LOG_EFFECT_SIZE="0.04559498560764593" ORDER="123" O_E="0.0" SE="0.20365131779586804" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2673" TOTAL_2="2672" VAR="0.04147385923999364" WEIGHT="2.571867404558825">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00092521?term=NCT00092521&amp;rank=1&amp;sect=X30156#evnt. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.213674588113903" CI_START="0.5581703290894956" EFFECT_SIZE="0.8230656986262368" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="56" LOG_CI_END="0.0841022587896149" LOG_CI_START="-0.2532332532203547" LOG_EFFECT_SIZE="-0.08456549721536992" ORDER="124" O_E="0.0" SE="0.19815254959237136" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="6021" TOTAL_2="6033" VAR="0.039264432909957195" WEIGHT="2.7115476174705493">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00092534. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7597156924263966" CI_START="0.44149169666678306" EFFECT_SIZE="0.8814192343604108" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.24544250691398764" LOG_CI_START="-0.355077459981561" LOG_EFFECT_SIZE="-0.05481747653378667" ORDER="94" O_E="0.0" SE="0.3527484011762232" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1890" TOTAL_2="1888" VAR="0.12443143453238169" WEIGHT="0.8765235897046239">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00090220?sect=X30156#evnt. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8520340656884979" CI_START="0.4016564756990793" EFFECT_SIZE="0.585" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="65" LOG_CI_END="-0.06954304109623625" LOG_CI_START="-0.39614522673940294" LOG_EFFECT_SIZE="-0.23284413391781958" ORDER="95" O_E="0.0" SE="0.19184774055368897" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="480" TOTAL_2="468" VAR="0.03680555555555556" WEIGHT="2.8859842151911828">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00378560?sect=X30156#evnt. Follow-up: 6 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.9204409152833515" CI_START="0.032105758988946735" EFFECT_SIZE="0.5042735042735043" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8987493585774473" LOG_CI_START="-1.4934170587854823" LOG_EFFECT_SIZE="-0.29733385010401747" ORDER="96" O_E="0.0" SE="1.4051703949737266" STUDY_ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="117" TOTAL_2="59" VAR="1.9745038389106186" WEIGHT="0.055826572836786964">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00157950?sect=X30156#evnt. Follow-up: 7 month.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.981832852297567" CI_START="0.2063438717214804" EFFECT_SIZE="1.0138888888888888" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6973891522364998" LOG_CI_START="-0.6854084248581248" LOG_EFFECT_SIZE="0.00599036368918742" ORDER="89" O_E="0.0" SE="0.8122621417437832" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="288" TOTAL_2="292" VAR="0.6597697869101978" WEIGHT="0.16683473161838228">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00365716?sect=X30156#evnt. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.591428579373753" CI_END="1.9816007735133698" CI_START="0.8455101051321365" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2943969554751016" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="0.2970161631036802" LOG_CI_START="-0.07288119755541692" LOG_EFFECT_SIZE="0.11206748277413159" METHOD="IV" NO="7" P_CHI2="0.6795728713629696" P_Q="0.6212018264144394" P_Z="0.2349842876364321" Q="0.24418205561739492" RANDOM="YES" SCALE="444.5583277178812" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35770" TOTAL_2="35406" WEIGHT="100.0" Z="1.1876171794466626">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1130" TOTAL_2="1150" WEIGHT="0.0" Z="0.0">
<NAME>Monovalent vaccine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="262" O_E="0.0" SE="0.0" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_1v_x0029_" TOTAL_1="1130" TOTAL_2="1150" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>No death data neither in Koutsky, N Engl J Med (2002) nor on the website: https://clinicaltrials.gov/ct2/show/results/NCT00365378?sect=X30156#evnt.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.888897311822259" CI_END="2.2167838667173942" CI_START="0.6598164815837335" DF="5" EFFECT_SIZE="1.2094091662332707" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="15.094461063835372" ID="CMP-007.07.02" LOG_CI_END="0.34572335208258975" LOG_CI_START="-0.1805768403949952" LOG_EFFECT_SIZE="0.08257325584379725" NO="2" P_CHI2="0.31718050493349925" P_Z="0.5385464462799239" STUDIES="15" TAU2="0.0887634183875667" TOTAL_1="23261" TOTAL_2="22970" WEIGHT="67.07980713405095" Z="0.6150125341135875">
<NAME>Bivalent vaccine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="229" O_E="0.0" SE="0.0" STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="450" TOTAL_2="226" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Sow, J Infect Dis (2013) or https://clinicaltrials.gov/ct2/show/results/NCT00481767?sect=Xe0156#outcome8. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="258" O_E="0.0" SE="0.0" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_-adolescent" TOTAL_1="374" TOTAL_2="376" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Zhu, Hum Vacc ImmunoTher (2014) or https://clinicaltrials.gov/ct2/show/results/NCT00996125?sect=X30156#evnt. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="73.49682077411437" CI_START="0.12245427632387892" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662685533682617" LOG_CI_START="-0.9120260439289366" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1022" O_E="0.0" SE="1.631983999232433" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_mid_x002d_adult" TOTAL_1="606" TOTAL_2="606" VAR="2.663371773750686" WEIGHT="1.772580127948885">
<FOOTNOTE>Zhu, Hum Vacc ImmunoTher (2014) or https://www.gsk-clinicalstudyregister.com/files2/d6eb0c75-b164-41e6-8295-f2718bce6adc. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.763555501134348" CI_START="0.007379870387559951" EFFECT_SIZE="0.14280994855821416" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.44146819104348367" LOG_CI_START="-2.1319512656108075" LOG_EFFECT_SIZE="-0.8452415372836619" ORDER="234" O_E="0.0" SE="1.5116393274704871" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="3026" TOTAL_2="3025" VAR="2.285053456355427" WEIGHT="2.066052269525597">
<FOOTNOTE>Zhu, Int J Cancer (2014) or http://www.gsk-clinicalstudyregister.com/files2/51a30ca8-56c6-4668-b492-d1e4081bd46c. Follow-up: 72 month.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.158536292974433" CI_START="0.4161885877043614" EFFECT_SIZE="1.1465368546130552" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.49948587149411083" LOG_CI_START="-0.3807098327379774" LOG_EFFECT_SIZE="0.059388019378066675" ORDER="238" O_E="0.0" SE="0.5170313137049339" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="3727" TOTAL_2="3739" VAR="0.2673213793514498" WEIGHT="17.66053987505297">
<FOOTNOTE>Hildesheim, Vaccine (2014). Follow-up: 54 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="256" O_E="0.0" SE="0.0" STUDY_ID="STD-Hong-Kong-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="148" TOTAL_2="146" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Ngam, Hong Kong Med J (2010) or https://www.gsk-clinicalstudyregister.com/files2/gsk-106001-clinical-study-report-redact.pdf. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="257" O_E="0.0" SE="0.0" STUDY_ID="STD-Immunobridging_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1035" TOTAL_2="1032" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Medina, J Adolesc Health (2010) or http://www.gsk-clinicalstudyregister.com/files2/dd2c22ba-f6f9-4077-a122-caa47214e007. Follow-up: 12 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="259" O_E="0.0" SE="0.0" STUDY_ID="STD-Indian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="176" TOTAL_2="178" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Bhatla, J Obstet Gynecol Res (2010) or http://www.gsk-clinicalstudyregister.com/files2/20003.pdf. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="73.75540721003317" CI_START="0.12296541024441267" EFFECT_SIZE="3.0115384615384615" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8677938651301582" LOG_CI_START="-0.9102170369559074" LOG_EFFECT_SIZE="0.4787884140871254" ORDER="260" O_E="0.0" SE="1.6318173552610995" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="519" TOTAL_2="521" VAR="2.6628278809313293" WEIGHT="1.7729421842463384">
<FOOTNOTE>Konno, Hum Vacc Immunother (2014) or http://www.gsk-clinicalstudyregister.com/files2/43786c49-586e-4a14-ad61-499683804812. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="237" O_E="0.0" SE="0.0" STUDY_ID="STD-Korean-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="160" TOTAL_2="161" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Kim, J.Korean Med.Sci (2010) or https://www.gsk-clinicalstudyregister.com/files2/gsk-107291-clinical-study-report-redact.pdf. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="261" O_E="0.0" SE="0.0" STUDY_ID="STD-Korean-trial-_x0028_ph3b_x002c_2v_x0029_" TOTAL_1="149" TOTAL_2="76" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Kim, J Gynecol Oncol (2011) or https://www.gsk-clinicalstudyregister.com/files2/b9fddc53-e326-40a9-aa58-8d736ee8dd2c. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="276" O_E="0.0" SE="0.0" STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="135" TOTAL_2="136" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Lim, Med J Malaysia (2014) or http://www.gsk-clinicalstudyregister.com/files2/786bc06a-75ce-4bba-819b-cc9e7b77f649. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7544998401281244" CI_START="0.3376906374608674" EFFECT_SIZE="0.7697260353124716" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2441533329780556" LOG_CI_START="-0.4714809800973337" LOG_EFFECT_SIZE="-0.11366382355963903" ORDER="232" O_E="0.0" SE="0.4203671379474653" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="9319" TOTAL_2="9325" VAR="0.17670853066614328" WEIGHT="26.716536330721546">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011) or http://www.gsk-clinicalstudyregister.com/files2/0595d189-d8bf-46d2-8787-2dd8ec2dafeb. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="263" O_E="0.0" SE="0.0" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_2v_x0029_" TOTAL_1="560" TOTAL_2="553" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>De Carvalho, Vaccine (2010) or http://www.gsk-clinicalstudyregister.com/files2/20398.pdf. Follow-up: 84 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.265809350208596" CI_START="0.9258630824637429" EFFECT_SIZE="2.59367396593674" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8612839980906023" LOG_CI_START="-0.033453232461633745" LOG_EFFECT_SIZE="0.41391538281448426" ORDER="233" O_E="0.0" SE="0.5255730782471051" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2877" TOTAL_2="2870" VAR="0.2762270605781377" WEIGHT="17.091156346555614">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016) or http://www.gsk-clinicalstudyregister.com/files2/dd3cf931-232e-41de-a818-6525cf6a6a78.Follow-up: 71 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.38905056071240607" CI_END="3.2346665876412786" CI_START="0.733062221861362" DF="3" EFFECT_SIZE="1.5398739804662671" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="0.0" ID="CMP-007.07.03" LOG_CI_END="0.5098295225287066" LOG_CI_START="-0.1348591611512599" LOG_EFFECT_SIZE="0.18748518068872333" NO="3" P_CHI2="0.9424949993899219" P_Z="0.2542971096504085" STUDIES="7" TAU2="0.0" TOTAL_1="11379" TOTAL_2="11286" WEIGHT="32.92019286594905" Z="1.1399741024996715">
<NAME>Quadrivalent vaccine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="286" O_E="0.0" SE="0.0" STUDY_ID="STD-African_x005f_3-country-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="79" TOTAL_2="19" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Mugo, Hum Vacc Immunother (2014) or https://clinicaltrials.gov/ct2/show/results/NCT01245764?sect=X30156#evnt. Follow-up:7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.115562266053719" CI_START="0.14140353931987096" EFFECT_SIZE="1.003078106964217" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8522092233797446" LOG_CI_START="-0.849539720045112" LOG_EFFECT_SIZE="0.0013347516673162813" ORDER="254" O_E="0.0" SE="0.9996157531608879" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="2599" TOTAL_2="2607" VAR="0.9992316539674092" WEIGHT="4.7246700609871">
<FOOTNOTE>Garland, New Engl J Med (2007) or https://clinicaltrials.gov/ct2/show/results/NCT00092521?term=NCT00092521&amp;rank=1&amp;sect=X30156#evnt. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.430073520653864" CI_START="0.44675969423626133" EFFECT_SIZE="1.4068327162571526" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6464109337511348" LOG_CI_START="-0.34992601496638936" LOG_EFFECT_SIZE="0.14824245939237268" ORDER="231" O_E="0.0" SE="0.5852532556241112" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="5942" TOTAL_2="5971" VAR="0.3425213732186213" WEIGHT="13.783197921716665">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007) or https://clinicaltrials.gov/ct2/show/results/NCT00092534. Follow-up: 48 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.623479263902401" CI_START="0.6026347651522029" EFFECT_SIZE="1.9978835978835978" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8210861810075728" LOG_CI_START="-0.21994581810199848" LOG_EFFECT_SIZE="0.3005701814527872" ORDER="230" O_E="0.0" SE="0.6115073494684674" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1890" TOTAL_2="1888" VAR="0.3739412384539503" WEIGHT="12.625084890367932">
<FOOTNOTE>https://clinicaltrials.gov/ct2/show/results/NCT00090220?sect=X30156#evnt. Follow-up: 120 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="235" O_E="0.0" SE="0.0" STUDY_ID="STD-Japanese-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="480" TOTAL_2="468" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Yoshikawa, Cancer Sc (2013) or https://clinicaltrials.gov/ct2/show/results/NCT00378560?sect=X30156#evnt. Follow-up: 30 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="36.88321869952895" CI_START="0.06308878765120306" EFFECT_SIZE="1.5254237288135593" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5668288137495054" LOG_CI_START="-1.200047818155144" LOG_EFFECT_SIZE="0.18339049779718067" ORDER="236" O_E="0.0" SE="1.6252770298410095" STUDY_ID="STD-Korean-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="117" TOTAL_2="59" VAR="2.6415254237288135" WEIGHT="1.787239992877356">
<FOOTNOTE>Kang, Int J Gynecol Cancer (2008) or https://clinicaltrials.gov/ct2/show/results/NCT00157950. Follow-up: 7 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="264" O_E="0.0" SE="0.0" STUDY_ID="STD-Phase2-trial-_x0028_ph2_x002c_4v_x0029_" TOTAL_1="272" TOTAL_2="274" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Villa, Lancet Oncol (2005) or https://clinicaltrials.gov/ct2/show/results/NCT00365716?sect=X30156#evnt.Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Pregnancy outcomes</NAME>
<DICH_OUTCOME CHI2="4.323916735484149" CI_END="1.0216956747976558" CI_START="0.9714744075902898" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9962686386771462" ESTIMABLE="YES" EVENTS_1="3118" EVENTS_2="3183" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.00932155486140182" LOG_CI_START="-0.012568635917225837" LOG_EFFECT_SIZE="-0.0016235405279119877" METHOD="IV" NO="1" P_CHI2="0.7418036444551338" P_Q="1.0" P_Z="0.7712568908668771" Q="0.0" RANDOM="YES" SCALE="5.238808290482777" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4343" TOTAL_2="4439" WEIGHT="100.00000000000001" Z="0.2907312224300454">
<NAME>Normal infant</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8231572928868427" CI_START="0.2798464420065372" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.2608241390257549" LOG_CI_START="-0.5530802103822309" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="280" O_E="0.0" SE="0.4780914437337575" STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="14" TOTAL_2="10" VAR="0.22857142857142862" WEIGHT="0.07233564436960756">
<FOOTNOTE>Sow, J Infect Dis (2013).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2382210820255561" CI_START="0.8756396773897832" EFFECT_SIZE="1.0412663006177076" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="124" LOG_CI_END="0.09279819406343295" LOG_CI_START="-0.05767456770594632" LOG_EFFECT_SIZE="0.017561813178743318" ORDER="641" O_E="0.0" SE="0.08838844511551694" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="188" TOTAL_2="229" VAR="0.00781251722993875" WEIGHT="2.116329613563699">
<FOOTNOTE>Zhu, Int J Cancer (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1147660640706585" CI_START="0.9479056149337791" EFFECT_SIZE="1.0279557439258784" ESTIMABLE="YES" EVENTS_1="411" EVENTS_2="394" LOG_CI_END="0.047183739363853235" LOG_CI_START="-0.023234904174744074" LOG_EFFECT_SIZE="0.011974417594554575" ORDER="272" O_E="0.0" SE="0.041364259792479346" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="618" TOTAL_2="609" VAR="0.0017110019881797238" WEIGHT="9.66326262880958">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0585439912538954" CI_START="0.9513774849368803" EFFECT_SIZE="1.0035312252711313" ESTIMABLE="YES" EVENTS_1="855" EVENTS_2="871" LOG_CI_END="0.024708911256540515" LOG_CI_START="-0.02164713069977853" LOG_EFFECT_SIZE="0.0015308902783809698" ORDER="271" O_E="0.0" SE="0.027229768511250266" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1255" TOTAL_2="1283" VAR="7.414602931762765E-4" WEIGHT="22.299051914658925">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2318492332739979" CI_START="0.8699425976136171" EFFECT_SIZE="1.03519955654102" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="88" LOG_CI_END="0.09055755753304376" LOG_CI_START="-0.06050940297001686" LOG_EFFECT_SIZE="0.015024077281513446" ORDER="270" O_E="0.0" SE="0.08873748039301255" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="123" TOTAL_2="135" VAR="0.007874340426500285" WEIGHT="2.0997138394668586">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.640516596053805" CI_START="0.015148550878180109" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.4216889014408508" LOG_CI_START="-1.8196289101128882" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="283" O_E="0.0" SE="1.3165611772087666" STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2" TOTAL_2="2" VAR="1.7333333333333332" WEIGHT="0.009538766290497703">
<FOOTNOTE>Lim, Med J Malaysia (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.014943833435074" CI_START="0.9491398099514351" EFFECT_SIZE="0.9814904977522437" ESTIMABLE="YES" EVENTS_1="1401" EVENTS_2="1449" LOG_CI_END="0.006442009240220067" LOG_CI_START="-0.022669810525057944" LOG_EFFECT_SIZE="-0.008113900642418933" ORDER="105" O_E="0.0" SE="0.017100427035956278" STUDY_ID="STD-PATRICIA-_x0026_-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1786" TOTAL_2="1813" VAR="2.9242460481206437E-4" WEIGHT="56.54059644133574">
<FOOTNOTE>Wacholder, BMJ (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.132400977040789" CI_START="0.9384596727735134" EFFECT_SIZE="1.0308795518207283" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="250" LOG_CI_END="0.054000235404510294" LOG_CI_START="-0.02758438502263407" LOG_EFFECT_SIZE="0.01320792519093811" ORDER="201" O_E="0.0" SE="0.047923209889288935" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="357" TOTAL_2="358" VAR="0.0022966340460928406" WEIGHT="7.199171151505102">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.53679405975955" CI_END="1.1363636840358236" CI_START="0.680465313737409" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8793498000097769" ESTIMABLE="YES" EVENTS_1="637" EVENTS_2="704" I2="78.10426391840727" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.055517346069146684" LOG_CI_START="-0.16719400776611978" LOG_EFFECT_SIZE="-0.055838330848486536" METHOD="IV" NO="2" P_CHI2="1.4000321329477039E-5" P_Q="1.0" P_Z="0.32570254316029135" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09145728134502182" TOTALS="YES" TOTAL_1="4266" TOTAL_2="4352" WEIGHT="100.0" Z="0.9828068083211969">
<NAME>Spontaneous abortion/miscarriage</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.113617715814286" CI_START="0.05044723816630582" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0049065337289855" LOG_CI_START="-1.2971626050854617" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="281" O_E="0.0" SE="1.3522468075656264" STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="14" TOTAL_2="10" VAR="1.8285714285714285" WEIGHT="0.8913580627574937">
<FOOTNOTE>Sow, J Infect Dis (2013).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4959671407981823" CI_START="0.35960644250575635" EFFECT_SIZE="0.9473995271867612" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.39723886359693916" LOG_CI_START="-0.444172536294659" LOG_EFFECT_SIZE="-0.0234668363488599" ORDER="642" O_E="0.0" SE="0.4942492213499274" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="188" TOTAL_2="229" VAR="0.2442822928050095" WEIGHT="5.0975017635100475">
<FOOTNOTE>Zhu, Int J Cancer (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4217029809498007" CI_START="0.8233560385223744" EFFECT_SIZE="1.0819277861069465" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="87" LOG_CI_END="0.15280887402516335" LOG_CI_START="-0.08441232501989786" LOG_EFFECT_SIZE="0.03419827450263275" ORDER="607" O_E="0.0" SE="0.1393449065829425" STUDY_ID="STD-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="736" TOTAL_2="737" VAR="0.019417002990608973" WEIGHT="15.435798134481464">
<FOOTNOTE>Wacholder, BMJ (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2147989908230599" CI_START="0.7733855321081704" EFFECT_SIZE="0.9692821900366068" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="122" LOG_CI_END="0.0845044224624291" LOG_CI_START="-0.11160395662855688" LOG_EFFECT_SIZE="-0.013549767083063864" ORDER="275" O_E="0.0" SE="0.11519503263017776" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="618" TOTAL_2="609" VAR="0.01326989554266772" WEIGHT="16.34182379560613">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0868241947143265" CI_START="0.779636109477934" EFFECT_SIZE="0.9205038766097436" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="241" LOG_CI_END="0.03615929805093478" LOG_CI_START="-0.10810805438786937" LOG_EFFECT_SIZE="-0.03597437816846729" ORDER="274" O_E="0.0" SE="0.08474335695746557" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1255" TOTAL_2="1283" VAR="0.007181436548420428" WEIGHT="17.350520240527956">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.4804158384952549" CI_START="0.23604900885250904" EFFECT_SIZE="0.33675166297117515" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="88" LOG_CI_END="-0.3183826830807423" LOG_CI_START="-0.6269978187904038" LOG_EFFECT_SIZE="-0.47269025093557315" ORDER="273" O_E="0.0" SE="0.18128205838541492" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="123" TOTAL_2="135" VAR="0.03286318469245299" WEIGHT="13.76630192806716">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="47.96252310806922" CI_START="0.18764650849833714" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6809020214470198" LOG_CI_START="-0.7266595120076947" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="285" O_E="0.0" SE="1.414213562373095" STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2" TOTAL_2="2" VAR="1.9999999999999998" WEIGHT="0.8182969294066911">
<FOOTNOTE>Lim, Med J Malaysia (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5417417000314062" CI_START="0.8993474874766884" EFFECT_SIZE="1.177523470789981" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="89" LOG_CI_END="0.18801161907968628" LOG_CI_START="-0.046072474300771535" LOG_EFFECT_SIZE="0.07096957238945739" ORDER="606" O_E="0.0" SE="0.137502155186631" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="973" TOTAL_2="990" VAR="0.018906842680968355" WEIGHT="15.507150411549167">
<FOOTNOTE>Wacholder, BMJ (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3569021233700225" CI_START="0.7369728315527909" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="67" LOG_CI_END="0.1325485220787893" LOG_CI_START="-0.13254852207878937" LOG_EFFECT_SIZE="0.0" ORDER="202" O_E="0.0" SE="0.15571931598969402" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="357" TOTAL_2="357" VAR="0.02424850537229817" WEIGHT="14.791248734093891">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.752016897563476" CI_END="1.015997200527742" CI_START="0.7999924302578871" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9015487061636761" ESTIMABLE="YES" EVENTS_1="452" EVENTS_2="511" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.00689251129728147" LOG_CI_START="-0.09691412239903464" LOG_EFFECT_SIZE="-0.04501080555087654" METHOD="IV" NO="3" P_CHI2="0.878775663644384" P_Q="1.0" P_Z="0.0891892180200184" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5420" TOTAL_2="5489" WEIGHT="100.00000000000001" Z="1.69969017689058">
<NAME>Elective termination/induced abortion</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.837196047481147" CI_START="0.1798268688854302" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.4528893461580515" LOG_CI_START="-0.7451454175145276" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="282" O_E="0.0" SE="0.7037315505489968" STUDY_ID="STD-African_x005f_2-country-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="14" TOTAL_2="10" VAR="0.49523809523809526" WEIGHT="0.7507777179621249">
<FOOTNOTE>Sow, J Infect Dis (2013).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="35.68412767300154" CI_START="0.44837862218796865" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5524750845472723" LOG_CI_START="-0.3483551018913478" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="245" O_E="0.0" SE="1.116557060775219" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_mid_x002d_adult" TOTAL_1="606" TOTAL_2="606" VAR="1.2466996699669965" WEIGHT="0.29823840973713384">
<FOOTNOTE>Zhu, Hum Vaccin Immunother (2014). *All pregnancies were terminated in both arms.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0794408385028416" CI_START="0.5468867754402503" EFFECT_SIZE="0.7683306055646482" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="65" LOG_CI_END="0.03319884471022804" LOG_CI_START="-0.2621025784040518" LOG_EFFECT_SIZE="-0.11445186684691191" ORDER="643" O_E="0.0" SE="0.1734615177029475" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="188" TOTAL_2="229" VAR="0.03008889812380996" WEIGHT="12.357173249110867">
<FOOTNOTE>Zhu, Int J Cancer (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3152477252696615" CI_START="0.6348411196732289" EFFECT_SIZE="0.9137687555163283" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="55" LOG_CI_END="0.11900755935443667" LOG_CI_START="-0.1973349510589327" LOG_EFFECT_SIZE="-0.03916369585224798" ORDER="278" O_E="0.0" SE="0.18582115653749456" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="618" TOTAL_2="609" VAR="0.03452950221693206" WEIGHT="10.768001364596627">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1479727063223157" CI_START="0.7124317643781379" EFFECT_SIZE="0.9043518234753295" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="130" LOG_CI_END="0.05993156259634527" LOG_CI_START="-0.14725672538705237" LOG_EFFECT_SIZE="-0.043662581395353506" ORDER="277" O_E="0.0" SE="0.12170342596001392" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1255" TOTAL_2="1283" VAR="0.014811723890404591" WEIGHT="25.102663926353433">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.700126083974497" CI_START="0.32556730982731097" EFFECT_SIZE="1.0975609756097562" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5682165231592711" LOG_CI_START="-0.48735920904805463" LOG_EFFECT_SIZE="0.04042865705560822" ORDER="276" O_E="0.0" SE="0.6200504102827282" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="123" TOTAL_2="135" VAR="0.3844625112917796" WEIGHT="0.9671000840666791">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="47.96252310806922" CI_START="0.18764650849833714" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6809020214470198" LOG_CI_START="-0.7266595120076947" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="284" O_E="0.0" SE="1.414213562373095" STUDY_ID="STD-Malaysian-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2" TOTAL_2="2" VAR="1.9999999999999998" WEIGHT="0.18590686349538335">
<FOOTNOTE>Lim, Med J Malaysia (2014).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1106048786843483" CI_START="0.7784710220374902" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="228" LOG_CI_END="0.045559576917060716" LOG_CI_START="-0.10875754906046543" LOG_EFFECT_SIZE="-0.03159898607170235" ORDER="715" O_E="0.0" SE="0.09064664368129222" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2257" TOTAL_2="2257" VAR="0.008216814010683155" WEIGHT="45.250352083830805">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4851136535149527" CI_START="0.470226865574328" EFFECT_SIZE="0.8356676003734828" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.1717596908287571" LOG_CI_START="-0.32769256186064444" LOG_EFFECT_SIZE="-0.07796643551594365" ORDER="203" O_E="0.0" SE="0.2933807255582785" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="357" TOTAL_2="358" VAR="0.08607225012910193" WEIGHT="4.319786300846951">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1747415918615576" CI_END="1.8298269094011934" CI_START="0.681004486511593" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1162976013778112" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.2624100100324831" LOG_CI_START="-0.16685002691128317" LOG_EFFECT_SIZE="0.04777999156059994" METHOD="IV" NO="4" P_CHI2="0.6730663552854648" P_Q="1.0" P_Z="0.6626056119978274" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4327" TOTAL_2="4427" WEIGHT="100.00000000000001" Z="0.4363185695419004">
<NAME>Stillbirth</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.343716498296395" CI_START="0.07670352936172863" EFFECT_SIZE="1.2180851063829787" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2865399185390431" LOG_CI_START="-1.1151846523866271" LOG_EFFECT_SIZE="0.08567763307620814" ORDER="644" O_E="0.0" SE="1.4107849016901037" STUDY_ID="STD-Chinese-trial-_x0028_ph3_x002c_2v_x0029__x005f_young" TOTAL_1="188" TOTAL_2="229" VAR="1.9903140388367557" WEIGHT="3.1944383785289623">
<FOOTNOTE>Zhu, Int J Cancer (2014)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4632410978069688" CI_START="0.1419231408921676" EFFECT_SIZE="0.5912621359223301" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3915069219173435" LOG_CI_START="-0.8479467860619371" LOG_EFFECT_SIZE="-0.22821993207229682" ORDER="281" O_E="0.0" SE="0.7280612434618342" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="618" TOTAL_2="609" VAR="0.5300731742311923" WEIGHT="11.99444880455711">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.6607315231249276" CI_START="0.6908265729751254" EFFECT_SIZE="1.5902611775121736" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5635678790315204" LOG_CI_START="-0.160630965437951" LOG_EFFECT_SIZE="0.2014684567967847" ORDER="280" O_E="0.0" SE="0.42539798608346324" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1255" TOTAL_2="1283" VAR="0.1809634465638664" WEIGHT="35.13381111881756">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.89156587112878" CI_START="0.015031893382864434" EFFECT_SIZE="0.3655913978494624" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9489782502060085" LOG_CI_START="-1.8229863132293682" LOG_EFFECT_SIZE="-0.43700403151168" ORDER="279" O_E="0.0" SE="1.6282657060078258" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="123" TOTAL_2="135" VAR="2.6512492093611635" WEIGHT="2.3980905033507223">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4544900855475134" CI_START="0.5589426252468883" EFFECT_SIZE="1.1712895167542423" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.38996128218830123" LOG_CI_START="-0.25263276960465025" LOG_EFFECT_SIZE="0.06866425629182547" ORDER="114" O_E="0.0" SE="0.37746292691503686" STUDY_ID="STD-PATRICIA-_x0026_-CVT-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="1786" TOTAL_2="1813" VAR="0.14247826119526646" WEIGHT="44.62389909623873">
<FOOTNOTE>Wacholder, BMJ (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.162781849848133" CI_START="0.00966271527986508" EFFECT_SIZE="0.2005586592178771" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6193836523257408" LOG_CI_START="-2.0149008171288885" LOG_EFFECT_SIZE="-0.697758582401574" ORDER="205" O_E="0.0" SE="1.5473917372760784" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="357" TOTAL_2="358" VAR="2.39442118859028" WEIGHT="2.655312098506931">
<FOOTNOTE>Skinner,Lancet (2014)</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.179699755790487" CI_END="1.6874483863203165" CI_START="0.8833918497875332" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2209333116155412" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="95" I2="22.77544667471658" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.22723049801916104" LOG_CI_START="-0.05384661187933567" LOG_EFFECT_SIZE="0.08669194306991268" METHOD="IV" NO="5" P_CHI2="0.2693512223144524" P_Q="1.0" P_Z="0.2266574735304845" Q="0.0" RANDOM="YES" SCALE="304.87433824497066" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.031014383187605375" TOTALS="YES" TOTAL_1="4610" TOTAL_2="4642" WEIGHT="99.99999999999997" Z="1.2090140405114103">
<NAME>Abnormal infant</NAME>
<GROUP_LABEL_1>Vaccinated</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less harm in vaccinated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More harm in vaccinated</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5556119488312188" CI_START="0.5846224471542947" EFFECT_SIZE="0.9536486063263389" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" LOG_CI_END="0.1919012703532401" LOG_CI_START="-0.2331245134943415" LOG_EFFECT_SIZE="-0.02061162157055073" ORDER="284" O_E="0.0" SE="0.24966224934363093" STUDY_ID="STD-FUTURE-I-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="618" TOTAL_2="609" VAR="0.06233123874732134" WEIGHT="29.203318776952976">
<FOOTNOTE>Garland, New Engl J Med (2007). Follow-up: 36 months.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.7584843519952624" CI_START="1.138307282325605" EFFECT_SIZE="1.7720053120849935" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="30" LOG_CI_END="0.4406705246862236" LOG_CI_START="0.056259514259792996" LOG_EFFECT_SIZE="0.2484650194730083" ORDER="283" O_E="0.0" SE="0.225804930389676" STUDY_ID="STD-FUTURE-II-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="1255" TOTAL_2="1283" VAR="0.05098786658828642" WEIGHT="33.24301420081316">
<FOOTNOTE>The FUTURE II study group, New Engl J Med (2007).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.207258532594973" CI_START="0.41230690332484693" EFFECT_SIZE="1.3170731707317074" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6239991998776057" LOG_CI_START="-0.38477939367113967" LOG_EFFECT_SIZE="0.11960990310323304" ORDER="282" O_E="0.0" SE="0.5925615393851058" STUDY_ID="STD-FUTURE-III-trial-_x0028_ph3_x002c_4v_x0029_" TOTAL_1="123" TOTAL_2="135" VAR="0.3511291779584463" WEIGHT="7.133449915061492">
<FOOTNOTE>Castellsague, Br J Cancer (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.078852598691557" CI_START="0.6718582239814027" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.3178236967175468" LOG_CI_START="-0.17272236242032327" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="115" O_E="0.0" SE="0.28814918337973977" STUDY_ID="STD-PATRICIA-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="2257" TOTAL_2="2257" VAR="0.0830299518824109" WEIGHT="23.90300186436266">
<FOOTNOTE>Lehtinen, Lancet Oncol (2011).</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.940363962880117" CI_START="0.16922726031077412" EFFECT_SIZE="0.5730292116846739" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2878832001595283" LOG_CI_START="-0.7715296764687548" LOG_EFFECT_SIZE="-0.24182323815461323" ORDER="204" O_E="0.0" SE="0.6223043679097697" STUDY_ID="STD-VIVIANE-trial-_x0028_ph3_x002c_2v_x0029_" TOTAL_1="357" TOTAL_2="358" VAR="0.3872627263195781" WEIGHT="6.5172152428097005">
<FOOTNOTE>Wheeler, Lancet Infect Dis (2016).</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES />
<FEEDBACK />
<APPENDICES />
<EXTENSIONS />
</COCHRANE_REVIEW>
